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CTCs. DNA size markers of 20 and 80 nt were co-electrophoresed with the LDR 
products. ....................................................................................................................................143 
Figure 3.3 Two µl of amplicons from PCR were used for analyzing point mutation in the 
KRAS gene for blood samples spiked with and without 10 SW620s. The LDR products 
were analyzed using capillary electrophoresis. The capillary electrophoresis responses 
for sample after processing blood with no SW620 are shown in A, and B shows the 
electropherogram for 10 spiked SW620s in blood. Peak ‘a’ represents the primer and 
peak ‘b’ is the LDR product for SW620. ...............................................................................144 
Figure 4.1 Fluorescence dot plots showing typical CD antigen expression on RPMI-
8226 cells. All plots were gated on CD45-. The resulting dot plots indicate: (A) 74% of 
these cells express CD56+; (quadrant R6); (B) 90% of the cells express CD138+ 
(quadrant R6); and (C) 98% of the cells express CD38+ (quadrant R6).  Fluorochromes 
used for each antibody was PE for CD56, APC for CD38, Pacific blue for CD138 and 
FITC for CD45...........................................................................................................................166 
Figure 4.2  (A) Schematic of the CMMC selection device with an array of 50 parallel 
sinusoidal microchannels and inlet/outlet channels arranged in a z-configuration. Flow 
of blood is indicated by the green arrow. (B) SEM of the selection bed depicting high-
aspect ratio (30 x 150 µm, w x d) sinusoidal microchannels and the output channel. (C) 
Blood processing setup in a biological safety hood showing blood filled syringes set on 
a Harvard apparatus multi–syringe pump. The syringes are each connected to inlet 
capillaries interfaced to the CMMC selection devices. (D) DAPI fluorescent image of 
CMMCs captured on either side of a sinusoidal microchannel.........................................168 
Figure 4.3  (A) Graph showing cell capture efficiency versus cell translational velocity. In 
these experiments an estimated 500 RPMI-8226 cells were seeded into RPMI-1640 
total cell medium. The cells were prestained with a live nuclei cell dye and were 
introduced in the CMMC selection device at linear velocities ranging from 0.4-2 mm/s. 
Capture efficiency was determined by the ratio of RPMI-8226 cells captured on the 
CMMC selection device to the total number of RPMI-8226 cells selected on chip and 
collected in the effluent. Number of cells captured was determined by both brightfield 
and fluorescence microscopy. (B) Calibration plot of RPMI-8226 cells seeded (20-500 
cells/0.5 mL) of healthy donor blood and processed through the device at the optimized 
linear velocity of 1.1 mm/s.  Capture sensitivity for the CMMC selection assay was given 




Figure 4.4 In-situ immunophenotyping and cytoplasmic staining of CMMCs.  Panels (A) 
and (B) represent RPMI-8226 cells and CMMCs selected in a polymer microchannel via 
anti-human CD138/CD138, respectively. Positive CMMC surface markers are presented 
by micrographs: (b,g) CD56-PE; (c,h) CD38-APC; while (d,i) are negative control 
marker CD45-FITC for leukocyte identification. DAPI was used for nuclei identification 
(a,f,l). Panel (C) represents cytoplasmic staining of RPMI-8226 cells, which are the λ 
light chain expressing cells, using anti human Igκ-PE (m) and anti-human Igλ-APC (n). 
(D) H&E image of a released plasma cell from the CMMC selection bed using 
enzymatic release via trypsin. All bars represent 10 µm. ..................................................173 
Figure 4.5  Alternative confirmatory phenotypes for CMMCs isolated from a patient 
sample. Panel (A) represents 6 CD138 selected cells that were found to be CD56+ (b) 
and CD38– (c). Panel (B) shows a mix of two phenotypes side-by-side, 3 CD38+/CD56+ 
positive cells (g,h) next to 2 CD56+/CD38- cells (h). Both panels show dim to no 
expression of CD45 (c,i). Nuclei were stained with DAPI (a,f). Composite images are 
show in e & j for both panels. .................................................................................................175 
Figure 4.6 Panels A and B represent cytoplasmic staining of a clinical sample with 
active MM (B) using anti-human Ig κ-PE (b,e) and anti-human Ig λ-APC (c,f)  and (C) 
cytoplasmic staining of RPMI-8226 cells as a control. Results indicated strong Kappa 
expression for approximately 70% of the cells enumerated and weak expression of 
about 10% of the total cells captured on the device for the clinical sample. Imaging 
conditions:  5x objective, 1.2 s exposure time for PE (Kappa) and 9 s exposure time for 
APC (Lambda). Bars represent 150μm. ...............................................................................176 
Figure 4.7 Box plots presenting count of CMMCs selected in chip from MM patient blood 
samples. Data are normalized to 1 mL. Lower and upper edges of box show 25th and 
75th percentiles, respectively. Solid line in box represents median, and solid diamond 
represents mean. Error bars show maximum and minimum values................................177 
Figure 4.8 Agarose gel electrophoresis of PCR products generated from (A) RPMI-8226 
cells and (B) CMMCs from 4 patient samples. PCR was run with 35 cycles with an initial 
denaturation step of 2 min and final extension for 7 min. Each cycle consisted of: 94°C 
(30 s), 59°C (30 s), 72°C (40 s). The gel was stained with ethidium bromide and run at 
4.8 Vcm-1. (A) Gel electropherogram for PCR performed on RPMI-8226  cells with; (a) 
no gDNA template; (b) gDNA template from HT-29 directly (positive control); (c) gDNA 
from 20 RPMI-8226 cells; (d) gDNA from 150 RPMI-8226 cells; (e) gDNA from 500 
RPMI-8226 cells; and (f) gDNA from 750 RPMI-8226 cells. Lanes a-f contain 5 µL of 
DNA amplicons. (B) Gel electropherogram for PCR performed on CMMCs obtained 
from 4 clinical samples analyzed using the CMMC selection device: (a) No gDNA  and 
used as a negative control; (b) gDNA template from RPMI-8226 directly used as a 
positive control. (c) gDNA from patient 35; (d) gDNA from patient 36; (e) gDNA from 




29 or RPMI-8226 cells from the culturing dish (~1,000 cells), lysing them, performing a 
solid-phase extraction of the gDNA followed by PCR of the purified sample. ................180 
Figure 4.9 LDR and Sanger sequence analysis of sequence variations in the KRAS 
gene for codons 12 and 13 with the gDNA secured from RPMI-8226 cells, HT-29 cells, 
and CMMCs isolated from clinical samples. LDR consisted of 20 cycles. Initial 
denaturation was performed at 95°C for 2 min. Each cycle consisted of: 95°C (30 s); 
60°C (2 min); and 4°C as a final hold. LDR products were analyzed using CGE 
performed at a capillary temperature of 60°C with an initial denaturation step prior to 
injection at 90°C for 3 min.  CGE injection was performed at 2.0 kV for 30 s and 
separation was done at 6.0 kV.  CGE electropherograms for various samples are shown 
in (A-F). LDR product peaks are represented with an asterisk *. (A) shows the 49 nt 
LDR product denoting the G12A mutation found in RPMI-8226; (B) and (D) show no 
LDR products at the c12.2 C locus for HT-29 and patient 35, respectively; (C) shows a 
54 nt LDR product denoting the G12S mutation for patient 35; and (E) shows a 42 nt 
product denoting the G13D mutation for patient 36. DNA size markers of 20 and 80 nt 
were co-electrophoresed with the LDR products. (F) Sanger sequencing trace for gDNA 
secured from patient 36 at codons 12 and 13 with an additional peak at c13.1A denoting 
the presence of mutant copies bearing the G13S mutation. .............................................182 
Figure 5.1 Schematic of the bio-processor, an integral component of the CTC 
workstation. The bio-processor is composed of modules for CTC affinity selection 
(Seprase and EpCAM), impedance sensor (CD), cell array with valving fluidic layer, 
SPE module, and imaging module for the real-time monitoring of molecular beacons via 
FRET produced as a result of a successful LDR. The fluidic motherboard also contains 
continuous flow thermal reactors for lysis, PCR and LDR. The PCR is multiplexed 
containing primers for the appropriate gene fragments to be interrogated. The LDRs are 
spatially multiplexed with each thermal reactor monitoring a specific locus. While the 
system shows a 6-plex LDR, this can be scaled for higher multiplexing as needed. The 
workstation also contains a scanning microscope for phenotyping cells in the 2D array, 
the imaging microscope for CCD-TDI readout, thermal control units, electronic control 
boards for data processing, and fluid handling hardware (syringe pumps), which are not 
shown. ........................................................................................................................................194 
Figure 5.2 Effect of thermal fusion bonding on the stability of oligonucleotide bifunctional 
linkers. After modified oligonucleotide linkers were covalently attached to UV-activated 
PMMA, the PMMA was (A) heated to 107ºC for 20 min or (B) not heated. The 
fluorescence intensity profiles from a vertical section of two spots (see dotted yellow 
line) in (A) and (B) are shown in (C). To interrogate the stability of the attached 
oligonucleotide linkers, solution complements to the linkers bearing a fluorescent 
reporter were hybridized to the linkers. As can be seen in (C), no difference in the 
fluorescence intensity resulted. (D) UV-activated PMMA reacted with EDC/NHS 
coupling reagents and a single-stranded oligonucleotide linker containing a 5’ amino 




coupling, the linker was subjected to the USER system, which cleaves the linker at the 
dU residue. The loss of fluorescence is indicative of the cleavage. Spot (a) is a linker 
with no dU residue, while spot (b) contained the dU residue in the linker  ......................197 
Figure 5.3 The top panel shows the process strategy for performing 3D molding using a 
PDMS intermediate molding tool containing nano-textures. The finished nano-textured 
chip is shown with ridges, but the nano-structure architecture can be altered through 
lithographic changes imposed on the PDMS intermediate molding tool. (A-C, E) SEM 
images of PMMA CTC selection channels containing nano-textures with bumps that 
range from 200 nm (A-D) to 5 µm (E). (D, F) Fluorescence microscope images of nano-
textured channels that were sealed with a cover plate using solvent-assisted bonding. 
Fluorescein was used as the dye seed in a 1X TBE buffer (pH = 8.5). These images 
demonstrate no leakage following cover plate bonding. For SEMs (A, E), the CTC 
device was sealed with a cover plate, dipped in liquid N2 and fractured so as to produce 
a cross section of the nano-textured channel to show the integrity of the nano-features. 
In (A), the nano-texture structures are not visible at the magnification used but can be 
seen in (B), before cover plate bonding; (C), after clover plate bonding. In (E), the 
features are clearly visible. .....................................................................................................199 
Figure 5.4  Expression differences of Seprase and EpCAM for various cancer cell lines
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Figure 5.5 Single-cell electrical impedance detection. (A) Histograms for impedance 
response for leukocytes (blue bar) and SW620 cancer cells (red bar). (B) SW620 (red) 
and leukocyte (blue) cell size measured optically. (C) Plot of impedance response, 
phase and magnitude, as a function of the voltage frequency applied to the electrodes. 
Taken from ref.[42] with permission.  (D) New electrode design in which thin films 
electrodes are deposited on both top and bottom plates...................................................202 
Figure 5.6 (A) Schematic of the 2D cell array. The array consists of microwells made 
from PMMA and a transparent FEP layer (3 layers) that serve as the fluidic, valving and 
through-hole units for this module. (B) Fabrication method for the polymer valves; this is 
accomplished using 2-sided embossing and laser drilling. The small arrows show the 
flow direction when the valve is open. To close the valve, a mechanical solenoid is 
used.[29] (C) Cross-sectional view of the microwell with the FEP layers serving as the 
well floor with access hole to the fluidic network. The total force (FT) acting on the cell to 
resist movement is gravity (FG), hydrodynamic (if applied, FH) and Stokes (FS). For a 
HeLa-type cell, FT ≈ FG ≈ 29.9 pN. For a 1064-nm laser beam of modest intensity, a 
scattering force, FS, will be able to eject the cell from this well. FH is applied using either 
positive or negative operation of a syringe pump and valves, poised on the backside of 
this module (they are not visible in this schematic). ...........................................................205 
Figure 5.7 (A) Schematic of the optical readout module that consists of input connects 




This module consists of a cover plate with an embedded COC planar waveguide and 
readout channels that are approximately 2 µm in width and 350-500 nm in depth at the 
detection zone (evanescent excitation of solution molecular beacons). (B) Molding tool 
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Cancer research is centered on the discovery of new biomarkers that could unlock 
the obscurities behind the mechanisms that cause cancer or those associated with its 
spread (i.e., metastasis). Circulating tumor cells (CTCs) have emerged as attractive 
biomarkers for the management of many cancer-related diseases due primarily to the 
ease of securing them from a simple blood draw. However, their rarity (~1 CTC per mL 
of whole blood) makes enrichment analytically challenging. Microfluidic systems are 
viewed as exquisite platforms for the clinical analysis of CTCs due to their ability to be 
used in an automated fashion, minimizing sample loss and contamination. This has 
formed the basis of the reported research, which focused on the development of 
microfluidic systems for CTC analysis. The system reported herein consisted of a 
modular design and targeted the analysis of CTCs using pancreatic ductal 
adenocarcinoma (PDAC) as the model disease for determining the utility of the system. 
The system was composed of 3 functional modules; (i) a thermoplastic CTC selection 
module consisting of high aspect ratio (30 µm x 150 µm) channels; (ii) an impedance 
sensor module for label-less CTC counting; and (iii) a staining and imaging module for 
phenotype identification of selected CTCs. The system could exhaustively process 7.5 
mL of blood in <45 min with CTC recoveries >90% directly from whole blood. In 
addition, significantly reduced assay turnaround times (8 h to 1.5 h) was demonstrated. 
We also show the ability to detect KRAS gene mutations from CTCs enriched by the 
microfluidic system. As a proof-of-concept, the ability to identify KRAS point mutations 
using a PCR/LDR/CE assay from as low as 10 CTCs enriched by the integrated 




microfluidic device for the analysis of circulating multiple myeloma cells (CMMCs) was 
demonstrated as well. Parameters such as translational velocity and recovery of 
CMMCs were optimized and found to be 1.1 mm/s and 71%, respectively. Also 
demonstrated was on-chip immunophenotyping and clonal testing of CMMCs, which 
has been reported to be prognostically significant. Further, a pilot study involving 26 
patients was performed using the polymer microfluidic device with the aim of correlating 
the number of CMMCs with disease activity. An average of 347 CMMCs/mL of whole 




CHAPTER 1. MATERIALS AND MICROFLUIDICS: ENABLING THE CLINICAL 
UTILITY OF CIRCULATING TUMOR CELLS 
1.1  Introduction  
CTCs are exfoliated cells from primary or secondary neoplasms that have been 
implicated in metastasis. [1] Studies based on mouse models indicate that growing or 
regressing tumors shed ~3.2 to 4.1 x 106 cells per day per g of tissue. [2] [3] Although a 
great number of these cells turn out to be apoptotic, [4, 5] there exists a certain 
aggressive population that under particular micro-environmental conditions, may 
acquire mesenchymal characteristics, evade the body’s immune surveillance system 
and infiltrate distant organs giving rise to metastasis. [6, 7] Recent findings have 
suggested CTCs exist in circulation as single cells or aggregates (CTM-circulating 
tumor microemboli) of which the latter have been found to be associated with increased 
metastatic potential (see Figure 1.1). [8, 9] Clinical studies based on CTCs have 
associated the frequency of occurrence of these cells with poor progression free and 
overall survival for metastatic breast, colorectal and prostate cancer. [10-12] 
Consequently, they have been viewed as attractive new cancer biomarkers for 
managing many cancer diseases. CTCs have been suggested to serve as surrogates 
for tumor biopsy tissue allowing for less invasive sampling, which is especially beneficial 
for cancers that are anatomically inaccessible, such as pancreatic tumors. They can 
also be a source of material for understanding basic tumor biology, such as genotype or 





Ninety percent of all cancer-related deaths are due to metastatic disease. 
Unfortunately, many conventional methods for cancer diagnosis, such as imaging with 
the appropriate contrast agents, are not sensitive enough to detect micro-metastatic or 
pre-metastatic conditions, where treatment interventions can result in improved overall 
survival compared to therapies administered after the onset of metastatic disease. A 
number of studies have indicated that CTCs can be used for detection of pre-metastatic 
conditions besides being restricted to managing metastatic disease only. [17-19]  
  Various technologies have been used to isolate and enumerate CTCs from 
blood, however, in spite of the rapidly evolving technology there are still challenges. 
CTCs are a very rare population in blood, which is populated with a variety of cell types 
in much higher abundance than CTCs. Further, CTCs are phenotypically 
heterogeneous with a short half-life; 1 – 2.4 h in circulation. [20, 21] In addition, CTC 
enrichment can be complicated by the fact that their genotype and phenotype profiles 
Figure 1.1 CTCs escape immune surveillance and result in metastatic malignancy. 




are likely to be modified dynamically once exfoliated due to EMT-like (Epithelial-
Mesenchymal Transition) processes. [21-23] There is currently no single antigenic 
marker that is uniformly expressed on all CTCs that can effectively be used to identify 
the various sub-populations of CTCs that may be present in circulation and be key 
effectors in the metastatic cascade. [24] Enrichment strategies (>109) are therefore 
necessary to obtain various CTC sub-populations possibly found in circulation and also, 
secure pure populations of these CTCs so as to enable downstream characterization of 
such sub-populations via genotyping or the propagation of these cells for biological 
studies. 
CellSearch™ (Veridex LLC) is the only system cleared by the FDA as a 
diagnostic tool for the enrichment and enumeration of CTCs, but only for metastatic 
breast, colon and prostate cancers. This system is based on antibody functionalized 
magnetic particles that specifically bind to CTCs expressing unique antigen(s), such as 
the epithelial cell adhesion molecule, EpCAM. Upon application of a magnetic field, 
CTCs bound to the magnetic particles are extracted and further identified with tumor 
specific phenotypic markers. The technology has been clinically validated by several 
studies. [11, 25] Advantages of CellSearch include; its ability to predict progression free 
and overall survival of breast cancer patients; and it is a semi-automated process that 
has facilitated use in several centers where clinical trials are currently being carried out. 
[26] However, it suffers from low purity (0.01-0.1%) and low clinical sensitivity with 
recent reports indicating very low CTC median yields (1 CTC/7.5 ml) in some cancers. 




Newer platforms, such as microfluidics, have demonstrated higher purities and 
clinical yields. [29-34] Microfluidic devices are attractive platforms for the analysis of 
CTCs for several reasons: (i) They can be configured to select CTCs based on several 
different modalities including biological cell properties, such as expression of antigens 
specific to the CTC type or physical cell properties, such as cell size or deformability; (ii) 
microfluidic devices operate in a closed architecture minimizing the potential of sample 
contamination artifacts that may provide false positive results, especially in clinical 
laboratory settings; (iii) microfluidics can be produced in a high production mode and at 
low-cost. For example, devices can be produced in thermoplastics using micro-
replication, the same technology used to produce CDs and DVDs; (iv) CTC selection 
devices can be integrated to other steps to fully automate sample processing negating 
the need for operator intervention and thus, minimizing false negative or false positive 
results. [35, 36] [34] 
Challenges with microfluidics include the high surface-to-volume ratio associated 
with these devices requiring special attention to engineer surfaces that reduce non-
specific adsorption artifacts, especially when dealing with clinical samples such as 
whole blood. Also, microfluidics are many times incompatible with high throughput 
processing; for typical volume flow rates of 300 nl/min (50 x 50 µm2 microchannel cross-
section, 0.2 cm s-1 linear velocity), 3,333 min (55.5 h) would be required to exhaustively 






Figure 1.2 Enrichment of circulating tumor cells (CTCs) from the peripheral blood of 
cancer patients is based on physical or biological properties of CTCs. (A) Physical 
properties include size (membrane filter devices), deformability (microfluidic system in a 
chip), density (Ficoll centrifugation), and electric charge (dielectrophoresis). (B) 
Biological properties include expression of cell surface markers and invasive capacity. 
Cell surface markers include an epithelial cell adhesion molecule (EpCAM) for positive 
selection and CD45 for negative selection; anti-EpCAM or anti-CD45 antibodies 
conjugated with magnetic beads, used to enrich CTCs in a magnetic field; and anti -
EpCAM antibodies on microposts or columns of nanobeads. Invasive capacity refers to 
adherence and invasion of fluorescent matrix. Abbreviations: glyco A, glycophorin A (a 
131-amino-acid protein present at the extracellular surface of the human red blood cell); 
CAM, cell adhesion matrix; fluo-CAM, fluorescent cell adhesion matrix; RBC, red blood 




CTC enrichment from blood is based on two criteria that differentiate CTCs from 
normal hematopoietic cells: (i) Biological properties, such as surface and cytoplasmic 
protein expression, viability, and invasion capacity. CTCs can be directly targeted, in 
which case, this is referred to as positive selection while the converse, negative 
selection clears hematopoietic cells to obtain CTC fractions indirectly; (ii) physical 
properties such as size, density, cell membrane electric potential, and deformability (see 
Figure 1.2). [37, 38] 
Assessment of CTC enrichment technologies is based on 5 important figures-of-
merit: (i) Throughput, defined as the maximum volume processing rate; (ii) recovery, an 
indicator of the number of target cells selected from the input sample with respect to the 
seed level of the target in that same sample; (iii) purity, which is defined as the ratio of 
CTCs selected to the total number of cells enriched; (iv) clinical sensitivity, which refers 
to the ability of the assay to correctly identify those patients with the disease; and (v) 
clinical specificity, which refers to the ability of the assay to correctly identi fy those 
patients without the disease. [39, 40] While throughput is primarily a function of the 
mechanical properties of the device, purity is in most cases material dependent whether 
the selection modality is based on biological or physical properties of the CTC. Clinical 
sensitivity and specificity are a complex function of the biological and physical 
properties of the CTC, but also on the topographical features of the device.  
Material considerations play an important role in the development of devices 
targeted for CTC enrichment, especially for microfluidic-based devices. For example, 




beads decorated with antibodies directed against antigens unique to the CTC. The 
magnetic susceptibility of these particles must be sufficient to collect with high efficiency 
all CTCs, even those with low expression levels of the target antigen. In addition, 
devices with biocompatible surfaces are required so as to maintain CTC integrity and 
viability as well as minimize non-specific adsorption of hematopoietic cells to their 
surfaces. From a commercial perspective, material selection can determine the cost and 
manufacturability of the CTC device. The manufacturing modality is highly dictated by 
the type of material used; for example thermoplastics can be produced in high 
production modes and at low cost using micro-replication. These considerations are 
important in order to facilitate the use of devices in clinical-based settings, where a high 
turnover is expected for cancer screening and diagnosis and the fact that devices are 
used for only one assay and then, discarded to minimize false positive results. [41, 42] 
As noted, material properties play an integral role in determining the performance 
characteristics of a device irrespective of the selection modality employed (i.e., 
biological or physical). For selection based on the CTC’s biological properties, device 
surface properties are dictated by the pendant functional groups found on the substrate 
material both in terms of number density and type. These functional groups and their 
surface density determine the surface load of affinity agents, such as antibodies used 
for CTC enrichment. Typically, high loads of antibodies are required to select with high 
efficiency CTCs, especially those with low antigen expression. The topography of the 
surface is critical as well, because it can increase the contact area between the CTC 




recovery of CTCs even with low antigen expression levels. Optical transparency of the 
substrate is an important consideration as well because efficient enumeration of the 
CTCs utilizes immunofluorescence, where low-levels of fluorescence must be detected. 
In addition, the substrate material must accommodate the fluorescence microscope 
used to image the CTCs, such as the refractive index and cover slip thickness to 
provide high image quality of the CTCs. For devices and assays based on IMAC 
(immunomagnetic assisted cell sorting), the magnetic susceptibility of the beads is 
critical for effective enrichment of CTCs from complex sample matrices. For CTC 
microfluidic devices based on physical selection, such as micro-filters, the material 
selection is based upon the ability to generate reproducible and accurate pore or filter 
structure dimensions optimized for CTC selection while at the same time minimizing 
non-specific adsorption of hematopoietic cells.  
 While many CTC reviews have appeared in the literature, the primary goal of 
these reviews have been to focus on the enrichment protocols employed to select CTCs 
and/or clinical studies. [38, 43-46]  This review is unique in that it will provide an 
overview on the interplay of materials and microfluidics for CTC enrichment. 
Specifically, we will discuss the role of material considerations on the performance 
metric(s) of the microfluidic selection mechanism for CTC analysis including, recovery, 





1.2  Substrates Commonly Used by Microfluidics for CTC Enrichment 
Material options for any microfluidic device depend on several factors such as 
machinability, optical transparency, inertness to the assay conditions, thermal 
tolerances and a surface conducive to modification. [42, 43, 47, 48]  Silicon, glass, 
polymers and magnetic beads are commonly employed in CTC enrichment microfluidic 
devices. Here we will look at how these materials have been selected for the fabrication 
of various CTC enrichment devices and the material property effects on CTC 
enrichment.  
1.2.1 Silicon and Glass Materials for CTC Enrichment Microfluidic Devices 
Silicon and glass and their hybrids are the most commonly used materials for 
CTC enrichment microfluidic devices primarily because of their well-established surface-
modification chemistries.  Silicon is a semiconductor material that has been well 
characterized in terms of its physical and chemical properties as well as micromachining 
techniques used to form structures relevant for the device’s operation. Silicon has been 
used in both for the affinity and size selection of CTC using microfluidic devices. [31, 49-
51]  Characteristics that make silicon an attractive material for CTC enrichment are its 
solvent compatibility and well established surface chemistries for ligand attachment. In 
the case of size selection, silicon offers good mechanical stability, especially in the 
construction of different filter structures such as pores, slots and traps for high 




Silicon can also be used as a master in soft lithography for the fabrication of 
PDMS microfluidic devices for CTC enrichment. [52-54] Microfabrication of silicon can 
be carried out using photolithography followed by wet etching, plasma etching or 
reactive ion etching. [55] More specifically, deep reactive ion etching (DRIE) has been 
utilized to create micropost structures as deep as 50 to 100 µm for CTC selection 
devices based on affinity capture, [31] and the GEDI (geometrically enhanced 
differential) devices, [29] both of which utilize affinity capture of CTCs. Nanostructured 
silicon nanopillar (SiNP) devices for CTC capture were fabricated using a wet etching 
method implementing a micro-electrochemical redox reaction involving HF and silver 
nitrate. [56]  
Filter-based microfluidic devices for CTC enrichment have also used silicon as 
the substrate material for the generation of pore or filtering structures.  One such 
example was the multi-obstacle architecture device that utilized silicon-on-glass (SOG) 
to create high-aspect ratio microfilter structures for CTC isolation. Basically, lapping and 
chemical/mechanical polishing (CMP) were performed on the silicon layer, which 
determined the optimal height of the structures (50 µm). Glass was bonded onto the 
silicon using anodic methods. As a consequence, CTC visualization was enabled 
through the use of optical microscopy with high aspect ratio structures generated for 
CTC isolation. [50] In another report, the authors produced uniform depth honeycomb 
structures on a silicon micro-sieve (see Figure 1.3) to generate a CTC enrichment 
device. The fabrication strategy employed a SOI (silicon-on-insulator) wafer instead of 




structures were formed, the embedded SiO2 layer was then removed by dielectric 
reactive ion etching. [49]  
 
Glass microfluidic devices are particularly favored due to their well-defined 
surface chemistry and outstanding optical properties. These properties are highly 
desired for maximizing signal output during the fluorescence imaging phases of the 
assay to allow for immunophenotyping of the cells. In fact, a number of CTC microfluidic 
devices consist of hybrid forms of two materials, such as glass and silicon or glass and 
PDMS where glass is primarily used as a cover plate for high resolution imaging 
purposes. For example, a herringbone device, which consisted of a PDMS substrate 
Figure 1.3 (A) SEM image of a silicon microsieve filter with uniform honeycomb pore 
structures fabricated using silicon on insulator technology (SOI), (B) SEM image of the 
backside of the microsieve membrane showing the supporting rings. The dimension of 
the silicon microsieve and membrane area is 7.5 mm and 5 mm in diameter, 
respectively. (C) Composite fluorescent images of enriched MCF-7 cells (red and blue) 
and leukocytes (green and blue) stained with fluorescent labeled antibodies against 
membrane antigens EpCAM (red) and leukocyte marker CD45 (green). All nuclei were 





bonded to a glass cover plate, enabled high-resolution imaging for in situ FISH assays 
and RNA ISH analysis of WNT2 gene expression of CTCs enriched by the device from 
both human and patient-derived xenograft models. [57] [32]  
There are some challenges involved with the fabrication of both glass and silicon-
based microfluidic devices. First, glass is limited to the production of low aspect ratio 
structures due to the isotropic nature of wet etching producing shallow structures. [47, 
58] While this can be alleviated using DRIE dry etching techniques, it makes the 
fabrication protocol more costly compared to wet-etching microstructures. Also, both 
materials involve at least 5 fabrication steps with some requiring harmful and toxic 
agents, such as acids for wet etching. This necessitates the need to use clean room 
facilities, which also adds to the cost of producing devices, which can be problematic for 
scenarios where in vitro diagnostics are required such as CTC assays, which require 
one-time use operation.  Device cost is compounded by low manufacturing yields when 
using DRIE as well. [59, 60] 
1.2.2 Polymer Substrates for Microfluidic Devices used for CTC 
Enrichment 
To ensure clinical accessibility of microfluidic devices for CTC diagnostics, low-cost 
and high fidelity large-scale production of single-use devices is critical. [61, 62] For this, 
polymers, such as poly (methylmethacrylate), PMMA, cyclic olefin copolymer, COC, 
poly(carbonate), PC, or poly(dimethyl siloxane), PDMS, are well suited. Microfluidic 
devices fabricated in silicon [62-66] require time-consuming photolithography and 
etching (wet or dry) to microstructure components required for each device adding to 




microstructures can be patterned into silicon substrates [62, 67-69] or spin-coated 
photoresist layers [70-78] that can be used as molding masters. PDMS can be cast 
against a mold master and cured to form the desired microstructures; this curing 
process requires from 45 min to 24 h. [62, 67-79] The elastomeric PDMS is then peeled 
from the master and the microstructured PDMS sealed against a glass cover plate; both 
are treated with oxygen plasma and irreversibly bonded to yield the sealed device. After 
removing the PDMS, the molding master is free for repetitive uses and the time and 
expense of lithography for producing each device eliminated. [62, 67-79] However, this 
process requires several hours of curing time and thus, is difficult to effectively compete 
with the throughput capabilities offered by hot embossing or injection molding, where 
thermoplastic replicas can be produced within a few seconds with high fidelity. [34, 61, 
70, 80, 81] 
Thermoplastics, such as PMMA and COC for selection of CTCs and PC have been 
hot embossed from a metal molding master. In many cases, the master can be 
mechanically machined into brass using micrometer-sized milling bits and thus, no 
clean room is required. [61, 80] Alternative strategies, such as UV or X-ray LiGA 
(lithography, electroplating, and molding) offer the ability to fabricate sub-micrometer 
structures with high fidelity. [79, 82] Hot embossing consists of heating a thermoplastic 
substrate to above its glass transition temperature (Tg) and under controlled pressure, 
transferring the master’s microstructures into the heated substrate, then cooling and 
releasing the patterned substrate. [61, 79, 80] Figure 1.4 shows pictures of a 




used to micro-mold devices from the metal masters generated via micromilling. 
Similarly, injection molding can be used to create devices via micro-replication and 
requires pellets of the thermoplastic to be passed through a heated barrel with the 
molten thermoplastic forced through a nozzle and into a cavity produced by the molding 
master. The thermoplastic then solidifies following cooling transferring the master 
mold’s structures into the polymer. [79] While set up costs for injection molding are 
higher than that associated with hot embossing, production rates for injection molding 
















Figure 1.4 (A) Kern micromilling machine (MMP) is a  computer numerically 
controlled (CNC) milling machine  that is used to pattern microstructures on 
metal mold inserts using very small milling bits (down to 25 µm diameter) rotated 
at very high speeds in the range of 40,000 – 200,000 rpm.  Mold inserts can then 
be used as masters for the production of microstructures on polymer substrates 
(B)  Hex03 hot embossing equipment capable of molding polymer parts 
containing features with micro- and nano-dimensions including high aspect ratios 
(>10 : 1) through a combination of heat and pressure. It is commonly used to 




Because both hot embossing and injection molding use a top-down fabrication 
approach leaving open-faced microstructures, sealing the patterned thermoplastic must 
be undertaken to form the final device. Sealing strategies can employ simple 
approaches such as the use of commercially available adhesive coverslips.[83] 
However, the fluidic pressure of processing whole blood within micrometer-sized 
channels necessitates strong sealing of the coverslip to the substrate to prevent device 
failure. Thus, thermal fusion bonding has been employed due to the high tensile 
strength bonding between the substrate and coverslip it generates. Here, a thin (125 – 
500 µm) coverslip composed of the same thermoplastic as that used for the substrate is 
pressed against the patterned substrate and the pair is heated to near their glass 
transition temperature, which allows the polymer chains to rearrange, bond, and seal 
the microfluidic device with similar tensile strengths as PDMS-to-glass bonding. [34, 61, 
80, 81] 
Whichever fabrication modality is used, the polymer substrate must possess the 
following characteristics to serve as a viable substrate for fluidic devices targeted for the 
selection of CTCs: (i) Functional scaffold for the surface attachment of the affinity agent 
(antibody, peptide, aptamer); (ii) optically transparent and void of autofluorescence; and 
(iii) surfaces that show minimal amounts of non-specific adsorption of blood cells to their 
surfaces to provide high purity of the enriched CTC fractions; and (iv) biocompatible 
surfaces so as not to compromise the viability of isolated CTCs for on-chip culturing or 
drug delivery studies. Point (i) is particularly important for CTC selection modality using 




Strategies for immobilizing affinity agents to polymers are diverse amongst 
current CTC technologies but for either PDMS or thermoplastics, successful 
immobilization of the affinity agents has been demonstrated by introducing reactive 
functional groups onto the substrate. For example, PDMS surfaces use alkoxysilane 
molecules,[63, 67, 84] while thermoplastics depend on generating carboxylic acid 
moieties for amide coupling of affinity agents; the activating source for generating these 
functional scaffolds typically use UV or ozone. [61, 80, 81] [34] Furthermore, 
thermoplastic UV/ozone modifications require the thermoplastic to be sufficiently 
transparent to provide uniform modification throughout the CTC selection conduit. [81] 
 A polymer’s optical qualities also impacts the identification or enumeration 
process of the isolated CTCs via immunofluorescence.[62] PDMS’s optical transparency 
is nearly glass-like making it ideal for fluorescence visualization.[85] Both unmodified or 
UV/ozone modified PMMA and COC thermoplastics have comparable fluorescence 
backgrounds to glass, [85, 86] and thus, they are certainly compatible with 
immunofluorescence identification of CTCs. [61, 80, 81] [34] PC, however, has a much 
higher fluorescence background,[86] and following UV/ozone modification for the 
attachment of affinity agents, the polymer’s autofluorescence overwhelms CTC 
fluorescence, disqualifying it in many cases for CTC isolation and immunofluorescence 
analysis. [81]  
Lastly, the hydrophobicity of native PMMA, [87] COC, [88] and PDMS [89] lends 
to issues related to biocompatibility. But, modifications of the polymer using, for 




[81] is necessary to improve the material’s biocompatibility. In the case of PDMS, 
hydrophobic recovery can affect the surface’s biocompatibility (adherent cells were 
~98% viable after 24 h [90]), while for thermoplastics, hydrophobic recovery is not as 
pervasive, but thermal processing above the Tg of the material can enhance this 
process.[81] UV/ozone treated COC exhibited the same biocompatibility as PDMS, [90] 
but the UV/ozone treated PMMA exhibited elevated cytotoxicity (~89% viability after 24 
h [90]) due to the leaching of peroxide and oligomeric and monomeric methyl 
methacrylate by-products following the UV/ozone activation process. [81, 90]  
Further aspects of thermoplastic biocompatibility are more subtle. Firstly, if CTC 
culturing is attempted on-chip, the CTCs must be provided with an adequate supply of 
carbon dioxide and oxygen to maintain pH; [90] the gas permeability (permeability 
constants given in Table 1.1) of elastomeric PDMS is far greater than most 
thermoplastics, [91-96] thereby requiring continuous flow of fresh media to cells cultured 
within thermoplastic devices. [90] Secondly, on-chip monitoring of cellular response to 
drugs can be biased by adsorption of small, hydrophobic molecules to the polymeric 
substrate; this effect has been shown to occur in PDMS [90, 97, 98] and PMMA [90] 
(detailed values are shown in Table 1.1).  
As a final note, thermoplastics can be used for the fabrication of filters for size-
based selection of CTCs from other mononucleated blood cells. [99, 100] Commercially-
available PC filters are track-etched; [101] this process produces pores randomly 
distributed across the filter and larger, fused pores through which rare CTCs may pass. 




Table 1.1  Various polymer materials used in CTC enrichment devices 








(Brass or Nickel) 





Immobilization of  Functionalization [84] Excellent Excellent Moderate Poor/Moderate 
Affinity Agents (Method) [84] (alkoxysilane) (UV/ozone) (UV/ozone) (UV/ozone) 
Immunofluorescence Autofluorescence [85, 
86] 
Very Low Low Low Very High 
Visualization 
Biocompatibility 
Cytotoxicity [90] Excellent Excellent Moderate Excellent 
(Viability after 24 h) (98%) 98% 89% 98% 
Adsorption of 

















695 0.765 0.0653 2.96 
† 7-EC ≡ 7 ethoxycoumarin. Similar results were found for testosterone. 
‡ Permeability constant (P) units: (
      
        
).  
* References [93-96]. 
 Measurements were done at standard pressure and the temperatures were 25 °C for COC and PC and 35 °C for 




To this end, microfabrication techniques utilizing photoresists and reactive ion etching 
have been used to construct 2-D and 3-D filters with controlled pore sizes and spacing.
Three-D filters offer lower fluidic stress on filtered CTCs for the isolation of live rather 
than fixed cells. [99, 100, 104] Parylene C has also been used as a polymeric substrate 
for these filters due to its mechanical flexibility, biocompatibility, and optical 
transparency for immunofluorescence CTC enumeration. [99] 
1.2.3 Magnetic Materials for CTC Enrichment using Microfluidic Devices  
The use of magnetic particles for CTC isolation is ubiquitous largely because the 
CellSearch technology remains the only FDA approved assay for CTC enrichment and 
analysis. In this section, we will focus on several technologies that utilize magnetic 
particles and discuss how the nature of the particles affects the CTC enrichment 
process. 
Magnetic particles have been researched for over two decades, resulting in the 
commercialization of an array of products, including those catered specifically for the 
isolation of CTCs. Many other commercially available products or slight modifications 
thereof are used for CTC isolation. [105] The choice of magnetic particles for CTC 
enrichment is predicated on the requirement of only low strength magnets (such as 
inexpensive neodymium magnets generating on the order of a T) necessary to remove 
these magnetic particles and their payload from solution (achieving saturation 
magnetization in fields on the order of tens to hundreds of mT). [105-108] There are 
material properties that should be assessed when considering magnetic particles for the 




To process a blood sample using CellSearch, a pre-processed blood sample is 
dosed with a ferrofluid consisting of ~100 nm iron oxide nanoparticles [108] coated with 
a polymer to improve solubility [109] with the particles functionalized with anti-EpCAM 
antibodies. [110] After incubation, cells bound to these magnetic nanoparticles are 
isolated by applying an external magnetic field. [105, 106, 110] Rigorous evaluations of 
the CellSearch technology have shown a recovery of ~85%; [110, 111] however, the 
purity is poor (<0.01-0.1%) complicating further characterizations of the isolated CTCs. 
[112-115] Because the interaction of the nanoparticles with cells occurs by diffusion, 
shear forces are not induced that could disrupt weak, nonspecific interactions of 
contaminant cells; the use of shear forces to improve purity is a fundamental construct 
of the MagSweeper. [115, 116] 
The MagSweeper utilizes a magnetic stirring rod with a non-adherent, 25 µm 
thick plastic sheath to isolate cells that have been labeled with 4.5 µm magnetic beads 
in a similar fashion as that of CellSearch. By sweeping through a diluted blood sample 
contained in a well, the MagSweeper captures labeled cells under shear stress, thereby 
detaching nonspecifically and weakly adhering cells to achieve higher purities compared 
to CellSearch. Of 50 MCF-7 cells, a metastatic breast cancer cell line, spiked into a 
diluted blood sample, 62 ±7% were isolated with a purity of 51 ±18%. [115] A second 
generation MagSweeper device was compared directly with CellSearch for patients with 
metastatic prostate cancer. The MagSweeper exhibited similar recoveries to that of 
CellSearch, but with lower purity. [116] The lower purity may have been attributed to 




beads; [116] the authors previously iterated that antibody specificity and micro-bead 
quality was critical for assay purity because contaminating cells are generally attached 
to the magnetic beads rather than to the sheathed magnetic rod itself. [115]  
A challenge in terms of clinical utility of the MagSweeper is its incompatibility with 
whole blood. The high viscosity, cell density, and protein content of whole blood caused 
magnetic micro-beads to aggregate, precipitate, and/or prevent antibody-antigen 
complexation. [117] Thus, additional workflow was necessary to process blood samples, 
for example removal of RBCs or dilution. [68, 111, 115-117]  
For nanoparticle-based technologies, CTC isolation from whole blood has been 
demonstrated using 30 nm, iron oxide nanoparticles functionalized with amphiphilic 
polymers (providing stability in whole blood matrices) and capture antibodies. From 
unprocessed, unfractionated whole blood, cultured SK-BR3 cells were isolated with a 
73.6% recovery and 33.2% purity. [117] However, to our knowledge, clinical 
demonstrations of using magnetic nanoparticles in unprocessed whole blood have not 
been demonstrated.  
 Compared to magnetic micro-beads, iron oxide nanoparticles offer several 
advantages: (i) The nanoparticle solution is quasi-homogenous, improving the kinetics 
of cell-particle interactions; and (ii) more of the cell’s surface is reactive (by 
approximately two to three orders of magnitude) due to the nanoparticle’s enhanced 
surface area to volume ratio. [117] However, there are limitations as to the use of 
nanoparticles, many of which arise from cellular uptake of the nanoparticlesXu, Aguilar 




CTC viability, and alteration of the CTC’s molecular profile. [109, 118] Even with 
CellSearch, it has been shown that many CTCs isolated are apoptotic. [119, 120] In 
comparison, great care was taken to ensure that the MagSweeper did not induce any 
statistically significant change in the viability of the selected CTCs and had minimal 
effects on single cell transcriptomes. [116] In contrast to the free solution mixing of 
functionalized magnetic particles with their target cells, the Ephesia microchip utilizes 
magnetic micro-beads in a unique format (see Figure 1.5). A PDMS casted 
microchannel was sealed over a glass coverslip previously patterned with magnetic ink 
by micro-printing. Upon the application of a magnetic field, the magnetic inks 
concentrated the magnetic field lines vertically and 4.5 µm antibody-coated magnetic 
micro-beads self-assembled into high aspect ratio pillars that were used for CTC 
isolation. [105, 121] The Ephesia chip achieved >94% recovery with 78 – 97% purity for 
the isolation of cultured Raji (B-lymphocyte) cells mixed with different numbers of Jurkat 
(T-lymphocyte) cells (minimum ratio of 1 Raji cell to 100 Jurkat cells). Furthermore, B-
lymphocytes were isolated from blood and fine needle aspirate patient samples; good 
correlation with flow cytometry was observed for cell morphology and antigen 
expression. [105] The Ephesia chip is compatible with mass-production modalities such 
as those used for the production of thermoplastic devices and the batch 
functionalization of micro-beads simplifies the practical aspects of functionalizing 
individual devices. [105] A concern with the Ephesia chip was that it was designed for 
processing very low sample volumes (10 µL). The stability of the micro-bead pillars 





Figure 1.5 (A) Principle of magnetic self-assembly. A hexagonal array of magnetic 
ink is patterned at the bottom of a microfluidic channel. Beads coated with an 
antibody are injected in the channel. Beads are submitted to Brownian motion. The 
application of an external vertical magnetic field induces the formation of a regular 
array of bead columns localized on top of the ink dots. (B) Two levels PDMS 
integrated microchip. Channels were filled with colored water. Delivery and 
separation channels for the cells appear in yellow. Inlets ports appear in orange. 
The separation channel is the longer vertical branch. The area bearing magnetic 
posts is marked by the dotted white box. Channels in the upper PDMS layer, 
controlling the opening and closing of the inlet channels, appear in blue. The green 
wire is a thermocouple for in situ control of the temperature in the system. (Scale 
bar: 0.5 cm.) (C) Magnetically assembled array of columns of 4.5 μm beads coated 
with anti-CD19 mAb (specifically retaining Raji B-Lymphocytes). Typical column 
shapes are shown in the insets. (Scale bar: 80 μm.) (D) Optical micrograph of the 
columns after the passage of 1,000 Jurkat cells. No cell can be seen. (Scale bar: 80 
μm.) (E) After the passage of 400 Raji cells, numerous ones are captured and 
rosetted on the columns. (Scale bar: 80 μm.) (Reproduced from Saliba et.al [122] 
with permission from the Proceedings of the National Academy of Sciences of the 




3.6 µL/h. The low throughput was also partly due to the constrained size of the 
microfluidic channel (40 x 250 µm, W x D). [105] 
1.3 Biological and Physical Properties for CTC Enrichment 
CTCs possess intrinsic properties that differentiate them from hematopoietic cells, 
the major component of peripheral blood. These properties can be placed into two 
broad categories. Biological properties, which are primarily focused on tumor associated 
surface antigen expression, viability and invasion capacity while physical properties take 
into account cell size, density, electrical charges and deformability. A plethora of 
microfluidic technologies have adopted different formats that target either biological or 
physical or both properties for CTC enrichment. In the following sections, we will 
discuss microfluidic devices based on biological or physical selection and how material 
properties affect the performance of these devices. 
 
1.3.1  Microfluidics for CTC Enrichment Based on Biological Properties   
These mainly employ affinity-based assays for CTC enrichment. These assays use 
specific but non-covalent interactions between a ligand (antibody, aptamers, and 
peptide) to a tumor specific membrane protein. CTC selection involves a solid phase 
(glass, silicon, polymers) in which the recognition element is covalently tethered to the 
surface of a fluidic conduit. [39] The correct choice of a solid surface and the application 
of suitable surface chemistry that is compatible with a diverse set of proteins and at the 




Blood samples are passed through the appropriately prepared conduit to invoke the 
CTC selection process. The following strategies are considered in order to maximize 
interactions of the blood-borne CTCs and the surface immobilized ligands: (i) 
geometrical configurations of the fluidic conduit that affect the fluid dynamics; (ii) the 
nature of the surface chemistry of the solid phase; and (iii) attachment chemistry of the 
bound ligand. 
1.3.1.1  Immobilization Strategies 
Critical to a positive or negative CTC selection assay is the immobilization of a 
biologic capture element, be it a protein (antibody, Ab), aptamer, or peptide, to the 
surface of a microfluidic channel. For the enrichment of CTCs from a clinical sample, 
which have varying levels of antigenic expression, [123] it is critical that a maximum 
number of active capture elements be immobilized onto a surface. As the surface 
density of these active elements increases, so does the adhesion force (FA) of an 
isolated CTC to the capture surface as noted by equation (1): 
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where    is the cell’s contact area to the surface, kB is Boltzmann’s constant, θ is the 
absolute temperature, NR is the receptor density (the CTC’s antigen expression level), lb 
is the extent of stretch to reach before breaking the antigen/Ab association, NL is the 




adjustable fitting parameter. Increasing FA by ensuring a large NR (active capture 
element surface density) prevents a captured CTC from being removed from the 
surface by hydrodynamic shear force, especially when antigen expression of the CTC 
(NL) is low. [61, 63, 81, 124] Critical to efficient CTC capture, then, is a strategy by 
which selection elements are immobilized in high densities. Attachment of the selection 
element can use either passive adsorption or covalent attachment techniques.  
For passive adsorption, reduction of Ab activity by physisorption is well known; it 
has been shown that 90% of Abs lose their activity through this process.[125] For this 
reason, few researchers directly adsorb CTC capture elements to their surfaces. 
However, an example has been documented; adsorption of epithelial antibodies and 
selection proteins onto halloysite coated microtubes to induce CTC capture along the 
microtube surface. [126, 127] In the majority of other cases where passive adsorption 
has been employed, a scaffolding protein such as an avidin protein, [116, 128] 
biotinylated BSA (subsequently following by an avidin protein), [71] or protein G [127] 
have been passively adsorbed first. Then, either biotinylated Abs are bound to the 
avidin decorated surface via strong avidin-biotin linkages or unmodified Abs are bound 
to the surface using protein G. In the latter case, protein G binds Abs specifically to the 
Ab’s Fc region, thereby ensuring the Ab is optimally oriented with its Fab regions 
(antigen binding regions) exposed to solution for binding CTCs. This is not true for 
avidin linkages, because biotinylation may occur with any reactive residue present in the 
Ab (i.e., on the Fc or Fab regions); [129] this results in a surface of Abs with non-




of CTC capture (effective reduction of NR in Eq. (1)). [130] Considering the costs of 
avidin proteins and protein G (as well as the analogous protein A) are comparable and 
the benefits of controlled Ab orientation are well established for bioassays in general, 
[131] the use of protein G in place of an avidin moiety is wise due to a higher 
percentage of effectively active Abs. In either case, the passive adsorption of biologic 
CTC recognition elements is attractive due to simplicity (no additional linkers or coupling 
agents are required).  
For the covalent attachment of Ab to selection surfaces, functional scaffolds must 
first be generated to which the Abs may be coupled via covalent bonds, typically 
involving primary amine groups present within the Fc or Fab regions of the Abs. For 
glass/PDMS substrates, the use of 3-mercaptopropyltrimethoxysilane (MPTMS) is 
commonly used to generate sulfhydryl surface groups after which a sulfhydryl-amine 
crosslinker, (N-(γ-maleimidobutyryloxy) succinimide ester, GMBS), is employed. [63, 67, 
73, 132] The succinimide ester of GMBS permits covalent amide linkages to lysine 
and/or arginine (primary amine) residues on the Abs. [84] The use of MPTMS and 
GMBS on glass/PDMS substrates has exclusively been used to immobilize neutravidin 
for subsequent introduction of biotinylated Abs. [63, 67, 73, 132] Alternatively, 
researchers utilizing magnetic nanoparticles coated with a polymer containing 
carboxylic acid moieties have directly immobilized peptides and Abs via the succinimide 
ester (generated via the ubiquitous 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
(EDC) and N-hydroxysuccinimide (NHS) crosslinking reagents) rather than proceed 




does not guarantee Ab orientation and adds several steps to the workflow and cost by 
the use of additional reagents, direct tethering between surface-confined carboxylic acid 
groups and Abs is an attractive approach.  
Myung, et al. used EDC and NHS crosslinking to activate carboxylated PAMAM 
dendrimers (7th generation), which were immobilized on a PEGylated surface and 
immediately reacted them with epithelial antibodies. These dendrimers served two 
purposes: (i) To increase the surface’s antibody load by multivalency per unit surface 
area; and (ii) to decrease the antibody/antigen dissociation constant (by six orders of 
magnitude), again by multivalent cell adhesion. However, the capture efficiency 
enhancements observed under flow were modest, 1.5 to 2.2 fold improvements 
compared to a PEGylated surface only. [134] However, a 1.1 to 1.7 fold improvement 
for the PEGylated surface relative to a bare surface, where the antibodies were 
covalently attached to an epoxy modified surface, was observed. [134]  
The use of PEG monolayers is well known in bioassays as they reduce 
nonspecific adsorption artifacts (enhancing the purity of isolated CTCs) and protein 
denaturation (retaining capture antibody activity) by entropic resistance to PEG-protein 
interactions. [104, 131] But, PEG coatings [133, 135] as well as polymeric linkers [136] 
or amphiphilic triblock polymers, [117] can improve solubility of inorganic nanoparticles 
permitting functionalization of the nanoparticles for targeting CTCs and increasing in 
vivo circulation time. [104, 137-139]  
It is also possible to directly and covalently tether CTC selection Abs (or 




into thermoplastics. Here, thermoplastic-based microfluidic devices for the analysis of 
CTCs must contain surface-confined carboxylic acids for EDC/NHS coupling of the 
selection Ab to the microchannel wall. The generation of carboxylic acids by UV/ozone 
treatment in three different thermoplastics has been reported (PMMA, PC and COC). 
[140] For this process, the polymer’s optical transparency to the 254 nm activating light 
was critical for high density carboxylic acid generation throughout the microchannel’s 
depth; PMMA’s absorption of the modifying radiation decreased carboxylic acid 
generation, especially in microchannels possessing high aspect ratios. COC’s superior 
optical transmissivity permitted higher carboxylic acid surface yields, and this was 
shown to directly impact CTC selection from whole blood in terms of both efficiency and 
purity (see Figure 1.6). [81] 
Lastly, we address the use of aptamers for CTC selection and their attachment to 
microfluidic device channels. In one case, an RNA aptamer with a pendant amino group 
on its 5’ end was immobilized to a PMMA surface in the same manner as an antibody, 
utilizing EDC and NHS coupling agents for covalent attachment. In another aptamer 
immobilization strategy, the researchers employed a biotinylated primer sequence 
bound to the surface via passively adsorbed avidin that annealed a circular DNA 














Then, they enzymatically polymerized the DNA template by rolling circle 
amplification creating long (on the order of 0.1 to 100 µm in length), repetitive patterns 
of CTC-binding aptamers extending into solution. [74] While the avidin layer is arguably 
unnecessary in this design, the utilization of rolling circle amplification to construct or 
rather extend, a pre-immobilized aptamer was a unique strategy that can be applied to 
essentially any microfluidic geometry. 
Figure 1.6 Box plots presenting count of CTCs and WBCs selected in UV-
PMMA (5 PDX (Patient Derived Xenograft models)) and UV-COC (4 PDX) chip 
from mice blood samples. Data are normalized to 1 mL. Lower and upper 
edges of box show 25th and 75th percentiles, respectively. Solid line in box 
represents median, and solid diamond represents mean. Error bars show 
maximum and minimum values. (Reproduced from Jackson et al. [30] with 




1.3.1.2 Geometrical Configurations for Biological Property CTC 
Selection 
 
Various geometrical configurations have been adapted using microfluidics with 
positive selection of CTCs to induce particle displacement in laminar flow, which is 
characteristic in micro-dimensions due to low Reynolds numbers. [141] The main 
objective is to increase the encounter rates between CTCs and the solid phase onto 
which the target ligands are attached. In one microfluidic rendition, 78,000 
functionalized microposts covering an area of 970 mm2 whose size, spacing and 
arrangement were optimized to yield non-linear flow streams and low shear forces. A 50 
µm vertical periodic shift was applied every 3rd micropost row to change the trajectory of 
the CTC to enhance the collision probability between CTCs and the posts. An 
equilateral micropost array arrangement was the best configuration that resulted in the 
highest hydrodynamic recovery (65%) for CTCs irrespective of their EpCAM expression 
level. This device was used in clinical studies for lung, breast, prostate, pancreatic and 
colon cancer. [31]  
This CTC chip later adopted a staggered herringbone (Hb) mixer format (see Figure 
1.7).[72] The Hb CTC chip consisted of 8 herringbone channels with a channel height of 
50 µm and groove height of 45 µm.  Chaotic flow was induced by the variation of the 
shape of the grooves as a function of the axial position of the channels. The Hb chip 
was found to be more efficient than its predecessor (CTC chip) in terms of throughput 
(from 1 mL/h to 4.8 mL/h), which resulted in a decreased processing time. Recovery 




also observed. [32] The Hb CTC chip has since then been used for various clinical 
studies. [32]  
 
 
Kirby and coworkers adopted a similar approach to Toner groups first CTC chip 
where they developed a micropost array in a device consisting of 5000 circular of 
hexagonal or circular posts (100µm tall and 80µm in diameter) centered in an 8 mm by 
25 mm channel (see Figure 1.8).  In the geometrical enhanced immunocapture device 
Figure 1.7 (A) The HB-Chip consists of a microfluidic array of channels with a single 
inlet and exit. Inset illustrates the uniform blood flow through the device. (B) Cartoon 
illustrating the cell-surface interactions in the HB-Chip, and (C) a traditional flat-walled 
microfluidic device. (D) Micrograph of spiked cancer cells captured on the HB-Chip, 
representative of capture cell viability (LIVE/DEAD). (Scale bar: 40 μm). (E) Micrograph 
of spiked cells captured on the herringbone chip and subsequently cultured on the 
device for 21 d. (F) On-chip FISH of captured LNCaP cells with nuclei stained with 
DAPI, CEPX (green) and AR gene locus (red). (G) Micrograph of a fluorescently labeled 
PC3 cell captured on the HB-Chip (top) and subsequent micrograph taken of the same 
cell stained with H and E. (Scale bar: 10 μm).  (Reproduced from Stott et al. [32] with 





(GEDI) the posts were arranged in way to create size dependent trajectories while 
creating maximum streamline distortions. The arrangement ensured the reduced 
capture of contaminating leukocytes by achieving a purity of 68% for LNCaP prostate 
cells spiked in blood and 62% for PCTCs from patient samples. 
The High Throughput Microsampling Unit (HTMSU) developed by Adams and 
coworkers adopted sinusoidal parallel channels. In this format travelling CTCs were 
propelled to the outer edges of the selection channel walls using curved channels due 
to cross stream velocities and centrifugal forces acting on the wall. A total of 51 
channels were deployed to increase the throughput and using a 2 mm/s volumetric 
linear velocity, selected to optimize CTC recovery, ~37 min was required to process 1 
mL of whole blood.  Recoveries of 97% were reported for MCF7 cells spiked into rabbit 
blood.  
The same group modified the HTMSU to adopt a z-configuration of sinusoidal 
microchannels to provide a higher number of channels (320) for higher throughput 
processing (7.5 mL of whole blood processed in <20 min).[34] Using this design (see 
Figure 1.9), the group demonstrated that high purity CTC fractions was achievable for 
devices made from COC (98%) with recoveries >90% for MCF-7 CTC surrogates was 
shown. In addition, findings based on computational simulations on the fluid dynamics 
revealed that higher shear forces 13.3 dyn/cm2 were obtainable for blood in the 
sinusoidal channels than posts (0.4 dyn/cm2) or herringbone structured channels, which 
was adequate to release loosely bound leukocytes.[30] The CTC selection device could 




following release from the capture surface and finally, the released CTCs shuttled to a 
staining and imaging device where the CTCs could be enumerated and phenotyped. 
(see Figure 1.9). 
 
 
Using this system, whole blood from locally resectable and metastatic pancreatic 
ductal adenoma carcinoma (PDAC) patients were analyzed. Using the CellSearch 
technology, metastatic PDAC patients typically yield 0-1 CTC per 7.5 mL of whole 
blood.[11, 142] Using this device and system, the authors demonstrated selection of 
EpCAM positive CTCs from PDAC patients in high purity (>86%) and with excellent 
yields (mean = 53 CTCs per mL for metastatic PDAC patients). In addition, they 
Figure 1.8 (A) GEDI microfluidic device design and (B) Image of silicon device with 
silicon gasket. (C) Top view of microfluidic obstacle array with array geometric 
parameters. ∆ = obstacle offset.  = obstacle spacing in the direction of bulk flow.  = 
obstacle spacing in the direction orthogonal to bulk flow. 2r = obstacle diameter. 
Streamlines (gray) denote fluid flow. Path lines (various colors) denote trajectories of 
cells of different diameters. Obstacle array spacing and orientation parameters are 
also defined.  (D) The rate of cell-wall collisions for cells traveling through the array is 
a strong function of the offset parameter of the array; the GEDI design methodology 
implies use of an offset parameter that leads to size-dependent collision rates. The 
results predicted for the flow through the geometry at left are shown at right by the 
solid line; the four specific cell sizes lead to results denoted by the four colored dots 
on this graph. Other geometric arrangements lead to different results, shown at right 
in the dotted and dashed lines. (E) Devices with the same surface area to volume 
ratio give vastly different results: straight arrays lead to collisions that decrease as 
the blood travels through the device; GEDI arrays lead to collisions that increase with 





demonstrated the ability to detect CTCs in PDAC patients with locally resectable 
disease (mean = 11 CTCs per mL). [34] 
 
Figure 1.9 (A) Schematic operation of the HT-CTC module with 50 parallel, 
sinusoidal microchannels and inlet/outlet channels arranged in the z-configuration. The 
large arrow indicates sample flow direction through the selection channels. (B) SEM of 
the selection bed showing high aspect ratio sinusoidal microchannels and the output 
channel (top). (C) SEM of one of the high aspect ratio sinusoidal channels. (D) Fluid 
dynamics simulation results showing the distribution of flow velocities and shear stress 
in microfluidic selection channels. (E) Box plot from CTCs isolated from 7 metastatic 
PDAC patients, 5 healthy donors, and 5 local resectable PDAC patients. Reproduced 
from Kamande et al. [34] with permission 
 
In all these cases, the geometry adapted for the CTC enrichment device plays a 
critical role in shaping the fluid dynamics within the device. The linear velocity and the 




purity. Recovery is maximized when shear rate is low in order to reduce the shear 
forces acting on the captured cells thus maintaining their viability as demonstrated by 
Nagrath and coworkers. [31] However this is at the expense of purity because low shear 
forces may not remove nonspecifically bound contaminating cells. A summary of the 
clinical performance metrics and comparisons to CellSearchTM technology, of the above 
mentioned devices in this section has been listed in Table 1.2. 
1.3.1.3 Nature of the Solid Phase Surface 
Various materials and surface textures have been applied by groups to enhance 
recovery of CTCs based on their external morphological characteristics. One approach 
is to mimic the nano-scale topography of the extra-cellular matrix (ECM) onto which 
epithelial tumor cells are firmly held. [143, 144] The ECM proteins located on the 
surface of the basement membrane contribute to the nanotextured surface which aid in 
cell anchorage and proliferation. [145-147] Results indicate significantly improved CTC 
recoveries from nanotextured surfaces in comparison to smooth surfaces. This occurs 
through the morphological differences seen on tumor cells, which possess filopodia and 
microvilli containing selection antigens.    
A nanotextured surface with silicon nanopillars (SiNP) coated with antibodies 
targeting EpCAM on CTCs has been reported. [69, 132, 148-151] The goal was to 
enhance local topographical interactions along with specific bioaffinity targets to 
increase the recovery for CTCs with filopodia and microvilli extensions. In an example 
using Si nanopillars, [69] the dimensions of the nanopillars were 100-200 nm in 





800 mm in length by 1 mm width. Fishbone structures were later incorporated into the 
serpentine channel in order to induce chaotic mixing to enhance recovery. [132] Results 
indicated a recovery of 4-14% on a flat Si substrate and 45-65% recovery for MCF-7 
cells using the nanostructured Si substrate. [69] Although an increased recovery was 
demonstrated by the incorporation of nanostructures, the abili ty to release the captured 
CTCs was only about 10% with a poor viability using the nanopillars format. Later, the 
authors utilized a thermoresponsive polymer, (poly (N-isopropyl acrylamide), PIPAAM, 
covalently grafted onto the SiNW substrate (P-SiNW). The P-SiNW was functionalized 
with anti-EpCAM for CTC capture. At 37˚C, the biotinylated anti-EpCAM Abs on the P-
SiNW were exposed on the nano-substrate surface for CTC contact. However, when 
the temperatures was reduced to 4˚C, conformational changes on the polymer 
backbone led to the internalization of anti-EpCAM Abs within the polymer backbone 
resulting in release of the CTCs.  Results indicated recoveries of ~70% and a release 
efficiency of 90% with a viability of 90%. [148]  
As an alternative to vertically aligned silicon nanopillars, horizontally oriented 
inorganic TiO2 nanofibers were demonstrated for CTC selection, which also consisted of 
anti-EpCAM antibodies grafted onto the nanofibers. [151] Several advantages of using 
this material were noted: i) The horizontal orientation was more representative of the 
nanostructures embedded in the ECM matrix leading to improved cell-to-substrate 
affinity; ii) more precise control over the packing density of the TiO2 nanofibers (TiNF) 
using electrospining (see Figure 1.10); and iii) flexibi lity in the choice of material that 




to TiO2). The authors demonstrated that the horizontal fibers were more sensitive and 
specific to EpCAM expressing cells. The CTC recovery was also found to be highly 
dependent on electrospining time; greater than 60 min electrospining time resulted in 
maximum recoveries. [151]   
A second generation device was designed to facilitate single CTC molecular 
analysis by the incorporation laser microdisection (LMD) to the platform, thus 
eliminating the concern of contaminating leukocytes affecting the analysis. The 
substrate consisted of a transparent LMD slide onto which poly(lactic-co-glycolic acid), 
PLGA, nanofibers were electrospun. These fibers were functionalized with a melanoma-
specific antibody (CD146) for the isolation of circulating melanoma cells (CMCs). The 
LMD microscope was used to cut out and harvest a positively identified CMC for further 
molecular analyses. Results indicated 87% recovery for the M229 cell line seeded into a 
cell culture medium at a flow rate of 0.5 ml hr-1. Molecular analysis from single CMCs 
isolated using the device from 2 patient samples successfully found BRAFV600E 
mutations using Sanger sequencing with results consistent with the patient’s tumor 
biopsy. [149] 
Nano-textured PDMS substrates for CTC isolation was also demonstrated to 
yield higher recoveries in comparison to glass and smooth PDMS substrates. [152] In 
this study, a 3D nanotextured PDMS substrate was prepared by casting PDMS over a 
nano-textured surface, such as NaOH-treated poly (D, L-lactide-co-glycolide), PLGA 
polymer. Aptamers against EGFR were immobilized onto the nano-textured PDMS 




isolation.  Findings from this study found an increase in probe density on the nano-
textured PDMS surface compared to a planar glass or PDMS substrates without the 
nano-texturing. However a decrease in specificity was observed when a mixture of 
fibroblasts and hGBM cells were sampled. [152] 
 
 
Recently, nanoporous posts instead of solid posts were found to increase the 
recovery of CTCs by increasing the interception efficiency (the fraction of particles in 
flow intercepted by a collector) and the association strength between the particles and 
affinity-agent decorated surface. The use of highly porous vertically aligned carbon 
nanotubes (VACNT) allowed fluid streamlines to pass through the posts bringing cells 
into direct contact with the posts, thus resolving the no-slip boundary condition observed 
at the liquid-to-solid post interphase. Secondly, the highly porous surface reduced 
  
Figure 1.10  Schematic of the horizontally packed TiNFs for improved CTC capture 
through combining cell-capture-agent (i.e., Anti-EpCAM) and cancer cell-preferred 




hydrodynamic resistance observed for solid posts. As a result, higher recoveries for 
PC3 cells (0.8%) within the first row of nanoporous posts was observed compared to 
solid posts (0.2%). [153]  
In a similar manner, Hughes and coworkers used halloysite nanotubes (300 nm 
diameter) along with a bimolecular surface of E-selectin to promote CTC rolling for 
EpCAM specific CTC capture in a microfluidic device. [127] The halloysite tube led to 
increased roughness that extended into the flow channel thereby increasing contact 
with CTCs. Increased purity of CTC fractions were observed due to less leukocyte 
spreading on the nanotube-coated surface compared to a smooth surface. 
Consequently, a recovery of 50% was obtained with purities of 18-80% for clinical 
samples of breast, prostate, lung and ovarian cancers.  
1.3.1.4 Negative Enrichment 
Negative enrichment of CTCs utilizes leukocyte-specific markers, such CD45, for 
the depletion of these cell types from whole blood leaving an unbiased population of 
CTCs following erythrocyte removal. Further, the EMT hypothesis suggests that down-
regulation of epithelial markers, such as EpCAM, is more apparent in circulation where 
CTCs take on mesenchymal characteristics; as such, not all CTCs express EpCAM. 
[24] Therefore, the reliance on EpCAM solely for the capture of CTCs in most 
technologies may exclude sub-populations of CTCs with different phenotypes lacking 
epithelial markers. [154-156] A common strategy used by various reports incorporates 
RBC lysis or density gradient centrifugation[157] followed by CD45 leukocyte depletion 




particles into the sample. [158] [159] The enriched sample is subsequently analyzed 
using confocal imaging, [160] flow cytometry [51] or molecular analyses, such as the 
use of RT-PCR for EGFR expression. [156, 160, 161] 
Few reports on microdevices have documented the use of CTC negative 
enrichment. Hyun and coworkers reported on a herringbone device termed the 
geometrically activated surface interaction device (GASI). [162] This device consisted of 
a PDMS-glass hybrid substrate with channels coated with CD45 antibodies for 
leukocyte capture with the CTCs collected in the effluent. The device was found to 
generate a capture efficiency <88% for leukocytes at a cell population of 106-107 
cells/ml. GASI is an enhanced version of the original device with altered channel 
dimensions such as increased apex dimensions, which resulted in 98.94% leukocyte 
capture efficiency. Demonstrations on using GASI for CTC isolation from clinical 
samples was reported for breast, lung and gastric cancers.  
Chen et al. reported a disk-based microfluidic platform capable of isolating CTCs 
via negative immunomagnetic separation. [163] Here, non-magnetically labeled MCF7 
cells were used as model CTCs while magnetically labeled Jurkat cells or MNCs 
(mononucleated cells) from blood were used as non-target cells. The device included a 
multistage magnet configuration and double trapping region to enhance depletion 
efficiency of non-target cells (~99%) while enhancing the collection of MCF7s (recovery 
~60%).  
One of the drawbacks to negative selection is the comparatively low purity of 




improved the purity of CTCs by integrating optical-induced dielectrophoretic (ODEP) 
force, which is based on cell manipulation for a laminar flow microfluidic system. CTCs 
were further separated from leukocytes into two flow streams based on cell size and 
electrical properties after conventional negative enrichment. The device consisted of a 
multilayer layered structure consisting of PDMS, indium tin oxide coated glass, adhesive 
tape with microfabricated channels and a lower ITO glass substrate coated with 
photoconductive material for ODEP manipulations. Purities of 74-82% and 64-66% were 
obtained for PC3 and OECM-1 cells, respectively. [150]  
Advantages of negative enrichment are that they do not rely on the speci fic 
phenotype of tumor cells for CTC enrichment. Thus, other rare cells can be enriched as 
well such as, circulating endothelial cells (CECs), cancer stem cells (CSCs), circulating 
progenitor cells (CPCs), and nucleated red blood cells (nRBC). Moreover, CTCs remain 
intact without any alteration and are available for downstream processing. However, the 
challenges are the relatively poor purities attained as well as the low CTC yields. Pre-
processing steps such as erythrocyte lysis and centrifugation may also contribute to low 
CTC yields. 
Materials that have been utilized in the above mentioned devices are similar to 
devices used for positive enrichment, such as PDMS, whose material properties are 
well suited for bio-affinity selection of CD45 expressing cells. A magnetic disk was 
utilized for the separation of magnetically-labeled leukocytes from unlabeled CTCs and 
finally, the ODEP integrated to a PDMS microfluidic platform consisted of ITO glass with 




1.3.1.5 Miscellaneous Microfluidic Devices for Positive or Negative 
Selection of CTCs 
 
Issadore and coworkers developed a µHall (micro-Hall) device for the detection 
of immunomagnetically functionalized CTCs from ovarian cancer patients. The µHall 
detector consisted of an array of 8 micro hall sensors that were able to sense the 
characteristic magnetic moments of cells in flow that had been immunolabeled with 
magnetic nanoparticles (MNPs). The signals generated depended upon the quantity of 
MNPs bound to the cells, which in turn were directly proportional to their targeted tumor 
marker expression level such as EpCAM, Her2/Neu, EGFR and Mucin1 (MUC1). Thus, 
CTCs with a high expression of these markers could be distinguished from leukocytes 
with low expressing tumor markers. The array was enclosed in PDMS with a chevron 
structured channel to facilitate hydrodynamic focusing of the cells over the hall sensors. 
A comparative study of 20 ovarian patient samples between the µHall detector and 
CellSearchTM indicated a high diagnostic accuracy rate of 96% for the µHall detector 
compared to 15% for CellSearch. The µHall device was fabricated from relatively low 
cost hall sensors adapted from the semiconductor industry and herringbone channels 
on the PDMS material. [164] 
CTC-iChip (inertial focusing Chip) is an integrated microfluidic platform that was 
recently developed by Ozkumur and coworkers that could be configured for either 
positive (posCTC-iChip) or negative enrichment (negCTC-iChip). [165] It was designed to 
integrate 3 sorting techniques in a single device. Briefly, the first section was the 




second section consisted of the alignment of nucleated cells within a single microfluidic 
channel using inertial focusing and finally, the third section was based on the 
displacement of magnetically labeled cells in a collection channel. The device could 
process large volumes of blood at a reasonable rate (8 mL/h). posCTC-iChip recovery 
rates for high EpCAM expressing SKBR3 cells was 98% while low EpCAM expressing 
MDA-MB231 was 78% with a sample purity of 0.2 to 43%.  For negCTC-iChip, the 
average depletion rate of white blood cells (WBCs) was 32,000 WBCs/mL with a 
recovery of 97% for mesenchymal expressing MCF10A-LBX1 cells.  Also the posCTC-
iChip was found to be more sensitive for CTC capture than CellSearchTM for patients 
that had low disease burden. 
1.3.2 Microfluidics for CTC Enrichment Based on Physical Properties 
 Physical-based assays are able to discriminate CTCs from hematopoietic cells 
on the basis of size, density, electric charges, or deformability. CTC diameters range 
from 10 µm to 30 µm while hematopoietic cells are typically below 8 µm in diameter. 
Reports on size-based separation devices have employed a number of strategies, such 
as microfabricated filter pores, traps and slots for the entrapment of CTCs from whole 
blood. [49, 50, 52, 68, 100, 166-168] A number of reviews have adequately discussed 
physical CTC enrichment devices. [38, 43, 169, 170] Table 1.2 lists some of these 
devices and shows their performance metrics for sample processing as well as 
compares their clinical metrics with the current FDA approve CellSearchTM technology.  
These devices achieve higher throughputs than biological enrichment microdevices 




the expense of purity values which are considerably much lower than biological 
enrichment microdevices (see Table 1.2).     
2.1.3.1 Dielectrophoretic Microdevices for CTC Enrichment  
There have been a number of reports on the enrichment of CTCs using 
dielectrophoretic separation. Dielectrophoresis is based on the inherent differences in 
the dielectric properties of CTCs from normal hematopoietic cells, which is dictated by 
their physical and electrical properties such as morphology, bilipid membrane 
characteristics, internal structure, cytosolic constitution, and nucleus size. [171, 172] 
Dielectrophoretic separations is based upon two dissimilar neutral particle populations 
subjected to non-uniform electric fields, which induce differences in translational motion 
and/or reorientation of the particles due to their dielectric properties. [173, 174] 
Within certain frequency ranges, cells tend to move in the direction of increasing 
electric field (towards the electrode); this is termed positive DEP while the converse is 
negative DEP. The DEP crossover frequency is the frequency at which the DEP force 
makes the transition from negative to a positive force and is dependent of the cell and 
medium conductivity and permittivity. [175],[176],[172] CTCs are attracted by positive 
DEP forces while blood cells remain levitated by negative DEP forces resulting in the 
separation of these two cell populations in a hydrodynamic flow. It has been 
documented that the mean crossover frequencies for breast, lung and ovarian cancer 
cells are low, 30-40 kHz compared to 90-140 kHz for the majority of peripheral blood 
cells. This difference forms the basis of CTC separation from the bulk of the blood cell 




positive DEP force while peripheral blood cells remain in the bulk fluid resulting in 
separation. The DEP force is given by; 
   F = 2πr3    Re [K] ∇ E
2                            (2) 
where    is the absolute permittivity of the suspending medium, ∇ E is the local electric 
field (rms) intensity, Re [K] is the real part of the dipolar Clausius-Mossotti factor and 
determines the sign of the force (positive or negative) being defined as: 
   K = 
  
    
 
  
     
        
 
 
                                        (3) 
where   
  and   
  are the complex permittivity of the particle and medium, respectively. 
The complex permittivity for a dielectric material can be described by its permittivity   
and conductivity    where   is the angle frequency of the applied electric field E. [177] 
DEP force is strongly dependent on the volume of the particle and the gradient of the 
electric field. [178]  Devices for CTC separation have been documented using different 
formats, such as electrode affinity columns, [172, 179-182] DEP-field flow fractionation 
devices, [176, 183-185] 3D asymmetric devices with continuous variation in electric 
responses [186, 187] and DEP devices with planar electrode configurations. [188, 189] 
We shall briefly highlight a few examples. Gupta and coworkers recently reported a 
device that is now commercially available, called the ApoStreamTM device, which is 
based on DEP-FFF (field flow fractionation). DEP-FFF uses the effect of viscous flow of 
liquid near a surface and the application of a force field that will place different particles 
at different heights from the surface. Particles will travel at different speeds according to 




the same time and point, they will exit the device at different times according to their 
heights above the surface and their reaction to the imposed field. [190] DEP-FFF uses a 
continuous flow mode rather than a batch processing configuration resulting in high 
throughput processing. The device consisted of a flow chamber with the floor containing 
a polyimide film sheet with electroplated copper and gold electrodes while acrylic sheets 
formed the ceiling of the chamber and a gasket formed the side walls. Here, high 
EpCAM expressing ovarian cancer model cells SKOV3 as well as low EpCAM 
expressing model breast cancer cells, MDAMB-231 spiked into PBMCs were 
continuously introduced at a low flow rate. Upon application of an AC electric field to the 
flow chamber, the CTCs were separated from the PBMC fraction. CTC recoveries as 
high as 75% and reduction efficiencies of the PBMCs of ~99% were obtained. Viability 
of CTCs obtained was as high as 98%. [191] 
DEP devices have been used in combination with other techniques in order to attain 
higher purities of CTC fractions. Moon and coworkers combined multi -orifice flow 
fractionation along with DEP for the isolation of MCF7 model breast cancer cells from 
RBCs and WBCs.  MOFF involves microparticles that are moved laterally by 





Extent of lateral movement varies according to particle size. Although this method 
has a throughput of 300 µL/min, the reduction efficiencies of both RBCs and WBCs 
were 88% and 61%, respectively.  Addition of a DEP module with electrodes consisting 
of gold and chromium sputtered onto glass and sealed with PDMS resulted in a 162-fold 





Figure 1.11 APO Cell device (A) Schematic of the top view of the flow chamber 
showing sample injection and sample collection port locations. (B) Still image 
from video demonstrating the flow and collection of fluorescently labeled SKOV3 
cancer cells through the collection port in the ApoStream flow chamber. Cancer 
cells are collected into the collection port when the DEP field is activated. (C) 
Still image from video demonstrating the flow of fluorescently labeled PBMCs 
through ApoStream flow chamber. The first half of the video (10 s) demonstrates 
that most PBMCs fall into the collection port when the DEP field is not active. 






RBC and WBCs fractions, respectively. In this report both high processing speeds and 
high purities were attained through the integration of these two techniques. [53]  
Materials used for DEP CTC enrichment devices are mainly selected to be 
compatible with biological-based separations. Joule heating is one of the major factors 
affecting DEP separations. In order to lower thermal heating in DEP devices, the 
application of 3D silicon electrodes instead of planar electrodes has been shown to 
maintain suitable temperatures for cell manipulations even as the voltage increases. 
[192] For optical DEP cell manipulations, Indium Titanium Oxide (ITO) over glass has 
been used as an alternative to gold or platinum electrodes due its transparency. [150]  
Recently a nanodetector referred to as the Gilupi device was designed for the in 
vivo detection and collection of CTCs. It has been made commercially available by 
GILUPI GmbH medical technology company. The device consists of an anti-EpCAM 
biofunctionalized structured medical seldinger guidewire wire (FSMW) that can be 
inserted into the vein of a patient’s arm by the use of a 20 gauge needle (see Figure 
1.12). The needle is a stainless steel wire coated with a gold layer and an anti-EpCAM 
functionalized hydrogel. It is inserted into the arm for a total of 30 min and over that time 
period, 1500 mL of blood is sampled allowing the potential for the capture of large 
numbers of CTCs. This device has been used in patients with breast, lung and prostate 
cancer and has successfully identified CTCs in 80% of these patients. Material 
considerations were mainly devoted to minimizing in vivo cytotoxity. FSMW was 




human dermal fibroblasts (NHDF) after contact. It was found that FSMW gave the 














The application of functional assays can be used as a means for the detection of 
viable CTCs. Epispot (epithelial immunospot) assay is based on the secretion of specific 
marker proteins. Nitrocellulose membranes are coated with an antibody against a 
specific protein marker. Cells are seeded and cultured for 48 h during which time 
secretion of proteins are directly captured on the plate. Cells are then washed off and 
fluorescently labeled secondary antibodies are then added. Immunospots are then 
detected via video camera imaging, which signifies the presence of viable cells. CK19 
and MUC1 have been used for breast cancer CTC detection while prostate specific 
antigen (PSA) was used for prostatic CTC detection for clinical trials. Findings indicated 
Figure 1.12 Outline of the Gilupi nanodetector (A) Section of the guidewire which 
remains inside the puncture cannula (B) 20 mm long gold coated tip of the stainless 
steel guidewire which is in direct contact with the blood circulation and biofunctionalized 





90% of breast cancer patients secreted MUC1 marker, 54% secreted CK19 while 83.3% 
of prostate cancer patients secreted PSA.[45]   
Similarly, the collagen adhesion matrix (CAM) technology has the ability to enrich 
CTCs based on their avidity to invade the CAM. [196] This assay targets more 
aggressive and invasive phenotypes of CTCs, which are capable of ingesting CAM. 
Mononucleated cell fractions from patient blood were placed in fluorescently labeled 
CAM coated 16-well chamber slides distributed by Vitatex Inc. and cultured with cancer 
cell culture (CCC) media. Studies on breast cancer patients revealed that enriched 
CTCs using this assay had distinct populations and were capable of propagation. 
Results indicated a CTC recovery rate of 54%, assay purity range of 0.5 - 35%  and a 
100 assay positivity rate. [197] 
AdnaTest is a molecular-based assay that selects CTCs via immunomagnetic 
enrichment after which gene expression profiling is performed using a multiplex RT-
PCR to evaluate tumor associated transcripts such as HER2, MUC-1n and GA773-2 for 
breast cancer specifically. This method boasts higher sensitivity compared to 
CellSearchTM with about 2 CTCs per 1 ml of blood.[26] CTCs  were detected in 69% of 
breast cancer patients and their expression profiles shown to be heterogeneous. [198] 
1.4   Beyond Enumeration of CTCs 
1.4.1 Phenotypic Characterization of CTCs  
 CellSearchTM, which is the only FDA approved technology for the isolation of 




phenotype CTCs: 1) EpCAM, which is usually used as the selection target; 2) 
cytoplasmic cytokeratins (8, 18, 19); 3) nuclear component confirmed by DAPI or 
Hoechst staining; and 4) CD45 as a negative indicator (indicative of leukocyte). Events 
are scored as CTCs if they stain positive with DAPI and cytokeratins, but negative for 
CD45. In addition, CTCs tend to have a larger nucleus to cytoplasmic ratio than 
leukocytes. Optical and fluorescence imaging is usually used to identify the phenotype 
of CTCs. [199] As a result CTCs enriched from blood using microfluidic devices typically 
follow the same labeling protocol for establishing CTC phenotypes. [30-32, 34, 57] 
However, studies on the EMT hypothesis suggests that CTCs are heterogeneous 
with mesenchymal as well as epithelial characteristics. [200] [201] Moreover, recent 
reports on CTC enrichment using the Herringbone device among others, identified cells 
that stained positive for both epithelial (CK 8, 18, 19) and CD45 markers. [32] [34] 
These cells could also be considered as artifacts in the device or nonviable cells that 
may nonspecifically absorb the staining markers.  
Studies also indicate a down regulation of EpCAM expression for metastatic 
cases thus technologies that use EpCAM as a selection target may miss CTCs with 
absent or low expressing epithelial antigens. Recent CTC enrichment devices are using 
different strategies such as negative enrichment [71, 163, 202] or the use of both 
epithelial and mesenchymal antibodies to select both CTC types. [33] As a result, 
increased CTC recoveries have been observed.[33] However, the use of multiple 
selection markers decreases the specificity of cells captured and thus the sample purity 




The process of CTC phenotype identification also requires the use of fixatives 
and permeabilization agents that can render the cells unusable for downstream 
analysis, such as propagation or genomic profiling. Due to the lack of consensus in CTC 
phenotyping, additional identification criteria such as CTC molecular analysis for gene 
expression or mutation analysis should be used as well.  
1.4.2 Genotype Characterization of CTCs selected by Microfluidics 
Cancers typically result from the disruption of cell signaling pathways that lead to 
the alteration of genes. This in turn leads to the formation of cells with uncontrolled 
growth patterns compared to normal cells. [41, 203, 204] Gene expression profiling is a 
genomic technique used to investigate genes encoded in the genome of cells. These 
genes are transcribed into mRNA, which dictates protein synthesis in a cell.  Gene 
expression is a major determinant of the behavior of both normal and malignant cells. 
Studies have shown that gene expression profiling can been used to predict clinical 
outcomes of breast, prostate and colorectal cancer patients. [205-210] It has also been 
used to predict the therapeutic response for drugs against cancer, such as docetaxel in 
breast cancer. [211] CTCs are also good candidates for tumor biology studies. Their 
molecular characterization may give insight to aberrant pathways, such as TGF-β 
signaling, Wnt signaling, and EMT markers associated with tumor development and 
progression. In addition they may be used to investigate drug targeting markers and 
cancer stem cell markers. Various techniques can be used for gene expression profiling 
such as reverse transcriptase polymerase chain reaction (RT-PCR), cDNA microarrays 




 Due to the higher purity many times obtained through the use CTC microfluidic 
devices compared to CellSearchTM, molecular characterization studies are feasible. The 
capacity to isolate concentrated, viable CTCs makes the microfluidic devices for CTC 
enrichment ideal tools for molecular access to rare CTC subpopulations such as 
metastatic precursor cells or cancer stem cells. To highlight a few examples, the PSA 
gene marker KLK3 was found expressed in CTCs isolated from metastatic prostate 
cancer patients as well as the TTF-1 (thyroid transcription factor-1) from pulmonary 
adenocarcinoma patients using a posted CTC microfluidic chip. [31] Protein expression 
was first determined by immunostaining and then cells were lysed on chip to extract 
genomic material. RT-PCR was used to interrogate the KLK3 and the PCR product was 
detected using slab gel electrophoresis. This was achievable due to the purity level of ~ 
50% obtained from the CTC microchip assay. [31]  
  Using a Herringbone microfluidic chip, various molecular tests on CTCs have 
been carried. For example, FISH analysis on spiked cells for prostate cancer as well as 
CTCs isolated from prostate patient samples were analyzed; the androgen receptor 
gene (AR) as well as TMPRSSR-Exon1 and –ERG in Exon 5 fusion transcripts were 
evaluated. [32]  
More recently, Min and coworkers developed a quantifiable dual colorimetric 
RNA-in situ hybridization assay to analyze epithelial transcripts Keratins (KRT 5, 7, 8, 
18 and 19) and EpCAM, and mesenchymal transcripts, FNI fibronectin, CDH2 (cadherin 
2) and SERPINE1 (Serpin peptidase inhibitor) in CTCs isolated from metastatic breast 




RNA-ISH on CTCs; i) CTCs expressed more EMT markers than tumor cells within the 
tissue of the primary tumor; and ii) a prominent association of the presence of 
mesenchymal markers were found in CTC clusters rather than in single migratory cells 
suggesting mesenchymal transformation of epithelial cells mediated by TGF-β release 
from platelets. [33]   
In another study, isolated CTCs from genetically modified mouse models as well 
as pancreatic cancer patient samples were analyzed for the WNT gene. [57] This gene 
is associated with an increased metastatic propensity in vivo through the suppression of 
anoikis and also enhances anchorage independent sphere formation in tumor cells. The 
Wnt gene is also a potential drug target for metastasis, because the suppression of 
TAK1 kinase suppresses the WNT effect. A RNA single-molecule sequence analysis 
assay was developed for digitized gene expression profiling (DGE) as a result of the 
minute amount of CTCs captured and low purity levels (0.1-6%) generated by the 
selection device.  
1.4.3 Drug Targeting and Response Monitoring from Microfluidically 
Selected CTCs 
 
In many cases, obtaining tumor tissue may involve invasive surgery and/or fine 
needle aspirations to secure material for various drug targeted studies. This has further 
led to the significance of CTCs as an important biomarker due to the ease of 
accessibility. [44, 46] [37, 38] Patient treatment response monitoring could be simplified 
if CTC changes were used as a response marker during the course of therapy. Specific 




disease and worse prognosis, such as HER2 gene expression in breast cancer patients. 
[212-214] Drug targeting studies as well as response to treatment have been employed 
in clinical studies involving CTC enrichment microfluidics.  
The posted CTC chips were the first microfluidic devices used for monitoring 
drug efficacy for patients by observing changes in CTC numbers and correlating them to 
clinical and radiographical changes. Gefitnib, an EGFR inhibitor was administered to 9 
patients with non-small cell lung cancer were serially monitored over the course of their 
therapy. A significant correlation (Pearson’s correlation = 0.68) was observed between 
the change in quantity of CTCs captured and the response to treatment measured by 
CT scans. [215]   
The GEDI device was also used to monitor CTC numbers during drug studies 
specifically for the assessment of microtubulin bundling upon application of 
Paclitaxel.[216] The GEDI devices with CTCs captured from prostate patient samples 
were placed in culture dishes and treated with Paclitaxel for 24 h. In all samples, 
microtubule bundling was clearly evident by the distorted shape orientation of 
microtubules as observed with increased fluorescence intensity indicating the 
effectiveness of the drug. [29] 
In another the report, a lectin aided filter-based CTC microfluidic device facilitated in 
vitro studies of Cytarabine, a leukemia drug that inhibits DNA and RNA polymerases on 
a K562 model leukemia cell line. Viability of filtered K562 cells greatly decreased with 





1.4.4 Culture of Viable CTCs Isolated from CTC Enrichment Microdevices 
 CTCs carry pertinent oncogenic information because they are shed from primary 
and metastatic tumors. It therefore follows that they could be used as surrogates for 
tumor tissue for tumor biology studies. Propagation of CTCs is one of the main interests 
for tumor biologists and a number of studies have demonstrated the ability to culture 
CTCs directly from patient blood. One such study utilized the CAM assay, which 
separates invasive CTC sub-populations by their ability to ingest collagenous matrices. 
CTCs enriched are cultured with cancer cell culture (CCC) media consisting of 1:1 
mixture of Dulbecco’s modified Eagles medium and RPMI 1640 medium supplemented 
with serum and glutamine and streptomycin for 12 h (see Figure 1.13). CTCs cultured 
using this method have been subjected to both cellular and molecular analysis such as 
gene expression profiling which revealed that subpopulations retained both epithelial 
and EMT stem cell ( CD44 and TWIST1) genes. [218, 219]  
Bo and coworkers used biocompatible parylene slot filter device to capture PC3 cells 
spiked into whole blood. Selected PC3 cells were cultured on or off the device. For off 
device culture, the PC3 cells were selectively removed from the slot filter device using a 
glass micropipette with a tip diameter of 20 µm suctioned by a P-87 micropipette and 
placed into culture media for 3 to 6 d. In both cases more than 90% of the PC3 cells 
were found to be viable.[166] For liquid-based non-adherent CTCs, Raji cells, which are 
immortalized B chronic lymphocytes, were captured on magnetic bead columns 





Figure 1.13 Viability and proliferation of circulating cells isolated by CAM from 
blood of breast cancer patients. (A) A mixture of live green fluorescent cells and dead 
red fluorescent cells were seen in the cell fraction of pre-CAM enrichment. Bar = 40 µm. 
(B) Viability of circulating cells prior to and post to CAM enrichment. Percentages of live 
cells in pre- and post-CAM fractions were measured as percentage of green cells in 
both green and red cells. (c, d) CAM-enriched cells were cultured on the CAM scaffold 
for 1–33 days. Live cells were photographed under phase contrast microscopy (PCM) 
and fluorescence microscopy (CAM, to reveal CAM uptake/labeling of tumor cells). 
Tumor cells grew as time increased. On day 1 (C), tumor cells were seen to associate 
with CAM uptakes and as round cells (large white arrows) larger than hematologic cells 
(small yellow arrowheads). On day 10 (D), tumor cells were seen as round cells (white 
arrows) larger than hematologic cells (red arrows). By day 33 (E), tumor cells grew in 
clusters with large epithelioid cells (open arrows) but hematologic cells decreased their 
number and not seen in the field. Reproduced from Lu et al. [217] with permission 
 
infused through the device while maintaining temperature between 36˚C and 37˚C via a 
microthermocouple embedded into the device with mitosis observed after 12 h of 
culture. [122] 
Unfortunately, very few reports involving microfluidic devices have shown the 




with regards to the use of cell lines as representative of tumor cells because they are 
already immortalized and adapted to growth in culture and as a result, are expandable 
without limitation. Some of the challenges involved with the culture of primary cells 
compared to established cell lines are: 1) Primary cells have a limited life span in culture 
and are not accustomed to culture media created for established cell lines; 2) primary 
cells are slow in proliferation; and 3) CTCs isolated from patient blood samples 
constitute heterogeneous populations and may contain contaminating cells that may not 
adapt well in existing growth media used for cell lines.  
Kirby and coworkers were able to demonstrate the culture of CTCs isolated from 
patient blood samples using the GEDI device for the purposes of drug target 
engagement. This was achievable due to their reported purity of 68% and high viability 
of the CTCs captured. Briefly, the GEDI microfluidic device containing CTCs enriched 
from prostate cancer clinical samples was placed in a culture dish with RPMI-1640 
media containing 2% serum and supplemented with either 0.1% DMSO control or 
paclitaxel at concentrations of 100 nM or 1 mM and incubated at 37oC for 24 h.  
Although the authors were able to demonstrate culture of CTCs from clinical samples 
for purposes of drug target engagement, CTCs grown in culture were fixed after a short 
time frame of 24 h; these conditions may not be a suitable for continuous long term 
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CTC Chip no 1-2 3.8-7.5 705  (n = 7) NR 53 [31] 
SiNP yes
† 
1 10.6 12 (n = 2) NR NR [51] 
Advanced  
Prostrate 
CTC Chip no 1-2 3.8-7.5 645  (n=19) 100 49 [31] 
HB  Chip no 4.8 1.6 2895 (n=15) 93 14 [220] 
SiNP yes† 1 10.6 51  (n=24), 5 81 NR [51] 
GEDI no 1 7.5  405( n=30), 2  100 68 [29] 
PFD no 
 
108 0.07 96( n=28), 18 100 NR [221] 





CTC  Chip no 1-2 3.8-7.5 593 (n=10) 100 60 [31] 
PFD no 108 0.07 25 (n=11), 12 100 NR [221] 
p-MOFF yes
†
 36 0.2 1 - 21   (n=24) 79 NR [53] 
µSieve yes
‡
 <120 0.06-0.13 218 (U),60 (D) (n=3) 100 <0.01 [49] 
Pancreatic 
 
CTC  Chip no 1-2 3.8-7.5 1470 (n=15) 100 53 [31] 
HB Chip no 4.8 1.6 135 (n= 15) 73 0.1-6 [220] 




CTC  Chip no 1-2 3.8-7.5 908 (n=10) 100 67 [31] 
PFD no 108 0.07 10 (n=12), 0.3 81 NR [221] 
µSieve yes
‡
 <120 0.06-0.13 60 (U),128 (D) (n=3) 100 <0.01 [49] 
Lung 
CTC  Chip no 1-2 3.8-7.5 1163 (n=55) 100 52 [31] 
VLBD no 2 3.8 187 (n=5) 100 83 [168] 
Bladder PFD no 108 0.07 10  (n=6), 0.3±0.5 50 NR [221] 
Ovarian µ-Hall no 0.1-1 7.5-75 57 (n=20),1 100 100 [64] 
Cervical µSieve yes
‡





NR  (Not Reported)  
† Blood sample was subjected to RBC lysis and centrifugation 
‡ Blood sample diluted with PBS, U (Undiluted blood sample) and D (Diluted blood 
sample) 
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CHAPTER 2. MODULAR MICROSYSTEM FOR THE ISOLATION, ENUMERATION 
AND PHENOTYPING OF CIRCULATING TUMOR CELLS: MANAGING PATIENTS 
WITH PANCREATIC CANCER 
2.1  Introduction 
The presence of circulating tumor cells (CTCs) in cancer patients was documented 
as early as1869. [1] They are shed from many solid tumors and have been implicated 
as key participants in the metastatic process. As such, CTCs have attracted 
considerable attention as an exciting new class of biomarkers that can provide valuable 
clinical information for staging of patients, early diagnosis of relapse, guiding therapy, 
monitoring response to particular therapies and detection of disease recurrence. [2-21] 
Another exciting attribute of CTCs is that they can easily be obtained through a simple 
blood draw (~7.5 mL), potentially obviating the need for securing biopsies, which can be 
anatomically difficult to obtain or problematic if monitoring response to therapy as this 
would require many biopsy samples taken over an extended period of time. 
The main challenge associated with the analysis of CTCs is their low frequency; 
1-100 CTCs per 109 erythrocytes. Thus, highly sensitive enrichment techniques are 
required to enable effective CTC clinical analysis. Three important metrics are 
considered when evaluating CTC enrichment techniques; (i) throughput, defined as the 
maximum volume processing rate; (ii) recovery, an indicator of the number of target 
cells selected from the input sample with respect to the seed level of the target in that 
same sample; and (iii) purity defined as the ratio of CTCs selected to the total number of 
cells enriched.  




CellSearchTM (Veridex) is the only FDA approved technology for CTC enrichment 
and has been approved for breast, prostate and colorectal cancers. It utilizes 
functionalized immunomagnetic beads that target tumor specific antigens associated 
with CTCs, which in most cases is the epithelial cell adhesion molecule, EpCAM. This 
system has been validated through many clinical reports, however, it suffers from low 
purity (0.01–0.1%) and poor clinical sensitivity; recent data has shown that 7/9 normal-
type breast cancer cell lines could not be recovered using the CellSearch system. [22, 
23] In addition significant sample preprocessing is required and the assay cost is 
prohibitively high. Thus, new technologies that can provide higher CTC sensitivity and 
specificity as well as automate the entire processing pipeline from CTC selection to 
enumeration are needed. 
CellSearch typically recovers fewer CTCs from clinical samples than newer 
platforms, such as those based on microfluidics, [24] which can directly process whole 
blood and search for CTCs with high recovery. [25-31] Microfluidic devices are attractive 
platforms for the analysis of CTCs for several reasons: (i) they can be configured to 
select CTCs based on several different modalities including biological cell properties, 
such as expression of antigens specific to the CTC type or physical cell properties, such 
as size. [32] (ii) Microfluidic chips operate in a closed architecture, minimizing the 
potential of sample contamination artifacts that may provide false positive results, 
especially in clinical laboratory settings. (iii) Microfluidic devices can be produced in a 
high production mode and at low-cost. For example, devices can be produced in 




consumables such as CD and DVDs. [29, 33, 34] (iv) CTC selection devices can be 
integrated to other processing steps to fully automate sample processing negating the 
need for operator intervention and thus, minimizing false negative results.  
Challenges with microfluidics include the high surface-to-volume ratio associated 
with these devices requiring special attention to engineer surfaces that reduce non-
specific adsorption artifacts, especially when dealing with clinical samples such as 
whole blood. Also, microfluidics are many times incompatible with high throughput 
processing; for typical volume flow rates of 300 nL/min (50 x 50 µm2 microchannel 
cross-section, 0.2 cm s-1 linear velocity), 3,333 min (55.5 h) would be required to 
exhaustively process 1 mL of sample.  
A common physical cell property used to enrich CTCs is based on differences in 
the size of a CTC compared to that of erythrocytes and leukocytes. Generally, these 
devices demonstrate very high throughputs (1 mL/min) but low purity. [35-40] For 
example, Hosokawa et al. reported a microcavity array device with circular pores 
possessing dimensions of 8.4 µm – 9.1 µm that could use flow rates of 0.2 – 1 mL/min 
with recoveries of 85%. [41] The device also demonstrated substantial amounts of 
leukocyte infiltration within the enriched samples; 1,000 – 3,000 per mL of processed 
blood. In addition, to secure high recoveries using size selection, the cells must be fixed 
prior to filtration, negating the ability to culture selected cells.  
Microfluidic devices using affinity-based assays (i.e., positive selection or 
biological cell property enrichment) typically demonstrate higher purities compared to 




affinity beds configured in microfluidic platforms have employed a variety of geometrical 
configurations (arrays of microposts, high aspect ratio microchannels) and fluid 
dynamics to optimize recoveries. [29, 30, 33, 34] Low throughputs result from the 
necessity of using low linear velocities imposed by the limitation set by the maximum 
shear forces that selected cells can withstand without being stripped from the selection 
surface. In addition, certain flow velocities must be employed to promote highly efficient 
antigen/antibody interactions. [29, 30] For example, a CTC chip utilizing a staggered 
arrangement of microposts produced a recovery of 65% at low shear (0.4 dynes/cm2) 
with a throughput of 1 mL/h. [30] Other geometries have employed herringbone 
channels to induce chaotic mixing leading to recoveries on the order of 91% and purities 
from 9% to 14%. [43] Recently, a nanotextured herringbone device consisting of silicon 
nanopillars poised on a fluidic channel was reported. [44] A flow rate of 1 mL/h was 
used for CTC selection from clinical samples. Adams and coworkers utilized sinusoidal 
high aspect ratio microchannels to reduce pressure drops and increased throughput to 
1.6 mL/h. A recovery of MCF 7 cells spiked into blood was reported to be 97%. 
Irrespective of the CTC selection modality employed, the enumeration process, 
which consists of staining the selected cells with DAPI, anti-CD45 antibodies and a 
cytokeratin cocktail, has been difficult and tedious to undertake requiring imaging of 
large areas and, in some cases, several imaging planes. For example, using a positive 
selection CTC microfluidic device developed by our group, [29] 6 h of imaging time was 
required using a confocal microscope to enumerate the cells based on staining results, 




reported a total scan time of 8 h for a CTC microfluidic chip utilizing positive selection. 
[43] Another challenge that has been observed for CTC assays is that some epithelial 
cancers do not show high sensitivity to the CTC assay, for example pancreatic cancer. 
Pancreatic ductal adenocarcinoma, or PDAC, is one of the deadliest forms of pancreatic 
cancer and the fourth-leading cause of cancer-related deaths worldwide. According to 
the National Cancer Institute, it is one of the most prognostically unfavorable human 
cancers with the rate of incidence nearly equal to the rate of mortality. [45-48]  Newly 
diagnosed patients have a median survival of 6 months and a 5-year survival rate of 
only 3 – 5%. Unfortunately, minimal advances have been made to improve patient 
outcome in PDAC over the past 20 years primarily because of failures at the diagnostic 
level. CTCs for this disease could be attractive biomarkers to manage this type of 
cancer. Unfortunately, several CTC technologies provide low clinical yields for this 
disease. For example, the CellSearch system demonstrated clinical CTC yields for 
metastatic PDAC patients in the range of 0-1 per 7.5 mL of blood using EpCAM-positive 
selection. [49, 50] With sized-based selection, the median yields are slightly higher (~9 
CTCs per 7.5 mL) but at the expense of purity. [51, 52] Recently, a micro-pillar-based 
CTC fluidic device has generated fairly high yields of CTCs for PDAC patients when 
using anti-EpCAM antibodies as the selection marker. [30] 
Herein we present a novel platform for the selection and subsequent analysis of 
CTCs directly from blood samples using a modular microfluidic system to achieve high 
throughput required for clinical sample processing, high recovery, high purity and full 




the modular system included: (i) A high throughput (HT) CTC selection module used for 
the affinity enrichment of CTCs with high recoveries and purities; (ii) an impedance 
sensor module for label-free enumeration; and (iii) a staining and imaging module for 
placing the CTCs in a small viewing area to reduce imaging time. The HT-CTC selection 
module consisted of a parallel network of high aspect ratio curvilinear channels (30 µm 
wide and 150 µm deep) arranged in a z-configuration. The z-configuration occupied a 
smaller footprint compared to our previously reported CTC selection device and allowed 
for uniform addressing of a large number of parallel microchannels. This module could 
be scaled from 50 to 320 microchannels depending on the blood volume processing 
needs while keeping the processing time below 45 min irrespective of the input volume. 
As a prescreening tool, we included an impedance sensor module that utilized two 
orthogonally placed Pt electrodes to enumerate CTCs released from the selection 
module. The third module, referred to as the staining and imaging module, was used for 
collection, staining, and visualization of the selected cells for phenotype identification. It 
consisted of a 2D array of 800 triangular-shaped microfabricated pores with dimensions 
of 8 µm by 6 µm. This module eliminated the arduous task of scanning large area 
selection beds by indexing CTCs within a small area and a single imaging plane. The 
clinical utility of this modular microsystem was tested using blood samples from PDX 






2.2  Experimental 
2.2.1 Materials 
Pt wires (75 µm diameter) were purchased from Sigma-Aldrich (St. Louis, MO). COC 
(Topas 6013S-04) plates (1/8” thick) and films (250 µm thick) were acquired from Topas 
Advanced Polymers, Florence KY. 1/8" thick PMMA hot embossing stock was acquired 
from SABIC Polymershapes (Raleigh, NC). 250 µm thick PMMA films used as the 
imaging module cover plates were purchased from Goodfellow Corporation (Oakdale, 
PA). PEEK tubing and connectors were purchased from IDEX Health & Science (Oak 
Harbor, WA). Chemicals used for PMMA and COC surface cleaning and modification 
included reagent grade isopropyl alcohol, 1-ethyl-3-[3-dimethylaminopropyl] 
carbodiimide hydrochloride (EDC), N-hydroxysuccinimide (NHS), fetal bovine serum, 
and 2-(4-morpholino)-ethane sulfonic acid (MES) all of which were acquired from 
Sigma-Aldrich. Monoclonal anti-EpCAM antibody was obtained from R&D Systems 
(Minneapolis, MN). Tris-glycine buffer was obtained from Bio-Rad Laboratories 
(Hercules, CA). PBS buffer and trypsin from porcine were purchased from Sigma-
Aldrich. For CTC immunostaining, the nuclear stain DAPI was obtained from Thermo 
Pierce Technologies (Rockford, IL). Anti-CD45-FITC antibody (HI30 clone) and anti-
cytokeratin antibodies (8/19 conjugated to Texas Red) were purchased from 
eBiosciences (San Diego, CA). Bovine serum albumin (BSA) in PBS buffer (pH 7.4) was 
secured from Sigma-Aldrich. MEM-non essential amino acids were obtained from 




2.2.2 Fabrication of Microfluidic Modules 
The CTC processing system (see Figure 2.1) consisted of three separate, task-specific 
polymer modules: (1) HT-CTC selection module; (2) impedance sensing module; and 
(3) the staining and imaging module. Hot embossing and laser ablation were used as 
the primary tools for fabrication of the polymer fluidic modules as described 
previously.53 Hot embossing mold masters were prepared in brass using high 
precision-micromilling (KERN 44, KERN Micro- und Feinwerktechnik GmbH & Co.KG; 
Murnau, Germany) and standard carbide bits (Performance Micro Tool, Janesville, 
WI).53 Hot embossing of polymer modules was performed using a HEX03 embossing 
machine (Jenoptik Optical Systems GmbH, Jena, Germany). The embossing conditions 
consisted of a temperature of 155°C and 30 kN force for 120 s for cyclic olefin 
copolymer, COC, substrates and 160°C and 20 kN force for 240 s for 
poly(methylmethacrylate), PMMA, substrates.  Laser milling was done using an ArF 
excimer laser (Rapid X 250, Resonetics Inc., Nashua, NH) with a laser fluence at the 
workpiece of ~15 J/cm2 and a repetition rate of 50 Hz.  
2.2.3 HT-CTC Selection Module 
The HT-CTC module (see Figure 2.2) was made from the thermoplastic, cyclic olefin 
copolymer, COC, due to its ability to be embossed with high aspect ratio 
microstructures, its optical clarity, its propensity to be UV functionalized with high 




adsorption of leukocytes it demonstrated providing high purity levels of enriched CTCs 
from whole blood. 54  
The HT-CTC module consisted of an array of high-aspect ratio sinusoidal 
microchannels with a nominal width of 30 µm and depth of 150 µm serving as the CTC 
selection bed. Selection beds were addressed using a single inlet and outlet 
microchannel arranged in a unique z-configuration. The selection bed employed 50 to 
320 sinusoidal microchannels with the maximum number of channels set by the 
maximum length of the chip, which was chosen to be 75 mm to match the length of a 
standard microscope slide, and the smallest channel-to-channel spacing that was 
machineable.  
After hot embossing, the HT-CTC module and cover plate were flood exposed to 
broad band UV light at ~22 mW/cm2 (measured at 254 nm) for 15 min using a home-
built system employing a low pressure Hg grid lamp (GLF-42, Jelight Company Inc., 
Irvine, CA). UV exposure produced carboxylic acid surface scaffolds that were used for 
the covalent attachment of monoclonal antibodies for CTC selection (anti-EpCAM 
antibodies).55, 56 After UV exposure, the substrate was enclosed with a cover plate by 
Thermal fusion bonding at a temperature of 132°C and a bonding pressure of ~1 
N/cm2. Bonding conditions were carefully selected to achieve high bond strength, but 







Figure 2.1 Modular microfluidic system for CTC analysis. (A) Schematic representation of 
the operation of the system and the three modules comprising the system including the 
HT-CTC module, the impedance sensing module and the staining and imaging module. 
Arrows indicate flow of sample (1 and 1’), wash buffer (2 and 2’), CTC release buffer (3 
and 3’), and fixation and staining reagents (4 and 4’). For detailed operational procedures 
please refer to the Experimental Section. (B) Picture of the assembled system. Roman 
numerals correspond to modules described in (A). (C) Micrographs and data plots 
showing the various outputs of the three different task-specific modules including: (I) HT-
CTC selection module, which used anti-EpCAM-coated sinusoidal microchannels for the 
positive selection of CTCs; (II) electrical signatures of CTCs obtained using the 
impedance sensor module; and (III) images of CTCs stained with DAPI and collected at 




After assembly, the surface of the microfluidic channels was modified using EDC-
NHS chemistry. This consisted of 50 mg/mL EDC (1-Ethyl-3-[3-
dimethylaminopropyl]carbodiimide hydrochloride), 5 mg/mL NHS (N-
hydroxysuccinimide) in 100 mM MES (pH 6), followed by incubation with a solution of 
anti-EpCAM monoclonal antibodies (0.5 mg/mL; 150 mM PBS buffer, pH 7.4) overnight 
at 4°C. The optimum concentration of the antibody was chosen based on studies to 
optimize CTC recovery (see Figure 2.5). 
 
 
Figure 2.2 (A) Schematic operation of the HT-CTC module with 50 parallel, 
sinusoidal microchannels and inlet/outlet channels arranged in the z-configuration. The 
large arrow indicates sample flow direction through the selection channels. (B) SEM of 
the selection bed showing high-aspect ratio sinusoidal microchannels and the output 
channel (top). (C) SEM of one of the high-aspect ratio sinusoidal channels. (D) SEM 
image of a portion of the high-precision micromilled brass molding tool showing the 
sample inlet port with continuously changing width and height for minimizing unswept 
volumes during sample (i.e., blood) introduction. (E) Assembled HT-CTC modules with 
different numbers of microfluidic sinusoidal channels designed for efficient processing of 





2.2.4 Evaluation of Flow Uniformity in HT-CTC Selection Bed 
Video microscopy was used to study the uniformity of the linear flow velocities 
through the HT-CTC selection bed with inlet and outlet all arranged in z-configuration. 
The HT-CTC chip with 320, 20 mm long sinusoidal microchannels was used for these 
experiments. The experimental setup for these measurements consisted of a syringe 
pump connected to the HT-CTC chip through a manual HPLC sample injector equipped 
with a 20 µL volume sample loop. During measurements, buffer solution was 
continuously pumped through the HT-CTC chip at volumetric a flow rate of 176 µL/min, 
which produced an average linear flow velocity in the sinusoidal microchannels of 2 
mm/s. Aliquots of 20 µL of red food dye were injected into the clear buffer solution and 
the time required for the dye plug to travel from the inlet channel to the outlet channel 
was then recorded. Because monitoring of the filling time for individual channels was 
not feasible due to the overall size of the chip and the limited optical resolution of our 
video recording system, the chip was divided into 16 observation windows with roughly 
20 selection microchannels per window and an average filling time was recorded for 
each window. The recorded times were divided by the channel length (20 mm) to obtain 
the average linear velocity as presented in Figure 2.4C.  
2.2.5 Impedance Module 
The impedance sensing module, which was made in poly(methylmethacrylate), 
PMMA, and consisted of two perpendicular microchannels. A microchannel with 




this module. The second microchannel (75 x 75 µm2) was used as guides to place two 
Pt wires, which were used as electrodes for making the single-cell impedance 
measurements. Impedance measurements were conducted using previously described 
circuitry. [29] Data were collected and analyzed using a NI-USB-6009 (National 
Instruments) data acquisition board and software written in LabView (National 
Instruments). Data were collected at 2 kHz, which allowed for sample processing 
through the sensor at a maximum flow rate of 20 µL/min (80 mm/s) without generating 
signal aliasing. The raw output data was subjected to a 1,000 point adjacent averaging 
algorithm to establish the baseline for the measurement without generating signal bias. 
Baseline was then subtracted from the data in order to correct for signal drift. 
2.2.6 Staining and Imaging Module 
The design of the staining and imaging module is presented in Figure 2.3. It 
consisted of two independent microchannel networks, one consisting of an array of 
smaller microchannels laser machined into the module cover plate and a second set of 
fluidic channels embossed into the substrate, which consisted of interleaving 
input/output channels of larger cross section. The smaller channels on the cover plate 
were positioned perpendicular to the interleaved input/output channels contained within 
the substrate. The input/output channels (50 µm depth; varying width) were hot 
embossed into PMMA using a high precision micromilled mold master. Laser ablation 
was used to fabricate the array of smaller microchannels into a thin PMMA film serving 




pressure of ~3 N/cm2 with the patterned surfaces facing each other. The staining and 
imaging module possessed 800 pores arranged in a 2D matrix and spaced by 100 µm 
Addressing of the microfluidic networks and connection between modules was 
accomplished using glass capillaries (Polymicro Technologies, Phoenix, AZ) affixed to 
inlet and outlet ports of each module via epoxy (Permapoxy, Permatex, Hartford, CT). 
Figure 2.3  Staining and imaging module. (A) Assembly process; (a) – cover plate with 
an array of 8 x 6 µm2 channels, which form pores for retaining cells between the 
interleaving inlet and outlet channels (b). (B) Schematic of an assembled module and its 
operation; Red – input channels; Blue – output channels; Yellow – interconnecting 
channels. (C) Image of the staining and imaging module filled with fluorescein. The 
lower fluorescence intensity in the interconnecting channels is due to the smaller cross-
sectional area of these channels compared to the input/output channels. (D) 
Fluorescence image of CTCs retained by pores. The cells were stained with DAPI for 
visualization. (E) High magnification fluorescence image of Hs578T cells retained at the 
pore structures of the staining and imaging module. These cells were stained with 




Capillaries were connected to each other using low dead volume interconnects secured 
from Polymicro. 
2.2.7 Cell Culture 
MCF-7 (breast), Hs578T (breast) and SW620 (colorectal) cancer cell lines were 
purchased from American Type Culture Collection (ATCC, Manassas, VA) and cultured 
according to recommended conditions. Briefly, all cell lines were incubated at 37˚C 
under a 5% CO2 atmosphere. Eagles minimum essential medium (MCF-7 and Hs578T) 
and Dulbecco’s minimum essential medium (SW620s) containing 1.5 mM L-glutamine 
supplemented with 10% FBS (GIBCO, Grand Island, NY) was used. A 0.01mg/mL 
solution of bovine insulin (GIBCO, Grand Island, NY) was added to the complete growth 
media for the MCF-7 cells. The Hs578T cell line required 1X non-essential amino acids 
to complete the final growth medium. The cell lines were grown as adherent monolayers 
in T75 culture flasks (Corning) to 80-95% confluence with media changes every 2-3d. 
Cells were washed in a flask with Dulbecco’s phosphate buffered saline, DPBS 
(GIBCO, Grand Island, NY), dissociated by using TrypLE™ Express (1X) (GIBCO, 
Grand Island, NY) at 37˚C for 5-7 min and subsequently seeded into culture flasks at a 
low concentration. 
2.2.8 Patient Samples 
Patients with pancreatic cancer were recruited according to a protocol approved by 
the University of North Carolina’s IRB. Blood specimens from healthy volunteers were 




metastatic PDAC and 6 patients with non-metastatic PDAC were used as positive 
controls. Five non-cancer patients also served as negative controls. All specimens were 
collected into BD Vacutainer® (Becton-Dickinson, Franklin Lakes, NJ) tubes containing 
the anticoagulant EDTA and were processed within 5 h of the blood draw.  
2.2.9 Patient-derived Xenograft (PDX) Models 
Tumors from de-identified PDAC patients were grafted onto the flanks of 
immunocompromised mice under approval by the Institutional Animal Care and Use 
Committee.  Terminal bleeds were obtained via cardiac puncture. Blood samples from 
the PDX models were then analyzed using the microfluidic system. 
2.2.10 Staining Procedure 
The staining protocol was as follows: 0.25% BSA in PBS buffer (pH 7.4) was infused 
through the staining and imaging module at a flow rate of 20 µL/min. Next, 100µL of 
0.0025mg/mL anti-human CD45-FITC was infused at a flow rate 10 µL/min and allowed 
to incubate at 4˚C followed by a 5 min wash with 0.02%TX-100/PBS at 20 µL/min. For 
fixation and permeabilization, 2-4% paraformaldehyde in PBS buffer was infused at a 
flow rate of 15 µL/min followed by 0.1%TX-100 in PBS buffer at the same flow rate. 
Next, 100 µL of 0.01mg/mL anti-cytokeratins 8/19 labeled with Texas Red was infused 
at 10 µL/min and incubated at 4˚C followed by a 10 min wash consisting of 0.25%BSA 
in PBS at 20 µL/min. For nuclear staining, 0.001mg/mL DAPI in PBS was infused at a 




2.2.11 HT-CTC Module Operation 
Prior to analysis of all samples, the HT-CTC selection module was thoroughly 
washed with PBS buffer at a flow rate of 40 µL/min for at least 5 min in order to remove 
unbound antibody from the microchannel walls. Blood specimens collected into BD 
Vacutainer® tubes were placed on a nutator for at least 10 min to allow for homogenous 
distribution of blood components. Following homogenization, 3 mL of patient blood or 
approximately 1 mL of PDX blood was transferred into a disposable Luer LokTM syringe 
(BD Biosciences, Franklin Lakes, NJ) using a BD vacutainer female luer transfer 
adapter. Immediately after transfer, blood samples were processed through the HT-CTC 
selection module. A PHD2000 syringe pump (Harvard Apparatus, Holliston, MA) was 
used to hydrodynamically drive the blood through the HT-CTC selection module at the 
appropriate volume flow rate to attain an optimal average linear velocity of sample 
through the sinusoidal microchannels (2 mm/s) to maximize recovery.[29] During the 
course of blood sample introduction, the syringe was rotated by 180° along its 
longitudinal axis and lightly tapped in order to prevent sedimentation of the blood 
components inside the syringe to assure exhaustive and representative sample 
introduction. Finally, the HT-CTC selection bed was flushed with 2.5 mL of PBS at a 
linear velocity of 4 mm/s to remove any nonspecifically bound cells.  
During blood infusion into the HT-CTC module and the subsequent washing step, 
the output capillary to this module was disconnected from the impedance sensing 
module and inserted into a microfuge tube for waste collection. When the release buffer, 




was reconnected to the impedance sensing module. The output port of the impedance 
sensing module was connected to the input port of the imaging and staining module 
(see Figure 2.1). 
2.2.12 Operation of the Integrated System and Data Collection and Analysis 
All three modules were connected in series using glass capillaries (see Figure 2.1). 
Following HT-CTC module washing, 200 µL of the CTC release buffer consisting of 
0.25% w/v trypsin in 25 mM TRIS/192 mM glycine buffer (pH 7.4) was infused through 
the HT-CTC selection module to allow for the release of CTCs from the antibody-
containing selection channels and into the downstream processing modules. As the 
CTCs traversed through the impedance sensor, an electrical signal was recorded using 
in-house designed and built electronics as described previously. [29] The raw output 
data was subjected to a 1,000 point adjacent averaging algorithm to establish the 
baseline for the measurement without generating signal bias. Baseline was then 
subtracted from the data in order to correct for signal drift. Impedance responses 
generated from CTCs were counted when the signal-to-noise ratio exceeded 3:1. Cells 
counted were directed into the staining and imaging module for staining with 
fluorescently labeled markers including cytokeratins 8/19, the nuclear stain (DAPI), and 
a negative control consisting of FITC labeled anti-CD45 antibodies.  
The staining protocol was as follows: 0.25% BSA in PBS buffer (pH 7.4) was infused 
through the staining and imaging module at a flow rate of 20 µL/min. Next, 100 µL of 
0.0025 mg/ml anti-human CD45-FITC was infused at a flow rate 10 µL/min and allowed 




fixation and permeabilization, 2-4% paraformaldehyde in PBS buffer was infused at a 
flow rate of 15 µL/min followed by 0.1%TX-100 in PBS buffer at the same flow rate. 
Next, 100 µL of 0.01 mg/ml anti-cytokeratins 8/19 labeled with Texas Red was infused 
at 10 µL/min and incubated at 4˚C followed by a 10 min wash consisting of 0.25% BSA 
in PBS at 20 µL/min. For nuclear staining, 0.001 mg/ml DAPI in PBS was infused at a 
flow rate of 15 µL/min followed by a wash with 0.25% BSA in PBS.  
The stained cells were imaged using an inverted Olympus 1X71 microscope (Center 
Valley, PA) using 10x, 20x, 40x, and 60x dry objectives equipped with a high resolution 
(1344 x 1024) CCD camera (Hamamatsu ORCA-03G) and a mercury arc lamp as an 
illumination source. Images were collected using 40× (0.6 NA) and 60× (0.7 NA) dry 
lens objectives and analyzed using Metamorph software (Olympus). Exposure times for 
the DAPI, FITC/CD45, and Texas Red/CK channels were 50, 600, and 600 ms, 
respectively.  
Statistical analysis was performed using the Kruskal-Wallis Test (p = 0.05) for three 
sample groups of healthy, non-metastatic and metastatic PDAC patients. For pairwise 
test analysis, Wilcoxon Rank-Sum (p = 0.05) was applied.. 
2.3  Results and Discussion 
2.3.1 HT-CTC Module 
The HT-CTC module utilized COC as the substrate material. COC demonstrates 
higher UV transmissivity compared to PMMA, therefore generating a higher surface 




groups serve as functional scaffolds for the attachment of CTC recognition elements. 
[53, 54] Higher UV transmission also resulted in a more uniform modification of the 
high-aspect ratio microchannel walls when made from COC. COC also demonstrated 
higher CTC purities due to lower non-specific adsorption of hematopoietic cells to its 
surface compared to PMMA. [54] 
Considering the requirements for the microfluidic channel geometry and linear 
velocity of the sample through the selection channels to maximize recovery, [29] it was 
clear that higher throughput could be achieved by either increasing the number of 
parallel microchannels or increasing the depth of the microchannels without changing 
the width. For results reported herein, we used larger number of parallel channels as a 
method for increasing throughput. For example, the previously reported device used 51 
parallel channels (cross-section 30 µm x 150 µm) and could process 1 mL of whole 
blood in 37 min. Thus, it would take nearly 4.7 h for this device to process 7.5 mL. By 
increasing the number of channels to 320, 7.5 mL input volumes could be processed in 
<45 min using an average linear velocity of 2 mm/s.   
To uniformly address all parallel channels within the selection bed employing 
large numbers of parallel sinusoidal channels, we adopted a unique z-configuration 
(Figure 2.2). In this configuration, fluid enters the selection bed through a single inlet 
channel with a larger cross-sectional area and exits through a single outlet channel also 
possessing a larger cross-section compared to the sinusoidally-shaped selection 
channels (see Supporting Information). Both inlet and outlet channels were 




(Figure 2.2A).  The z-configuration provides the smallest possible footprint for 
addressing the isolation bed and allows for easy scaling of the CTC isolation bed size. 
For example, in a recently proposed fluidic design for neutrophil isolation  [55], 
bifurcation was used for addressing parallel channels of the isolation bed, which nearly 
doubled the footprint of the proposed device in order to allocate space for the fluid 
distribution network. Furthermore, compared to previously reported design, [29] the high 
linear fluid velocities in the inlet and outlet channels of z-configuration allow for more 
efficient removal of persistent air bubbles that are inevitably introduced into device 
architectures during operation and may interfere with the fluid flow.  
Uniformity of the fluid flow in z-configuration is highly dependent on the flow 
resistance ratio between the inlet/outlet channels and the flow resistance in the parallel 
channels. In general, wider (lower fluidic resistance) inlet channels and longer and/or 
narrower (higher fluidic resistance) parallel channels show higher flow uniformity 
throughout the array. Inhomogeneity of the flow rate is exacerbated by the number of 
parallel channels in the array. As seen in Figure 2.4A, a parabolic fill profile was 
observed over the entire selection bed during filling.  Qualitatively, if each channel of the 
array was filling under a constant linear velocity, the filling profile of the array should 
show a linear gradient. 
To evaluate flow uniformity in the CTC selection beds with various numbers of 
sinusoidal channels and for various lengths of the selection bed, we performed 




sinusoidal microchannels. Due to the numerical limits of simulating large geometries 
using computational fluid dynamics (CFD), we employed a method described by Zhang 
and coworkers. [56] This method splits the selection bed into an interconnected system 
Figure 2.4 (A) Various stages of filling a 320-channel HT-CTC module (20 mm length) 
with a dye solution. (B) Numerical simulation results showing the distribution of flow 
velocities for different configurations of the CTC selection beds arranged in a z-
configuration. (C) Average linear velocity of fluid in 16 groups of 20 adjacent 
sinusoidal high aspect ratio microchannels based on the results depicted in Figure 
2.4A (filled bars) and theoretical values obtained via numerical simulation (empty 




of individually defined parallel channels and the addressing inlet/outlet channels. Each 
channel segment was treated as a fluidic resistor, and the flow dynamics through the 
entire system was described by pressure and mass balance equations. [56] 
Figure 2.4B presents solutions for microfluidic selection beds with 50, 250 and 
320 channels possessing dimensions of 0.03 x 0.15 x 30 mm3 along with the results for 
320 channels with varying lengths of 30, 20 and 8.4 mm. As can be seen from this data, 
for the 320 channel device with 8.4 mm selection channel lengths, the maximum and 
minimum flow velocities fall outside the range of 1 mm/s – 4 mm/s, a range that was 
determined to provide CTC recoveries >80%. [29] However, when using 320 channels 
and incorporating a length of 30 mm, the average flow velocity remains within an 
acceptable range for maximum CTC recovery. The simulated results were also 
confirmed experimentally (Figure 2.4C). The results indicated good agreement with the 
simulation results; the slowest flow rates were observed in the middle and fastest at the 
outer channels with an RSD of 16%. We also evaluated the distribution of selected 
MCF-7 cells inside a HT-CTC bed modified with anti-EpCAM antibodies. MCF-7 cells 
(~500) labeled with a PKH 67 fluorescent membrane dye were spiked into normal blood 
and processed using the selection bed comprised of 320 channels and the numbers of 
MCF-7 cells per channel were counted using a fluorescence microscope. Figure 2.4D 
shows the selected cell distribution within individual channels. A uniform distribution of 
cells across the entire series of microchannels occurred with most of the channels 
capturing 1 or 2 cells and only a few capturing 3 - 4 cells or no cells at all. The overall 




with at least 30 mm channel lengths were necessary to achieve recoveries >90% (see 
section on the effect of bed length on recovery).  
2.3.2 Optimization of anti-EpCAM Antibody Concentration  
In order to increase the probability of interaction between antigens on the CTC 
surface and selection channel wall bound antibodies, it is critical that there be a 
maximum coverage of the antibody on the channel walls. On the other hand, the 
amount of antibody used for the reaction should be kept to a minimum in order to keep 
the cost of the assay low. The amount of antibody required to produce a monolayer 
coverage of the walls within the selection bed can be estimated using the following 
assumptions. Theoretically, a monolayer of an IgG-type antibody has been reported to 
be on the order of 1.1 pmolcm-2. [57] For comparison, the surface density of carboxylic 
acid moieties produced on a polymer surface using UV activation has been reported to 
be on the order of1 nmolcm-2, indicating significant excess of carboxylic acid moieties 
compared to the surface density of antibodies for a monolayer coverage. [58] In studies 
previously published by our group describing CTC isolation using polymer microfluidic 
devices, a relatively high concentration of anti-EpCAM antibody was used (1 mg/mL). 
[29, 33] For microchannels with cross-sectional dimensions of 30 µm wide x 150 µm 
deep, a solution of antibody at 1mg/mL concentration injected into the microchannels 
provides an amount of antibody corresponding to nearly 10x excess to the theoretical 
amount required to achieve complete monolayer coverage. One has to also note that 




performance of the CTC recovery process as the activity of surface bound antibodies is 
important as well. The activity of the antibody is dependent on its conformation on the 
surface and possible steric effects caused by crowding.  
 
In order to establish the optimum concentration of anti-EpCAM antibody required 
during the covalent attachment process to optimize recovery, we evaluated the 
recoveries of MCF-7 cells obtained using selection beds prepared with different 
concentrations of antibodies. Figure 2.5 presents a summary of these experiments 
using beds modified with 1 mg/mL, 0.5 mg/mL, 0.25 mg/mL, and 0.1 mg/mL of anti-
EpCAM antibody. As can be seen from this data, there seems to be no difference in 
recovery when the antibody concentration is reduced 2-fold to 0.5 mg/mL. However, 
further reductions in the amount of antibody leads to significant drop in the recovery of 
Figure 2.5 Recoveries of MCF-7 cells using selection beds modified with EpCAM 
antibody at different antibody concentrations. Results were normalized to recovery 




the MCF-7 cells. Therefore, the concentration of 0.5 mg/mL was used throughout this 
work. 
2.3.3 Effect of CTC Selection Bed Length on Recovery 
We were also interested in evaluating whether the length of the selection channels 
was critical in regards to CTC recovery. The use of shorter selection channels can 
reduce pressure drops within the selection channels and require less use of antibody. 
To evaluate selection bed length on recovery, the location of MCF-7 cells recovered 
using 8, 20, and 26 mm long beds (320 channels) were recorded and assigned to one 
of three equidistant zones along the microchannel length (see Figure 2.6). The overall 
average recovery for beds with 8 mm long channels was 67%, the 20 mm long channels 
was 83% and the 26 mm length channels was 93%. Inspection of the location of the 
selected CTCs along the 20 mm length channel bed indicated that 69% of the cells 
captured were found in a 0-10 mm region of the channel (the 0 coordinate is the input 
end of the channel), 23% were 10-15 mm region from the inlet and 8% were within the 
15-20 mm zone with comparable numbers seen for the other two channel lengths. It is 
important to note that although the majority of the selected cells were captured within 
the first half-length of the selection channels, there was still a relatively large number of 
cells captured in the second half of the channels indicating that shorter selection beds 
do not provide optimal CTC recoveries. Indeed, evaluation of 8 mm long channels 
comprising the selection bed produced an overall recovery of 67%. For comparison, the 




microchannels and demonstrated recoveries >90% (see Figure 2.6). Therefore, all of 
the results reported herein used selection beds with channels ~30 mm in length. 
 
2.3.4 Impedance Sensor Module 
The impedance sensor adopted a geometry similar to that reported previously by our 
group. [29, 33, 59],[29] Using this sensor, we were interested in determining the ability 
to discriminate between leukocytes and CTCs based on size differences, which is the 
cell characteristic measured at the operating frequency (40 kHz). At this frequency, the 
amplitudes of signals produced by single cells are dominated by cell size. [59] This 
module was fabricated in PMMA and consisted of a pair of Pt electrodes placed 
orthogonally to a 50 µm channel through which released CTCs traversed. Figure 2.7A 
Figure 2.6  Capture efficiencies of MCF-7 cells using isolation beds with varying 
channel length. Zone 1 first 50% of channel length, zone 2 – 50-75% of channel 




provides results for SW620 cells spiked into buffer and traversing through the pair of Pt 
wires. Also shown are leukocytes that were isolated from a buffy coat of blood secured 
from a healthy donor and measured using the impedance sensor. There was only a 
slight overlap in the signal amplitudes between the two cell types with a 
misclassification frequency of ~15%. Similar results were observed when the cell sizes 
for the same populations were measured using an optical imaging technique (Figure 
2.7B). A 100% concurrence between the impedance sensor response and passing cells 
were observed when using a microscope to watch the passage of single cells through 
the pair of electrodes (data not shown). However, because there was some size overlap 
between CTCs and leukocytes, we could not clearly distinguish between these two cell 
types based solely on the magnitude of the impedance response. In spite of this 
limitation, the high purity of our selected CTC fractions from whole blood (>80%, see 
below) indicates that the leukocyte infiltration is low anyway. Nevertheless, the 
impedance sensor in its current format can measure signatures from single cells that 
are unlabeled and thus, can serve as a prescreening tool for assessing the need to 
immunocytochemically stain for CTCs. If no impedance signals are generated, the 
sample can be considered negative for CTCs and thus, forgo the need for staining 







2.3.5 Staining and Imaging Module 
PMMA was selected as the substrate of choice for the staining and imaging module 
due to the high quality machining it generated using laser ablation as well as its 
favorable optical properties. [60] The design and operation of the novel 2D imaging 
module are shown in Figure 2.3. It consisted of two independent networks of channels; 
an interleaving input/output channel network interconnected using an array of smaller 
channels positioned orthogonally to the input/output channels. The interconnecting/feed 
channel interface generated a pore structure, whose dimensions were determined by 
the size of the interconnecting channel (8 µm base and 6 µm height). During operation, 
CTCs released from the primary selection bed were transported through the impedance 
sensor to the staining and imaging module where they were retained due to their larger 
Figure 2.7  Single-cell electrical impedance sensing. (A) Histograms for impedance 
response for leukocytes (blue bars) and SW620 cancer cells (red bars). (B) SW620 




size as compared to the size of the pore. After collection at each pore, CTCs could be 
fixed, permeabilized, and immunostained directly within the staining and imaging 
module followed by fluorescence imaging. 
The unique geometry of the staining and imaging module offered important 
benefits: (i) A small footprint (0.16 cm2) as compared to the primary selection bed (4 
cm2 for the 50-channel z-configuration selection module), which significantly reduced 
the time required for imaging; (ii) cells are brought to a single focal plane further 
reducing imaging time; and (iii) the highly ordered configuration of the pores allowed for 
indexing cell position, which also reduced imaging time. 
To validate the performance of the staining and imaging module, we determined 
the collection efficiency of fixed and unfixed cells at a flow rate that was used to move 
the released CTCs from the selection channels to the staining and imaging module. We 
used Hs578ST cells seeded into PBS as a model for these studies. The collection 
efficiency was defined as the ratio of cells collected at the pores to the number of cells 
enumerated by the impedance sensor (see Figure 2.9). We determined that for fixed 
cells, the collection efficiency of the staining and imaging module was 96 ±6% (n=5) 
while for unfixed cells, the collection efficiency was 85 ±11% (n=5). The difference in the 
collection efficiency is indicative of the higher deformability of unfixed cells compared to 




We also found that the cells resident within a pore adhered to the pore structure 
even when the solution flow was terminated. Therefore, the cells could be trapped at the 
pore without requiring boundary conditions to contain the cells. Because of this 
adhesion, we could remove the staining and imaging module from the system and place 
it on a conventional microscope stage without losing cells from their respective pore 
location.  
 
Figure 2.8 Fluorescent images of CTCs collected in the staining and imaging module. 
(A-D) Images of a CTC from a PDAC patient after being released from the selection 
bed, impedance counted, and collected at a pore on the staining and imaging module 
followed by fixation and staining with DAPI, anti-cytokeratin antibodies (8/19) labeled 
with Texas Red, and FITC-labeled leukocyte antibody marker for CD45. (E) 
Fluorescent image of a CTC with the cytoplasm partially deformed and pulled into the 
pore and the interconnecting channel. Dashed lines indicate the edges of the input 




2.3.6 Correlation of Impedance Responses with Imaging Data 
We next evaluated the collection efficiency of the staining and imaging module for 
patient samples(n = 4, PDAC). Impedance responses from each sample were analyzed 
and correlated to the number of CTCs collected using the staining and imaging module 
that were scored as CTCs (DAPI(+), CD45(-) and CK(+)). A Pearson correlation of 0.93 
(n=4) was obtained between the impedance responses and the CTCs collected at the 
staining and imaging module. As seen from the impedance trace for one patient (Figure 
2.9A), 14 peaks were assigned as cell events. Variations of the peak amplitude 
responses for the impedance trace were most likely due to differences in CTC size 
and/or transduction of leukocytes (see Figure 2.7). The CTCs collected on the staining 
and imaging module were found to be 8 for this same sample and were definitively 
identified as CTCs by their staining pattern. For all PDAC samples analyzed, the 
collection efficiency of CTCs by the staining and imaging module was 72 ±13% (see 
Figure 2.9). While the staining and imaging module demonstrated higher collection 
efficiencies for the Hs578T cell line compared to the clinical samples, this difference 
could have arisen from impedance signals recorded for leukocytes as well as the CTCs, 
which were not present in the cell line studies. Also, most of the CTCs are in an 
apoptotic state and therefore, their cell membrane may not be rigid enough to withstand 






The high correlation between the impedance responses and those ascertained 
through immunostaining using the staining and imaging module also indicated that 
Figure 2.9 (A) Impedance counts generated from CTCs selected from 2.0 mL of blood 
from a patient with metastatic PDAC. The sample was processed through the HT-
CTC selection module at a linear flow velocity of 2.0 mm/s. CTCs were then released 
from the selection bed using a CTC release buffer at a volumetric flow rate of 10 
µL/min. A total of 14 CTCs were enumerated using impedance sensing based on a 
signal-to-noise threshold of 3 (dotted line). The red dotted line represents the 
threshold level, which was used to differentiate ‘true’ events from noise. Data 
presented here were smoothed using algorithms described in the Experimental 
Section. After impedance counting, the cells were directed to the staining and imaging 
module for phenotypic identification (DAPI, CD45 and cytokeratins). (B) Plot showing 
the correlation between the impedance counts versus CTCs enumerated via immuno-
staining on the staining and imaging module for 4 different metastatic PDAC patient 
samples. (●) Represents expected numbers of CTC events based on the impedance 
signatures and (□) shows the experimental enumeration data from the staining and 
imaging module (r = 0.93). (C) Interface between a capillary and plastic module 
showing the capillary inserted into a guide channel to accommodate the 365 µm od 





minimal cell loss was induced by the capillary interconnections between modules. Any 
potential loss of cells by these interconnects could be induced by shearing effects at 
module/capillary junctions or the unswept volumes created by these same junctions. 
However, the relatively large size of the CTCs and the small capillary diameters used as 
the interconnects (id = 150 µm) as well as the carefully designed capillary-to-module 
interface minimized unswept volumes. The interface between the capillary and module 
was accomplished by using multiple levels of microstructures. A guide channel for the 
capillary matching the capillary od (365 µm) was used as the capillary holder and the 
fluidic channel dimensions matched that of the capillary id (150 µm). Figure 2.9C shows 
this interface. 
2.3.7 Preclinical Studies Using PDX Models 
We processed blood samples from PDX models (n = 7) that were engrafted with 
biopsy tissue from metastatic PDAC patients. In addition, we analyzed blood from 
healthy mice (n = 3) to serve as negative controls. Cells were classified as CTCs only if 
they met the following criteria; (i) intact cells with nuclei; (ii) immunocytochemically 
positive for cytokeratins 8/19 and negative for leukocyte marker CD45; and (ii) 
morphological characteristics such as having a nucleus to cytoplasm ratio of 2:1 with a 
large visible nucleus (Figure 2.10C i. a-d). CTCs generated from PDX models were 
isolated within a range of 13 to 112 CTCs/mL (median = 24/mL, mean = 44 ±36/mL), 
while healthy mice (n = 3) generated a mean of 0.83 /mL (p = 0.022). A summary of this 




2.3.8 Clinical Studies in Metastatic and Local Resectable PDAC Patients 
For metastatic PDAC patient blood samples, we isolated an average of 53 ±29 
CTCs/mL, median = 51/mL with a range of 9 to 95 CTCs/mL. To establish assay 
reproducibility, we also processed three aliquots from the same patient sample through 
three different HT-CTC modules. An RSD value of 14% (n = 3) was obtained. CTCs 
were selected in all patients with metastatic PDAC. For the healthy blood donors, in 
most cases no CTCs were observed (p = 0.004). Metastatic patients had a statistically 
significant higher CTC count compared to healthy patients (p = 0.008).  
We also analyzed blood from 5 patients who had been determined to have local 
resectable PDAC by CT scans. We found an average of 12 CTCs/mL for this group of 
patients. Based on the Kruskal-Wallis test (p = 0.002), there was a significant difference 
in the CTCs/mL between metastatic, local resectable, and healthy patients. Pairwise 
Wilcoxon Rank-Sum tests suggested that there was a significant difference between 
metastatic and healthy patients (p = 0.005). Between local resectable PDAC and 
healthy patients there was also a statistically significant difference in terms of CTC 
numbers (p = 0.011). Comparison between metastatic and local resectable patients also 
indicated a significant CTC number difference (p = 0.023). These results remained 
significant when accounting for multiple testing using the Hochberg method (p-values of 
0.016, 0.022, and 0.023).This data is summarized in the box plot shown in Figure 
2.10B. The presence of CTCs from locally resectable patients may be indicative of 
micrometastatis, which is undetectable by conventional diagnostic methods. CT scans, 




micrometastatic nature of the tumor because they cannot detect tumors smaller than 1 
cm and thus, may not be effective for assessing the micrometastatic nature of PDAC as 
our assay has demonstrated. [45] Continuous monitoring of CTC counts from this group 
of patients may be important in predicting the reoccurrence of the disease after surgical 
resection.  
The purity of the assay when processing clinical blood samples was determined 
as well. The purity was calculated using the ratio of the number of CTCs selected to the 
total number of cells selected and was found to be 86 ±12% for all samples analyzed. 
For many CTC selection platforms, purity is calculated as the ratio of CTCs (DAPI(+), 
CK(+) and CD45(-)) divided by the total number of selected DAPI(+) cells. 
Unfortunately, the purity number when calculated in this fashion can be biased if the 
leukocyte numbers are relatively constant, but the CTC number per patient varies (can 
vary over 3-orders of magnitude). We show in Table 2.1 the numbers of those cells 
selected and classified as CTCs and cells classified as leukocytes or double stained 
cells (CK(+) and CD45(+)) for several patients (n=4) with different states of disease as 






Figure 2.10 Staining and enumeration of CTCs via immunophenotyping. (A) Box plot 
representing results from the phenotypic enumeration of CTCs isolated from 7 PDX and 
3 healthy mice. (B) Box plot from CTCs isolated from 7 metastatic PDAC patients, 5 
healthy controls and 5 local resectable PDAC patients. (C) Fluorescence images of 
various selected cells from a metastatic PDAC patient: (i) CTC; (ii) two white blood cells; 
and (iii) cluster of CTCs. (b, f, j) CTC marker for Cytokeratin 8/19 (red) with b, j positive 
for this marker and f negative for this marker; and (c, g, k) leukocyte antigen marker 
CD45 (green) with c, k negative for this marker and g positive for this marker. 
Micrographs (i-l) are of an aggregate of 6 CTCs captured in the HT-CTC module. This 
aggregate showed positive for cytokeratins 8/19 (j) and negative for leukocyte marker 





For these studies, the cells were not released from the selection module using 
trypsin, but were enumerated directly within the selection module following staining 
within the same module. Without release using trypsin, potential damage to antigenic 
membrane targets could be avoided, which could misrepresent specific cell population 
numbers, including the leukocyte population. The purity for the PDX models was found 
to be 89 ±16%. The high purity levels observed in our studies compared to others were 
mainly due to the relatively high shear forces applied to the selected cells during the 
post selection wash, which used a linear velocity of 4 mms-1. While the CTCs selected 
on the channel walls remained unaffected by the high shear forces due to the high Kd 
value (3.3 x 108 M-1) between the EpCAM antigen and EpCAM antibody and the multi-
point contact, [29] the non-specifically adsorbed leukocytes are more easily removed 
from the surface due to their apparent lower adhesion force to the surface.  
As can be seen from this data, the number of leukocytes selected ranged from 
approximately 1 – 9 per mL of blood processed with the lowest infiltration rate of 
leukocytes found for the local resectable PDAC patients and highest numbers 
associated with the metastatic PDAC patients. Also, the CTC number varied 
tremendously as would be expected and as shown in Figure 2.10 of the main text for 
these three cases. From this data, the purity level as calculated using the method 




Table 2.1  Average number of CTCs, leukocytes and double-stained cells selected 
using the HT CTC selection module depicted in Figure 2.2 for two different PDAC 
pathologies and healthy donors. For this data, the selected cells were stained within the 
selection module and not released from the surface using trypsin. The cells were 
stained with DAPI (nucleus), cytokeratins and CD45. Each row of the data set 
corresponds to a different patient analyzed, which was performed in triplicate (blood 
sample, split into three equal volumes and run on three different HT-CTC modules). The 
number shown represents the mean for each patient. 
 Pathology  CTCs/mL  Leukocytes/mL  Double Stained Cells/mL 































Means 12 (±4) 0.8 (±0.9) 0.3 (±0.5) 












Means 68 (±25) 9 (±4) 2 
(±1) 
 
Also seen in this data for the healthy donors, one case we detected CTCs, which 
could be classified as a false positive result. However, follow up on this individual may 
be warranted because the CTC number may be indicative of a non-diagnosed 
micrometastatic or metastatic condition for not just PDAC, but any solid tumor that can 
produce CTCs. In addition, our data clearly shows that all cases that were diagnosed as 




false negative rate is 0 in this limited data set. However, a larger cohort of samples still 
needs to be analyzed to reach a concise clinical decision as to the false positive and 
false negative rate of CTC detection using our assay. This is currently ongoing in our 
laboratory. In addition, a rigorous comparison to the standard CTC analysis platform, 
CellSearch, must be undertaken and this work is also currently being undertaken in our 
laboratory and will be reported in subsequent manuscripts. 
We also noticed microclusters of CTCs in some of the PDAC blood samples (71%) 
that were processed (Figure. 7C i-l). These clusters were predominantly found near the 
entrance to the sinusoidal microchannels of the HT-CTC selection module. Recent 
reports on CTC isolation have cited the presence of similar clusters or microemboli. [43] 
It is speculated that these clusters form in circulation or break off from the primary tumor 
as a cohort of cells. As a cluster, CTCs can escape the immune surveillance system 
more readily than individual CTCs and can be indicative of an increased metastatic 
potential of the cancer. [6, 65]  
We also noted the presence of cells that stained positive for all three markers (DAPI, 
cytokeratins, and CD45). The frequency of the "triple positive" cells was on the order of 
1.6 ±2.0 cells/mL, which was lower than the CTC and/or leukocyte occurrence. This is 
contrary to other reports, which indicated a much higher frequency of such cells. [43] 
Although at this point we do not understand the origin of these cells, they could be a 
sub-population of CTCs acquiring mesenchymal markers or leukocytes with an 




classified as CTCs, however, they were included in purity calculations as contaminating 
cells 
2.4  Conclusion 
In this study we adopted a modular approach with 3 task-specific modules for 
processing CTCs in an automated fashion. The first module consisted of a HT-CTC 
selection module designed with a z-configuration to obtain uniform flow properties 
throughout an array of microchannels and was scalable to process volumes of 7.5 mL in 
less than 45 min. The selected cells could be released from the antibody-decorated 
selection surface and shuttled through an impedance sensor module. The inclusion of 
the impedance sensor module was useful as a prescreening tool to allow the user to 
make decisions based on the impedance response as to whether staining and imaging 
of selected CTC fractions was necessary, which can result in a significant reduction in 
assay cost and time. 
We also described a unique staining and imaging module consisting of a high 
density array of pore structures made at the intersection of large input channels and 
smaller interconnecting channels. This module demonstrated a significant reduction in 
the analysis time for CTC imaging; 6 h processing time for analyzing cells in the 
selection module to 10 min when using the staining and imaging module. Although the 
collection efficiencies were slightly lower for CTCs generated from clinical samples 
compared to cell lines, this can be rectified by re-engineering the pore structures 
comprising this device to possess smaller dimensions and at the same time increasing 




Using this system, we have achieved some interesting clinical data for PDAC as 
well, both local resectable and metastatic PDAC. We have detected CTCs in all patients 
diagnosed with PDAC (see SI Table 2.1) and with high purity resulting from the high 
shear forces exerted on the cells following selection in the HT-CTC module. This high 
purity level should provide the ability to secure high quality molecular profiles of the 
CTCs that can be used to guide therapy by stratifying patients with PDAC and other 
solid tumors. 
Using our integrated and modular system, CTC assay time was significantly 
reduced compared to the approach requiring manual processing. For the manual case, 
the assay time was found to be ~8 h (CTC selection, staining and imaging) with the 
majority of time relegated to imaging the relatively large selection bed. For the 
microsystem presented in this manuscript, the assay time was reduced to 1.5 h (45 min 
CTC selection time even for 7.5 mL of blood, 15 min release time, 20 min fixation, 
permeabilization and staining time and 10 min imaging time). 
The modular approach presented herein provides multiple advantages toward 
constructing integrated, sample-to-answer systems. These include: (i) flexibility in the 
selection of materials used for construction of task-specific modules to optimize 
performance for each processing step; (ii) ease of reconfiguration of fluidic cartridges 
without re-engineering the entire system in order to accommodate alternative and/or 
improved processing steps; (iii) ability to use separate production schemes optimized 
for each module in order to reduce the overall assay cost; and (iv) high production 




with the proper interconnection technologies which will minimize the potential CTC loss 
during processing due to existence of unswept volumes that may trap the CTCs. Our 
current efforts are directed toward integrating the modular assay using interconnects 
recently described by our group which will provide zero-dead volume fluidic path. [66]  
* All technical and clinical data were mainly contributed by authors J.Kamande 
and M. Hupert. Collaborator and author J.J Yeh mainly obtained the blood samples 
under an approved IRB #11-1924 (see appendix and permissions sections). 
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CHAPTER 3. MOLECULAR PROFILING OF ENRICHED LOW-ABUNDANCE 
CIRCULATING TUMOR CELLS (CTCS) USING A HIGH-THROUGHPUT 
MICROFLUIDIC SYSTEM. 
3.1  Introduction 
Propagated malignancy is the main cause of cancer-related deaths. Despite the 
harmful and destructive growth at the site of origin, primary tumors are only responsible 
for only 10% of cancer-related deaths while 90% are due to metastases occurring at the 
time of diagnosis or as a recurrence of a previously diagnosed cancer [1-3]. It has been 
speculated that cancerous tissues shed cells into the bloodstream, which are 
responsible for the metastasis of cancer.  This process is not well understood however, 
mouse models of tumor spread have implicated the process of an epithelial to 
mesenchymal transition (EMT) by which adherent epithelial cells acquire migratory cell 
fates. These models, however, differ significantly from human cancer metastases and 
therefore the study of this process in mouse models is limited [4]. A better 
understanding of human metastases can be obtained only from the study of Circulating 
Tumor Cells (CTCs). In carcinomas, CTCs are epithelial in origin; they overexpress 
EpCAM surface antigens, which is only expressed on malignant tumors derived from 
epithelia and is usually targeted in peripheral blood using monoclonal antibodies 
specific for EpCAM. CTCs appear at very low frequencies of about 1 CTC in 1×109 
hematological cells.  
---------------------------------- 
* Reproduced with permission from the Analytical Chemistry. Work presented in this 
chapter is centered on the molecular profiling of colorectal CTCs and authors JK, UD, 




Elucidating the quantity of CTCs in peripheral blood can serve as an indicator for the 
clinical management of several cancer-related diseases by providing information on the 
success/failure of therapeutic intervention and disease stage forecasting. Isolation and 
enumeration of exfoliated CTCs in peripheral blood or bone marrow for a variety of 
cancer-related diseases has already been reported such as breast, colorectal, prostrate, 
renal, bladder and non-small cancers. [5-9] Studies have shown that the presence of >5 
CTCs in 7.5 mL of blood from metastatic breast cancer patients has been associated 
with poor prognosis and overall survival. [3, 9, 10] 
Multiple approaches have been used to detect CTCs, ranging from size-based 
separations to the use of immunomagnetic beads containing antibodies directed against 
EpCAM [11, 12]. Although the establishment of CTC levels in peripheral blood has been 
associated with poor prognosis, there are reports suggesting that this information may 
not correlate with the degree of metastases, but their molecular profiles should be more 
informative [13-16]. Tumors contain genetically heterogeneous cell subpopulations with 
different propensities to spawn metastatic disease and therefore, if the CTC population 
responsible for metastasis could be identified through unique genetic profiles, 
oncologists could match proper therapy to the individual patient. Molecular profiling of 
CTCs can provide additional clinical information that cannot be garnered simply by 
enumerating the selected cells. For example, mutations in certain gene fragments that 
are associated with metastasis, such as the KRAS mutations in colorectal cancer, can 
provide opportunities for personalized treatment of a patient. It has already been shown 




therapy, whereas  patients  with  wild-type  KRAS genotypes do benefit  from  ceturimab  
and panitumumab-based treatments. [17-19] In addition, it has been noted that non-
tumor epithelial cells can also be present in the blood and express antigens that would 
select these cells as well. 
Human colorectal carcinomas harbor 19 different KRAS mutations the majority of 
which are clustered in two codons. Approximately 90% of the activating mutations in the 
KRAS gene are scored in codon 12 (wild type: GGT) and 13 (wild type: GGC) in exon 1 
while only 5% are located in codon 61 (wild type: CAA) in exon 2. PCR/LDR assay is a 
sensitive and specific method to identify and score the presence of KRAS mutations. 
This assay was developed by Barany et al. and is presented schematically in Scheme 




Scheme 3.1 Overview of the molecular profiling strategy adopted for CTCs 




The attractive nature of this assay strategy for the mass-limited samples anticipated 
for CTC analyses is that two stages of amplification are used; exponential amplification 
associated with the polymerase chain reaction, PCR, and also a linear amplification 
using the ligase detection reaction LDR. In addition the assay can be configured in a 
highly multiplexed fashion to search for many mutations in a single processing step. 
In this Chapter, we will primarily focus on KRAS mutational analysis of CRC CTCs 
that were enriched via a previously reported microfluidic system. [20] The system 
included; (i) Selection, release and subsequent enumeration of CTCs via a previously 
reported high-throughput microsampling unit(HTMSU) (see Figure 3.1); and (ii) an 
electrokinetic micromanipulation unit for enrichment of low-abundant CTCs for 
subsequent molecular profiling of rare point mutations in gDNA of the CTCs. CTCs were 
enriched into a reservoir (2 µL) for subsequent molecular interrogation for detection of 
point mutations in gDNA. SW620 cells from colorectal circulating cancer cell line were 
used as a model. The selected cells were enumerated using on-chip conductivity 
transducer, thereby, the enumerated cells were directed to a manipulation section for 
pre-enrichment into a cell collection cassette. The enriched CTCs were collected and 
gDNA was extracted for genotyping. Because most KRAS mutations are localized to 
codon 12 and to a lesser extent codons 13 and 61, the PCR/LDR/CE assay was 
performed on KRAS oncogenes (codons 12) to detect the presence/absence of point 





3.2  Experimental 
3.2.1 Materials and Reagents 
PMMA substrates and cover plates (0.5 mm thickness) were purchased from Good 
Fellow (Berwyn, PA). Platinum wires were purchased from Alfa Aesar (Boston, MA). 
Polyimidecoated fused silica capillaries were purchased from Polymicro Technologies 
(Phoenix, AZ). Chemicals used for the PMMA surface cleaning and modification 
included reagent grade isopropyl alcohol, 1-ethyl-3-[3-dimethylaminopropyl] 
carbodimide hydrochloride (EDC), N-hydroxysuccinimide (NHS), fetal bovine serum and 
2-(4-morpholino)-ethane sulfonic acid (MES) and these were purchased from Sigma-
Aldrich (St. Louis, MO). Monoclonal anti-EpCAM antibody was obtained from R&D 
Systems (Minneapolis, MN). The SW620 (colorectal cancer cell line), growth media, 
HEPES buffer, Phosphate Buffered Saline (PBS) and trypsin were purchased from 
American Type Culture Collection (Manassas, VA). Citrated rabbit blood was purchased 
from Colorado Serum Company (Denver, CO). TRIS-glycine buffer was obtained from 
Bio-Rad Laboratories (Hercules, CA). All solutions were prepared in nuclease-free 
water, Invitrogen (Carlsbad, CA). Nuclease-free microfuge tubes were purchased from 
Ambion (Foster City, CA) and were used for preparation and storage of all samples and 
reagents. A fluorescein derivative, PKH67, was purchased from Sigma-Aldrich. 
Oligonucleotide probes and primers were obtained from two different sources, 




3.2.2 Cell Culture and Imaging 
SW620 cells were cultured to 80% confluence in Dulbecco’s Modified Eagle’s 
Medium supplemented with high glucose containing 1.5 g/L sodium bicarbonate 
(NaHCO3), 15 mM HEPES buffer, and 10% fetal bovine serum. A cell stripper solution 
was prepared in 150 mM PBS and used to harvest the SW620 cells from the culturing 
plate. SW620 cells were stained with PKH67 for microscopic visualization experiments 
using fluorescence. A modified protocol for cell staining was implemented whereby the 
dye concentration was increased twofold resulting in more evenly distributed fluorescent 
labels over the cell’s periphery. Cell counts were determined by counting three aliquots 
of cells in succession using a hemacytometer. The cell count accuracy was within 10%. 
In cases where the cells required optical visualization to assist in the operational 
optimization of the HTMSU or the electro-manipulation unit, the PMMA devices were 
fixed onto a programmable motorized stage of an Axiovert 200M (Carl Zeiss, 
Thornwood, NY) microscope and video images were collected during each experiment 
at 30 frames/s using a monochrome CCD (JAI CV252, San Jose, CA). A Xe arc lamp 
was used to excite the fluorescent dyes incorporated into the cells’ membrane. 
3.2.3 Fabrication of Microsampling Unit 
The microfluidic chips were hot embossed into PMMA substrates via micro-
replication from a metal mold master. A detailed description of the HTMSU fabrication 
protocol was given in Adams et al. [21] The HTMSU consisted of a series of 51 high-




channel was 150 µm (depth) × 30 µm (width) and shared common inlet/outlet ports 
(Figure 3.1A). Curvilinear shaped capture channels were used to improve the cell 
capture efficiency as described previously. [21] The cell-free marginal zone apparent in 
straight channels was not observed in curvilinear channels and the cell radial 
distribution was unaffected by changes in cell translational velocity. Cells migrate to the 
outside of the curved channels due to centrifugal forces acting on the cells and the 
cross-stream velocity component due to the reversal of the direction of curvature. The 
result is an increase in the antibody/antigen encounter rate as the cells moved through 
the capture beds at the relatively high-linear velocities used here. The channel width of 
the cell capture bed (30 µm) was comparable with the average target cell diameter, 
which was used to increase the probability of cell–antigen interactions with the solution-
borne target cells. The large channel depth (150 µm) was selected to reduce the 
pressure drop in high-volume flow rates and also, to increase sample processing 
throughput.  
Before final assembly, 1 mm holes were drilled into the electro-manipulation unit 
reservoirs, input port and electrodes. Then, the chips were washed with ~0.5% Alconox 
solution, rinsed and ultrasonicated with DI water followed by rinsing with 2-propanol, 
and again ultrasonication for 15 min in DI water. The channels were examined under a 
microscope to ensure they were not filled with debris. The embossed devices were 
assembled by heat annealing a coverplate made from the same material to the 
substrate. The coverplate and substrate were clamped together and placed in a 




unmodified HTMSU. After successful heat annealing, the 125 µm diameter Pt wire 
wrapped Cu electrodes were placed into the drilled holes in electro-manipulation unit. 
The other end of the Pt wire was inserted into the holes drilled in opposite ends of the 
microchannel.  
Appropriately cleaned PMMA HTMSUs devices and cover plates were exposed 
through a mask to UV radiation resulting in the formation of carboxylate moieties only in 
the exposed areas of the PMMA. The exposed areas were restricted to only the cell 
capture bed region of the device. UV irradiation was performed through an aluminum 
mask for 10 min at 15 mWcm-2 to facilitate the formation of the carboxylated scaffold.  
Pt electrodes (d = 76 µm) served as the contact conductivity sensor in the detection 
zone of the HTMSU and were placed into guide channels that were positioned 
orthogonal to the fluidic output channel following thermal assembly. Then, Pt wires 
positioned in HTMSU and the cover plate were aligned and clamped together between 
two borosilicate plates. Insertion of the electrodes was monitored using a microscope to 
carefully control the inter-electrode gap (~50 µm). The cell constant of the Pt 
conductivity sensor, K, was ~0.01 µm-1, which allowed for the specific detection of 
SW620 cells based on their average size (diameter=25 µm). 
3.2.4 Antibody Immobilization 
Antibody immobilization was carried out in a two-step process. The UV-modified 
thermally assembled HTMSU device was loaded with a solution containing 4mg/mL 
EDC, 6 mg/mL NHS in 150 mM MES (pH~6) for 1h at room temperature to obtain the 




removed by flushing nuclease-free water through the device. Then, an aliquot of 1.0 
mg/mL of the monoclonal anti-EpCAM antibody solution contained in 50 mM PBS 
(pH~7.4) was introduced into the HTMSU and allowed to react for 4 h. The device was 
then rinsed with a solution of PBS (pH~7.4) to remove any non-specifically bound anti-
EpCAM antibodies. 
3.2.5 SW620 Cell Capture, Release and Enumeration Using the HTMSU 
To connect the HTMSU to the pump, a luer lock syringe (Hamilton, Reno, NV) was 
placed on the pump equipped with a luer-to-capillary adapter (Inovaquartz, Phoenix, 
AZ). This was then attached to the capillary that was sealed to the input port of the 
HTMSU. A pre-capture rinse was performed with 0.2 mL of 150 mM PBS at 50 mm/s 
linear velocity to maintain isotonic conditions. Then, the appropriate volume of a cell 
suspension was introduced at the 27.5 µL/min volumetric flow rate, which is optimized 
by Adams et al. to produce the desired linear velocity of 2 mm/s in each microchannel 
comprising the capture bed. Next, a post-capture rinse was performed with 0.2 mL of 
150 mM PBS at 50 mm/s to remove any non-specifically adsorbed cells. 
Following a post cell capture rinse, a 0.25% trypsin solution in 0.2 mM TRIS/ 19.2 
mM glycine buffer (pH ~8.3) was infused into the HTMSU. The captured cells could be 
observed under a microscope until they were enzymatically removed with Stoke’s forces 
acting on the wall.   
The released cells from the capture surface were traversed at 1 µL/min (mm/s) linear 
flow rate through a set of Pt electrodes. We used a specially designed circuit as 




passing the detector as a function of time to create the desired conductivity trace from 






Scheme 3.2 CTC selection assay on PMMA based HTMSU device. First panel 
illustrates the exposure of PMMA to UV radiation to generate a monolayer of 
carboxylic acid moieties that facilitate antibody attachment. The second panel 
shows the selection of CTCs from blood after covalent attachment of anti - EpCAM 
to the PMMA substrate. Third panel illustrates the elution of unbound cells (RBCs 





3.2.6  DNA Extraction 
Genomic DNA (gDNA) was extracted from captured cells using Lyse-and-Go PCR 
reagent (Pierce Biotechnology, IL, USA). Following the manufacturer’s 
recommendations, 5 µL of Lyse-and-Go PCR reagent was added to a known number of 
cells and thermocycled using the following temperatures: 65 ˚C for 30 s; 8 ˚C for 30 s; 
65 ˚C for 90 s; 97 ˚C for 180 s; 8 ˚C for 60 s; 65 ˚C for 180 s; 97 ˚C for 60s; 65 ˚C for 60 
s. Prior to the addition of the PCR cocktail, the samples were put to hold at 80 ˚C 
3.2.7 PCRs, LDRs and CE 
PCR amplifications were carried out to generate 290 bp amplicons of SW620 using 
the gene-specific primer sequences: exon 1 forward –5’ TTA AAA GGT ACT GGT GGA 
GTA TTT GAT A 3’, (Tm = 55.4 
0C) and exon 1 reverse – 5’ AAA ATG GTC AGA GAA 
ACC TTT ATC TGT 3’(Tm = 56.3 
˚C).  In here, 45 µL of a PCR cocktail containing 10 
mM TRIS–HCl buffer (pH~8.3), 50 mM KCl, 1.5 mM MgCl2, 200 µM dNTPs, and 0.4 µM 
of each forward and reverse primers (sequences shown above) was added to the cell 
lysate previously held  at 80 ˚C in the thermo cycler. After a 2-min initial denaturation, 
1.5 U of AmpliTaq DNA polymerase (Applied Biosystems, Foster City, CA, USA) was 
added under hot-start conditions and amplification was achieved by thermally cycling for 
30 cycles at 95 ˚C for 30 s, 60 ˚C for 2 min, and a final extension at 72 ˚C for 3 min.  
To test the fidelity and yield of the PCR, slab gel electrophoresis was run on an 
aliquot of each reaction. From each aliquot either 2 µL PCR product for standard cell 




loading dye and 3 µL of 1X TBE buffer for standard cell solution or 2 µL of 1X TBE 
buffer for microchip processed solution, then the mixture was loaded into an individual 
well of a Ethidium bromide prestained 3% agarose gel (Bio-Rad Laboratories, Hercules, 
CA). The slab gel electrophoresis was typically run at 5 V/cm for 30 min. The developed 
slab gel images were captured using Gel Logic 200 Visualizer (Carestream Molecular 
imaging, New Haven, CT) 
Bench-top LDRs were executed in a total volume of 20 µL in 0.2 mL polypropylene 
microtubes using a commercial thermal cycling machine (Eppendorf Thermal Cycler 
(Brinkmann Instrument, Westbury, NY, USA). The reaction cocktail typically employed 
in this work consisted of 10 mM TRIS–HCl (pH~8.3), 25 mM KCl, 10 mM MgCl2, 0.5 mM 
NAD+ (nicotinic adenine dinucleotide, a cofactor for ligase enzyme), and 0.01% Triton 
X-100, 2 µL of 100 nM of the discriminating primer: 5’ 
AAACTTGTGGTAGTTGGAGCTGT 3’ (Tm=71.3 
0C) and fluorescently labeled freshly 
phosphorylated common primer: 5’ Phos/TGGCGTAGGCAAGAGTGCCT/Cy5.5Sp 3’ 
(Tm = 63.5 
0C) and 2 µL of the PCR product as template.  40 U of Taq DNA ligase (New 
England Biolabs) was added to the cocktail under hotstart conditions and the reactions 
were thermally cycled 20 times for 30 s at 94 0C and 2 min at 65 0C. The LDR products 
were stored at 4 0C until needed for capillary gel electrophoresis (CGE). 
The LDR products were separated using a CEQ 8000 Genetic Analysis System 
(Beckman Coulter, Fullerton, CA, USA). Data acquisition was performed using the 




3.3  Results and Discussion 
3.3.1 PCRs/LDRs/CE 
A method that can detect single point mutations in DNA is the ligase detection 
reaction (LDR) coupled to a PCR.[22-30] A schematic of the PCR/LDR is depicted in 
Scheme 3.1. Following PCR amplification of the appropriate gene fragments, which 
contain sections of the gene with point mutation(s), the amplicon is mixed with two LDR 
primers: common and discriminating that flank the point mutation of interest. The 
discriminating primer contains a base at its 3’-end that coincides with the single base 
mutation site. If bases are mismatched, ligation of the two primers does not occur. A 
perfect match, however, results in a ligation of the two primers and product length that is 
the sum of nucleotides from two primers.  
In our experiment, captured and enumerated cells (see Figure 3.1) were lysed and 
PCR/LDR assay has been performed using their purified genetic material. Specifically, 
point mutations in codon 12 in the KRAS gene (12.2V) have been targeted that occurs 
in cell line SW620. Most of KRAS mutations are localized in codon 12, but they are also 
present in 13 and 61 [31-38] and they are found in nearly 35–50% of all patients with 
colorectal cancer. [39-41] Once acquired, KRAS mutations are conserved throughout 






Figure 3.1 Diagrams of the microfluidic system made via micro-replication into 
PMMA from a metal mold master. and agarose gel electrophoresis of the PCR products. 
(A) Cell selection HTMSU. The capture bed consisted of curvilinear channels that were 
30 mm wide and 150 mm deep (51 channels). (B) Brightfield images represents time 
lapse micrographs of a captured SW620 cell(a) under 0.25%w/w trypsin processing 
which took 20 min for release(b).  Flow rate for cell capture was 27µl/min. linear flow 
velocity of 2mm/s (C) Impedance readout of approximately 26 SW620 cells released 
from the capture bed at linear velocity of 2mm/s. PCR was set for 32 cycles. Each cycle: 
94 °C (30 s), 60 °C (30 s),72 °C (40 s). Gel stained with EtBr products separated at 4.8 
V/cm. (D) Gel Electropherogram for PCR performed on  standard SW620 samples (a) 
no gDNA template, Negative control;  (b) DNA from 10 SW620 cells; (c) DNA from 20 
SW620 cells; (d) DNA from 50 SW620 cells; (e) DNA from 100 SW620 cells; (f) DNA 
from 500 SW620 cells; (g) DNA from 1,000 SW620 cells; (h) DNA from 5,000 SW620 
cells; (i) gDNA template from SW620, Positive control; Lanes a-i contains 3 µL of DNA 
amplicons. (E) Gel Electropherogram for PCR performed on SW620 cells obtained from 
HTMSU selection followed by electrokinetic enrichment a) gDNA template from SW620, 
Positive control; (b) PCR product from 10 SW620 cells selected from whole blood using 
HTMSU (c) PCR product from whole blood with no SW620 cells (d) no gDNA template, 






Before cells from the chip were tested using PCR/LDR, an assay was tested on 
varying number of SW620 cells;10, 20, 50, 100, 500, 1,000, and 5,000 cells to acquire 
information on limit of detection of the assay.  As shown in the gel image in Figure 3.1D, 
cells ranging from 5,000 to as low as 10 were successfully amplified to yield 300 bp 
PCR product. To demonstrate the capability of the integrated microenrichement system 
in the pre-concentration of the selected CTCs for subsequent molecular profiling, an 
average volume (~1 mL) of whole blood containing low abundant CTCs was processed. 
As a result, 10 SW620 cells were selected and enriched from 1 mL of whole blood and 
subjected to PCR yielding the results shown in the Figure 3.1E lane b. The presence of 
mutations within the amplified DNA sequence (~ 300 bp) was discerned by a follow-up 
allele-specific ligation. The LDR common primer possessed a Cy5.5 fluorescent label 
and a 5’ phosphorylation modification to facilitate covalent coupling with the unmodified 
discriminating primer in the event of successful ligation. Point mutations were confirmed 
by the formation of a 43 nt LDR product, which indicated that the ligation event had 
occurred between a 23 nt and 20 nt long discriminating and common primers. The 
capillary gel electrophoresis results of LDR product separation generated from PCR 
products of different number of cells are shown in Figures 3.2A-H. Clearly, LDR results 
showed a detectable signal generated from CTCs samples (43 nt peak labeled (b)) in 








Figure 3.2 The LDR mixtures contained a discriminating and common primers for 
KRAS c12.2V, could selectively detect mutations in G12V. Two µL of amplicons from 
PCR with SW620 (mutant) were used for analyzing point mutation in the KRAS gene. 
LDR was set for 20 cycles. Initial denaturation 95 °C for 2 min. Each cycle consisted 
of: 95 °C (30s), 65 °C (2 min), and 4 °C as final hold. LDR was performed at capillary 
temperature of 60°C, denaturation temperature of 90 °C (3 min),  Injection at 2.0 kV 
(30 s) and separation at 6.0 kV (20 min).  Peak a represents the primer and peak b is 
the LDR product. CGE analysis was acquired for the following samples; A) 0 B) 10 C) 
20 D) 50 E) 100 F) 500 and G) 5,000 SW620 CTCs. The insets shown in (A) and (B) 
represent a magnified view of the LDR product peaks. H) CGE trace for LDR analysis 
of 50 HT29 CTCs. DNA size markers of 20 and 80 nt were co-electrophoresed with 




Whole blood without CTCs and whole blood containing 10 CTCs was processed via 
HTMSU and electro-manipulation system, the results of which are shown in Figure 3.3A 
and 3.3B respectively. As expected, our results showed no mutation in the whole blood 
that contained no CTCs (Figure 3.3A) while the results of whole blood containing 10 
SW620 cells were positive (Figure 3.3B). These results indicated that the HTMSU and 
electro-manipulation system were very efficient platforms, which can be adopted for cell 
capture, release and enumeration for subsequent highly specific mutation profiling of 
low abundant CTCs. 
 
 
Figure 3.3 Two µl of amplicons from PCR were used for analyzing point mutation in 
the KRAS gene for blood samples spiked with and without 10 SW620s. The LDR 
products were analyzed using capillary electrophoresis. The capillary electrophoresis 
responses for sample after processing blood with no SW620 are shown in A, and B 
shows the electropherogram for 10 spiked SW620s in blood. Peak ‘a’ represents the 




3.4  Conclusion 
We have successfully demonstrated the ability to carry out KRAS mutational 
analysis from as low as 10 CTCs in blood using an integrated system via a high 
throughput microsampling unit (HTMSU) for selection and enumeration followed by the 
electrokinetic manipulation unit for pre-concentrating the cells into as low volumes of 2 
µL. Though only a single point mutation was analyzed as a proof of concept for CTC 
genotyping using the microfluidic system, we envision our technique being multiplexed 
through the use of a primary PCR of the gene of interest. This could be followed by 
multiplex LDR with different primer pairs that flank multiple mutation sites being 
interrogated. Finally, moving the PCR/LDR step to a microfluidic chip could reduce 
processing time, eliminate the potential of contamination when implemented in a 
centralized laboratory, and provide full process automation. Work is currently underway 
in our laboratory to realize such a system. Ultimately, evaluation of this assay for 
uncovering the presence/absence of prognostic mutations in the genome of CTCs 
isolated from blood samples secured from patients with metastatic CRC is the next step 
in evaluating the utility of our assay for assisting in the management of CRC-related 
diseases. 
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CHAPTER 4. ISOLATION AND CHARACTERIZATION OF CIRCULATING MULTIPLE 
MYELOMA CELLS (CMMCS) USING A POLYMER MICROFLUIDIC DEVICE 
4.1  Introduction 
Multiple myeloma (MM) is an incurable hematological neoplasm, which 
constitutes 1% of all cancers diagnosed. [1, 2] This condition is associated with the 
abnormal expansion of terminally differentiated B clonal plasma cells in the bone 
marrow. DNA breaks as a result of additional variable diversity joining (VDJ) gene 
rearrangements, hypersomatic genetic changes and isotype class switching that occur 
in the Ig heavy chain variable region in post germinal centers give rise to malignant 
clonal plasma cells. [3, 4] These pathological cells produce a toxic monoclonal-
paraprotein in the serum, which in turn affects the kidneys leading to renal failure.  
Anemia is also associated with MM as a result of suppression of other vital blood-
forming cells in the bone marrow by the plasma cells.[5]  
The prognosis for this condition is dim with a 5 year survival rate of 40%. High 
dose chemotherapy followed by autologous transplantation is the only current treatment 
option for this condition. The International myeloma working group (IMWG), has defined 
three stages of progression for MM: (i) MGUS (monoclonal gammopathy of 
undetermined significance), considered as the premalignant stage of MM. It is 
characterized by the presence of low monoclonal protein in the serum of less than 
30g/L, less than 10% of clonal plasma cells in the bone marrow and no symptoms of 
end organ damage such as hypercalcemia, renal insufficiency and bone lesions 




with a higher risk progression to symptomatic myeloma (10% per year) than MGUS (1% 
per year). It is characterized by the presence of equal or more than 30g/L of monoclonal 
protein in the serum and/or a proportion of more than 10% of clonal plasma cells in the 
bone marrow but no symptoms of end organ stage damage (CRAB). (iii) Final advanced 
stage is the symptomatic myeloma stage referred to as active MM and is characterized 
by greater than 10% of clonal plasma cells in the bone marrow, presence of monoclonal 
protein in the serum (≥30g/L) and urine and evidence of end organ stage damage 
(CRAB). [2, 6] 
The presence of circulating multiple myeloma cells (CMMCs) in peripheral blood 
have been considered clinically significant because: (i) Studies have shown that the 
frequency of occurrence of CMMCs can be used as a measure of disease activity; [7] 
(ii)  CMMCs can serve as an independent prognostic factor for survival in  MGUS, SMM 
and active MM; [8] and (iii) CMMC presence in blood may hinder autologous 
transplantation protocols that rely on circulating stem cells in the peripheral blood. [1, 7, 
9] It therefore follows that CMMCs have the potential to be viewed as critical biomarkers 
for MM disease staging, designing therapy, and monitoring patients with minimal 
residual disease. Furthermore, CMMCs could be used as surrogates for tissue biology 
studies.  
However, CMMCs are rarely found in the peripheral blood and when present, 
constitute approximately 0.1% of the total blood composition. [1] Conventional 
techniques for CMMC detection have been primarily based on slide-based 




molecular methods for Ig gene rearrangements. [15] Slide-based immunofluorescence 
techniques are routinely used for the clinical assessment of blood smears, however they 
suffer from poor sensitivity and thus, unsuitable for very low level of CMMC detection, 
especially in the asymptomatic MGUS stage. Though flow cytometry has been shown to 
be more sensitive (1 CMMC per 10,000 peripheral blood cells,  PBCs) than 
morphological based methods, flow cytometry requires a large sample volume and 
many complex sample processing steps such as red blood cell lysis and cell staining 
procedures that may lead to CMMC loss. Molecular methods, on the other hand, have 
been documented to be more sensitive (1 CMMC : 100,000 PBCs). [15]  
 Microfluidic devices have been shown to provide better sensitivity for the 
detection and enumeration of low abundant samples, such as circulating tumor cells 
(CTCs) in blood whose frequency of occurrence are on the order of 1:109 PBCs. [16-24] 
Advantages of using microfluidics for the enrichment of rare cells are;(i) they have the 
ability to select CTCs with low expression of the target antigen; (ii) there is less damage 
to fragile cells due to low shear stress; and (iii) minimal sample preparation is required 
prior to analysis. The detection of CMMCs in peripheral blood can be paralleled to the 
detection of epithelial CTCs in peripheral blood when considering the analysis modality 
based upon a positive selection process in which antibodies are used to capture cells 
expressing unique antigens targeted by the selection antibody. CTCs and CMMCs are 
both low abundant and have prognostic significance; the only difference is that CTCs 




A number of studies for the microfluidic enrichment of CTCs have been 
documented and have demonstrated superior performance criteria in terms of 
throughput, purity, and recovery compared to slide-based immunofluorescence, flow 
cytometry, and molecular techniques for the detection of these rare cells. [18, 22, 25] 
Microfluidics could offer several advantages for CMMC analysis such as: (i) Requiring 
smaller input volumes than flow cytometry as well as minimal reagents for staining 
producing a reduced assay cost; (ii) selected cells may be made available for post 
analysis, such as gene profiling and propagation; and (iii) in-situ immunofluorescence 
as well as in-situ FISH assays are feasible, which is significant for prognostic studies 
involving MM.  
 In a pilot study involving 20 MM patients with different disease classifications of 
SMM and active MM, we demonstrate the diagnostic utility of a polymer-based 
microfluidic device (coined here as a CMMC selection device) for the high sensitivity 
analysis of CMMCs directly from peripheral blood. We have previously demonstrated 
the isolation and enumeration of pancreatic CTCs using a similar device, which 
provided high purity (~86%) of the selected cell fraction and high sensitivity (51 
CTCs/mL) for clinical samples and utilized anti-EpCAM antibodies for the selection of 
the CTCs bearing EpCAM antigens. [24] In this work, we demonstrate the ability to 
select CMMCs via affinity selection using anti-human CD138 as the selection antibody. 
In addition, we perform in-situ immunophenotyping by using fluorescently-labeled 
CD56+/CD38+/CD45- markers for the positive identification of CMMCs with respect to 




identification of monoclonal CMMCs by cytoplasmic immunoglobulin (cIg) light-chain 
staining for the κ and λ light chains. The data presented in this work also describes the 
ability to correlate the number of CMMCs selected with disease classification (SMM and 
MM). Finally, we assess the ability to determine the KRAS mutational status of gDNA 
isolated from CMMCs selected from patient samples using a highly sensitive 
PCR/LDR/CE assay.  To the best of our knowledge, this is the first report on the use of 
a microfluidic device for the analysis of CMMCs directly from clinical patient samples. 
4.2  Experimental 
4.2.1 Fabrication of the CMMC Selection Device 
 Hot embossing and laser ablation were used as the primary tools for fabrication 
of the CMMC selection device as described previously.[26] Mold masters used for hot 
embossing were prepared in brass using high precision-micromilling (KERN 44, KERN 
Micro- und Feinwerktechnik GmbH & Co.KG; Murnau, Germany) and standard carbide 
bits (Performance Micro Tool, Janesville, WI).[26] Hot embossing of polymer 
microfluidic devices was performed using a HEX03 hot embossing machine (Jenoptik 
Optical Systems GmbH, Jena, Germany). The embossing conditions consisted of a 
temperature of 155°C and 30 kN force for 120 s for the cyclic olefin copolymer, COC, 
substrates and 160°C and 20 kN force for 240 s for poly(methylmethacrylate), PMMA, 
substrates. Laser milling was accomplished using an ArF excimer laser (Rapid X 250, 
Resonetics Inc., Nashua, NH) with a laser fluence at the workpiece of ~15 J/cm2 and a 




The CMMC selection device (see Figure 4.2) was made from the thermoplastic, 
cyclic olefin copolymer, COC, due to its ability to be embossed with high aspect ratio 
microstructures, its optical clarity, its propensity to be UV functionalized with high 
efficiency irrespective of channel aspect ratio, and the minimal amounts of non-specific 
adsorption of contaminating cells as reported elsewhere. [27] The CMMC selection 
device consisted of an array of high-aspect ratio sinusoidal microchannels with a 
nominal width of 30 µm and depth of 150 µm serving as the selection bed. Selection 
beds consisted of 50 sinusoidal microchannels, which were addressed using a single 
inlet and outlet microchannel arranged in a unique z-configuration.  
After hot embossing, the CMMC selection device and cover plate, both of which 
were made from the same material, were flood exposed to broad band UV light at ~22 
mW/cm2 (measured at 254 nm) for 15 min using a home-built system employing a low 
pressure Hg grid lamp (GLF-42, Jelight Company Inc., Irvine, CA). UV exposure 
produced carboxylic acid surface scaffolds that were used for the covalent attachment 
of monoclonal antibodies for CMMC selection (anti-CD138 antibodies).[28, 29] After UV 
exposure, the substrate was enclosed with the cover plate by thermal fusion bonding at 
a temperature of 132°C and a bonding pressure of ~1 N/cm2. Bonding conditions were 
carefully selected to achieve high bond strength to accommodate the high pressures 
generated from pumping high viscosity fluids (i.e., whole blood) at relatively high volume 
flow rates (~27 µL/min), but preserve structural integrity of the high-aspect ratio 




After assembly, the surface of the microfluidic channels was modified using EDC-
NHS chemistry. This consisted of 50 mg/mL EDC (1-Ethyl-3-[3-
dimethylaminopropyl]carbodiimide hydrochloride), 5 mg/mL NHS (N-
hydroxysuccinimide) in 100 mM MES (pH 6) followed by incubation with a solution of 
anti-CD138 monoclonal antibodies (0.5 mg/mL; 150 mM PBS buffer, pH 7.4) overnight 
at 4°C. The optimum concentration of the antibody was chosen based on studies to 
optimize CTC recovery as reported elsewhere. [24] 
In the case of impedance sensing of single cells, a separate device, which was 
made in PMMA, consisting of two perpendicular microchannels was fabricated via hot 
embossing from a mold master. A microchannel with dimensions of 50 µm width x 75 
µm depth served as a conduit for cells flowing through this module. The second 
microchannel (75 x 75 µm2) was used as guides to place two Pt wires, which were used 
as electrodes for making the single-cell impedance measurements. Impedance 
measurements were conducted using previously described circuitry.[30] Data were 
collected and analyzed using a NI-USB-6009 (National Instruments) data acquisition 
board and software written in LabView (National Instruments). Data were collected at 2 
kHz, which allowed for sample processing through the sensor at a maximum flow rate of 
20 µL/min (80 mm/s) without generating signal aliasing. 
Addressing the microfluidic network and connection between the CMMC 
selection device and the impedance sensor device was accomplished using glass 
capillaries (Polymicro Technologies, Phoenix, AZ) affixed to inlet and outlet ports 




(Permapoxy, Permatex, Hartford, CT). Capillaries were connected to each other using 
low dead volume interconnects secured from Polymicro. 
4.2.2 Materials 
Pt wires (75 µm diameter) were purchased from Sigma-Aldrich (St. Louis, MO). 
COC (Topas 6013S-04) plates (1/8” thick) and films (250 µm thick) were acquired from 
Topas Advanced Polymers, Florence KY. 1/8" thick PMMA hot embossing stock was 
acquired from SABIC Polymershapes (Raleigh, NC). 250 µm thick PMMA films were 
used as cover plates for the impedance devices and were purchased from Goodfellow 
Corporation (Oakdale, PA). PEEK tubing and connectors were purchased from IDEX 
Health & Science (Oak Harbor, WA). Chemicals used for PMMA and COC surface 
cleaning and modification included reagent grade isopropyl alcohol, 1-ethyl-3-[3-
dimethylaminopropyl] carbodiimide hydrochloride (EDC), N-hydroxysuccinimide (NHS), 
fetal bovine serum, and 2-(4-morpholino)-ethane sulfonic acid (MES) all of which were 
acquired from Sigma-Aldrich. Monoclonal anti-CD138 antibody was obtained from R&D 
Systems (Minneapolis, MN). Tris-glycine buffer was obtained from Bio-Rad Laboratories 
(Hercules, CA). PBS buffer and trypsin from porcine were purchased from Sigma-
Aldrich. For CMMC immunostaining, the nuclear stain DAPI was obtained from Thermo 
Pierce Technologies (Rockford, IL). For immunofluorescence analysis, antibodies, such 
as anti-CD138 pacific blue, anti-CD45-FITC (HI30 clone), anti-CD56-PE, anti-CD38-
APC, anti-Ig kappa light chain-FITC, and anti- Ig lambda light chain-APC, were 
purchased from eBiosciences (San Diego, CA). Propidium Iodide for viability analysis in 




Bovine serum albumin (BSA) in PBS buffer (pH 7.4) was secured from Sigma-Aldrich. 
MEM-non essential amino acids were obtained from GIBCO (Grand Island, NY GEAA).   
QIAamp DNA Mini Kit (Valencia, CA) for genomic DNA isolation and purification, 
custom made oligonucleotide probes and primers for both PCR and LDR reactions were 
obtained from Integrated DNA Technologies (IDT, Coralville, IA). Taq 2X master mix 
and Taq DNA ligase were purchased from New England Biolabs (NEB; Ipswich, MA). 
4.2.3 Cell Culture 
 The RPMI-8226 (multiple myeloma) cancer cell line was purchased from 
American Type Culture Collection (ATCC, Manassas, VA) and cultured according to 
recommended conditions. Briefly, the cell line was incubated at 37˚C under a 5% CO2 
atmosphere. RPMI 1640 with 2.5 mM L-glutamine supplemented with 10% FBS 
(GIBCO, Grand Island, NY) was used. For subculturing conditions, RPMI-8226 cells 
were grown as non-adherent cell suspensions in T25 culture flasks (Corning) by 
maintaining a cell density between 5 x 105 and 2 x 106 viable cells/mL with fresh media 
changes every 2-3 d either via dilution or replacement of new medium. 
4.2.4 Flow Cytometry: RPMI-8226 Surface Antigen Characterization 
 All flow studies were performed at the UNC Flow Cytometry Core Center. A 
Beckman Coulter (Dako) Cyan ADP instrument equipped with 11 parameter analysis 
capability – forward and side scatter and 9 colors of fluorescence using 405 nm, 488 nm 
and 635 nm excitations – was used. The software, which provided instrument control 




106 RPMI-8226 cells obtained from total culture media were centrifuged and 
resuspended in cold 0.5% BSA/PBS buffer in a 1.5 mL microcentrifuge tube. One-µg of 
Fc blocker (Human IgG) was added to the cell suspension and left to incubate on ice for 
15 min. Ten-µl of fluorescently-labeled antibody or Isotype control was added to the cell 
suspension and left to incubate for 45 min at 4˚C under dark conditions. Upon 
completion of immobilization of the surface antibody, cells were washed 3 times by 
centrifuging and replacing the buffer with cold 0.5% BSA/PBS. Right before flow 
cytometry analysis, propidium iodide (PI) was added for viability testing. 
4.2.5 Clinical Samples 
 Patients with different clinical stage classifications of multiple myeloma (MGUS, 
SMM or active MM) were recruited according to a protocol approved by the University of 
North Carolina’s IRB. Blood specimens from healthy volunteers were collected under a 
separate IRB-approved protocol. A total of 20 patients with unknown disease 
classifications were analyzed for CMMCs while a total of 6 healthy donor blood samples 
served as negative controls. All specimens were collected into BD Vacutainer® (Becton-
Dickinson, Franklin Lakes, NJ) tubes containing the anticoagulant EDTA and were 
processed within 5 h of the blood draw.  
4.2.6 CMMC Selection Device Operation 
Prior to blood sample infusion, the CMMCs selection module was thoroughly 
washed with 0.5%BSA/PBS buffer at a flow rate of 40 µL/min for at least 5 min in order 




into BD Vacutainer® tubes were placed on a nutator for at least 10 min to allow for 
homogenous distribution of blood components. Following homogenization, 0.5 mL to 2 
mL of patient blood was transferred into a disposable Luer LokTM syringe (BD 
Biosciences, Franklin Lakes, NJ) using a BD vacutainer female luer transfer adapter. 
Immediately after transfer, blood samples were processed through the CMMC selection 
device. A PHD2000 syringe pump (Harvard Apparatus, Holliston, MA) was used to 
hydrodynamically drive the blood through the CMMC selection device at the appropriate 
volume flow rate to attain an average linear velocity of sample through the sinusoidal 
microchannels (1.1 mm/s) that would maximize recovery of the CMMCs. During the 
course of blood sample introduction, the syringe was rotated by 180° along its 
longitudinal axis and lightly tapped in order to prevent sedimentation of the blood 
components inside the syringe to assure exhaustive and representative sample 
introduction. Finally, the CMMC selection device was flushed with 2.5 mL of 0.5% 
BSA/PBS at a linear velocity of 4 mm/s to remove any nonspecifically bound cells. At 
this point, the device was either submitted for on-chip immunofluorescence staining for 
phenotype identification or prepared for trypsin release of captured cells for impedance 
sensing of the selected CMMCs. 
4.2.7 On-chip Immunostaining of Phenotypic Cell Surface Antigens and 
Light Chain Cytoplasmic Immunoglobulins (λ light chains and κ light 
chains) 
Selected cells were analyzed for surface antigens via immunostaining by; (i) 
Treating with Fc blocker (IgG); (ii) incubation with anti-human CD45-FITC Abs, anti-




(iv) permeabilization with 0.1% Triton-X100; and incubation with nuclear staining dye, 
DAPI. For clonal population staining, selected cells were; (i) Fixed with 2% PFA; (ii) 
permeabilized with 0.1% Triton-X-100; and (iii) incubated with anti-human-Ig kappa light 
chain-FITC, and anti-human Ig lambda light chain-APC. The stained cells were imaged 
using an inverted Olympus 1X71 microscope (Center Valley, PA) using 10x, 20x, 40x, 
and 60x dry objectives equipped with a high resolution (1344 x 1024) CCD camera 
(Hamamatsu ORCA-03G) and a mercury arc lamp as an illumination source. Images 
were collected and analyzed using Metamorph imaging software (Olympus).   
4.2.8 Impedance Sensing 
 Following CMMC selection device rinsing, 200 µL of the CMMC release buffer 
consisting of 0.25% w/v trypsin in 25 mM TRIS/192 mM glycine buffer (pH 7.4) was 
infused through the CMMC selection device to allow for the release of CMMCs from the 
antibody-containing selection channels and the subsequent collection of the released 
CMMCs into a microcentrifuge tube. As the CMMCs traversed through the impedance 
sensor, an electrical signal was recorded using in-house designed and built electronics 
as described previously. [30] The raw output data was subjected to a 1,000 point 
adjacent averaging algorithm to establish the baseline for the measurement without 
generating signal bias. Baseline was then subtracted from the data in order to correct 
for signal drift. Impedance responses generated from CTCs were counted when the 
signal-to-noise ratio exceeded 3:1. Note that during blood infusion into the CMMC 
selection bed and the subsequent washing step, the output capillary of the CMMC 




going into a microfuge tube for waste collection. When the release buffer was 
introduced into the CMMC selection bed, the output capillary was then reconnected to 
the impedance sensing device. The output port of the impedance sensing device was 
also inserted into a 1.5 mL microcentrifuge tube where all released cells were collected 
for subsequent molecular analysis. 
4.2.9 KRAS Mutational Analysis of CMMCs 
 Genomic DNA (gDNA) was extracted and purified from HT-29 and RPMI-8226 
cell lines and released CMMCs using a QIAamp DNA Mini Kit (Valencia, CA). For on 
chip gDNA extraction, the lysing buffers provided in the kit were infused through the 
device and eluent was further processed and purified following the recommendations of 
the manufacturer.  
PCR amplifications were carried out to generate 290 bp amplicons of gDNA from 
HT-29, RPMI-8226 and CMMCs from clinical samples using gene-specific primer 
sequences (see Table 4.1 for KRAS primer sequence). The PCR cocktail consisted of a 
50 µL reaction consisting of 10 mM Tris-HCl, 50 mM KCl, 1.5 mM MgCl2, 0.2 mM 
dNTPs, 5% Glycerol, 0.08% IGEPAL® CA-630, 0.05% Tween® 20, 25 units/mL Taq 
DNA Polymerase, (pH 8.6) and cellular gDNA.  Amplification was achieved by thermally 
cycling for 35 cycles at 94˚C for 30 s, 59˚C for 2 min and a final extension at 72˚C for 3 
min. PCR was carried out using an Eppendorf Thermal Cycler (Brinkmann Instrument 




Table 4.1 KRAS PCR primer sequences 
KRAS  PCR 
primers 
Sequence Bases Tm(˚C) 
KRAS- Forward TTAAAAGGTACTGGTGGAGTATTTGATA 28 54.0 
KRAS- Reverse AAAATGGTCAGAGAAACCTTTATCTGT 27 54.8 
 
Slab gel electrophoresis was performed on an aliquot of the PCR products using 
a 3% agarose gel (Bio-Rad Laboratories, Hercules, CA) prestained with ethidium 
bromide. Amplicons were indexed against a DNA sizing ladder (50 – 1,000 bp, 
Molecular Probes, Eugene, OR).  Separation was performed at 4.8 V/cm in 164 1x TBE 
(Tris/Boric Acid/EDTA, Bio-Rad Laboratories). After separation, the gels were imaged 
using a Logic Gel imaging system (Eastman Kodak).  For KRAS mutational analysis, 
the PCR amplicons were either submitted for Sanger sequencing by Genewhiz 
Technologies(Research Triangle ParK N.C) or used for subsequent LDR analysis. For 
Sanger sequencing, DNA analyzer ABI 3730xl was used for capillary electrophoresis 
and fluorescent dye termination detection  
Bench-top LDRs were performed in a total volume of 20 µL in 0.2 mL 
polypropylene microtubes using a commercial thermal cycling machine (Eppendorf 
Thermal Cycler (Brinkmann Instrument, Westbury, NY, USA). The reaction cocktail 
typically employed in this work consisted of 10 mM TRIS–HCl (pH~8.3), 25 mM KCl, 10 
mM MgCl2, 0.5 mM NAD+ (nicotinic adenine dinucleotide, a cofactor for ligase enzyme), 
and 0.01% Triton X-100, 2 µL of 50 nM of the discriminating primers and fluorescently 
labeled freshly phosphorylated common primers (see Table 4.2 for the LDR common 




U of Taq DNA ligase (New England Biolabs) was added to the cocktail under hot-start 
conditions and the reactions were thermally cycled 20 times for 30 s at 94˚C and 2 min 
at 60˚C. The LDR products were stored at 4˚C until needed for capillary gel 
electrophoresis (CGE). The LDR products were separated using a CEQ 8000 Genetic 
Analysis System (Beckman Coulter, Fullerton, CA, USA). Data acquisition was 
performed using the Beckman P/ACE software.  
Table 4.2  KRAS LDR primer sequences 










Common_13.4 CGTAGGCAAGAGTGCCTTGAC-Cy5 21 58.1 
KRAS 12.1 WT TTTTTTTTTTTTTTTTTATATAAACTTGTGGTAGTTG
GAGCTG 
43 58.4 
KRAS 12.1 A TTTTATATAAACTTGTGGTAGTTGGAGCTA 30 54.5 
KRAS 12.1 C TTTTTTATATAAACTTGTGGTAGTTGGAGCTC 32 55.8 
KRAS 12.1 T TTTTTTTTATATAAACTTGTGGTAGTTGGAGCTT 34 56.1 
KRAS 12.2 WT TTTTTTTTTTTTTTTTTTTTAAACTTGTGGTAGTTGG
AGCTGG 
43 60.0 
KRAS 12.2 A TTAAACTTGTGGTAGTTGGAGCTGA 25 56.3 
KRAS 12.2 C TTTTAAACTTGTGGTAGTTGGAGCTGC 27 57.8 
KRAS 12.2 T TTTTTTAAACTTGTGGTAGTTGGAGCTGT 29 57.3 
KRAS 13.1 WT TTTTTTTTTTTTTTTTTTTTGTGGTAGTTGGAGCTGG
TG 
39 59.9 
KRAS 13.1 A CTTGTGGTAGTTGGAGCTGGTA 22 56.4 
KRAS 13.2 WT TTTTTTTTTTTTTTTTTTTTGTGGTAGTTGGAGCTGG
TGG 
40 61.0 





4.3 Results and Discussion 
4.3.1 Flow Cytometry Phenotype Characterization of RPMI-8226 as a Model 
Cell Line for CMMC   
Multiple myeloma cells have a characteristic antigen surface expression that 
distinguishes them from normal B-plasma cells. Normal B plasma cells go through 
somatic hypermutations (SHM) in the Ig gene that take place during the germinal center 
stage of differentiation while malignant clonal plasma cells are formed at the post 
germinal center stage of differentiation and do not go through SHM processes resulting 
in a different in surface antigen expression from normal B-plasma cells. The criteria for 
MM phenotype identification that has been well documented indicates that primary 
myeloma cells strongly express CD38 and CD138 and in some cases, the expression of 
CD56 is also observed. In addition, a weak to almost no expression of CD45 is 
observed in most stages of MM. [31] A number of studies have utilized cells lines as 
models for primary myeloma cells as they share some essential features, such as Ig 
gene re-arrangement, cytoplasmic idiotype expression and surface antigen expression. 
[31] In this study, we selected RPMI-8226 cells as a model for primary multiple 
myeloma cells.  
We first performed phenotypic characterization of these cells using flow cytometry in 
order to evaluate the fraction of RPMI-8226 cells expressing key myeloma surface 
antigens. Results indicated that out of a defined population of approximately 60,000 
RPMI-8226 cells, 98% expressed CD38, 90% expressed CD138, 74% expressed CD56 
while <0.01% showed minimal expression of CD45 (see Figure 4.1). This agrees well 




expressed CD38 than CD138, we chose to use anti-CD138 as the selection agent for 
CMMCs because CD138 is solely and strongly expressed on plasma cells as opposed 
to CD38, which is expressed in both lymphoid and myeloid cells and thus may not 
provide the necessary specificity. [31, 32] 
 
 
4.3.2 RPMI-8226 Cell Translational Velocity Optimization for Capture on 
the CMMC Selection Device 
The CMMC selection device has been utilized in previous studies in our research 
group for the specific selection of CTCs on the basis of antigen-antibody interactions 
(i.e., positive selection). [23, 24, 30, 33]  The selection bed consisted of 50 high 
aspect ratio curvilinear channels with dimensions of 30 µm (width) and 150 µm 
(depth) arranged in a z-configuration format (see figure 4.2 a & b). The channel 
Figure 4.1 Fluorescence dot plots showing typical CD antigen expression on RPMI-8226 
cells. All plots were gated on CD45-. The resulting dot plots indicate: (A) 74% of these 
cells express CD56+; (quadrant R6); (B) 90% of the cells express CD138+ (quadrant 
R6); and (C) 98% of the cells express CD38+ (quadrant R6).  Fluorochromes used for 





width dimension was designed to be as close as possible to the CTC diameters, 
which ranged from 10-25 µm, while a depth of 150 µm was selected to increase the 
throughput of the device. [30]  Similarly, plasma cells have been found to be oval 
with diameters ranging from 9-20 µm; the average cell diameter for RPMI-8226 was 
measured to be 13.7 ±2 µm via optical analysis. Based on the similar dimensions of 
CTC and CMMCs, we sought to use the same device for the selective capture of 
CMMCs.[34] Figure 4.2 d indicate DAPI stained CMMCs captured along the walls of 
a curvilinear channel in the CMMC selection device. 
In previous studies, tumor specific antibodies such as anti-EpCAM were 
immobilized onto the walls of a selection bed via commonly used peptide chemistry 
following activation of the selection bed surfaces with UV light to generate carboxylic 
acid moieties. [18, 30, 35] Based on the same premise, CD138 was anchored onto 
the channels walls of the CMMC selection device and used as the selection antibody 
for CMMCs.  
Optimal capture conditions for cells travelling through curvilinear channels were 
based on the Chang and Hammer model, which describes the dependence of the 
linear velocity of solution containing antigenic-bearing targets on the encounter rate 
and probability of reaction between solution-borne cells and surface tethered cell 
affinity agents. [36]  We proceeded to investigate the optimal linear velocity in order 






Based on our findings as presented in Figure 4.3A, the maximum cell capture 
efficiency (71% ± 6%) was found to occur at a translational velocity of 1.1 mm/s 
under the conditions employed. These flow rate dependent capture studies followed 
the same trend as seen in previous studies for CTCs, which indicated that the cell 
Figure 4.2  (A) Schematic of the CMMC selection device with an array of 50 
parallel sinusoidal microchannels and inlet/outlet channels arranged in a z-
configuration. Flow of blood is indicated by the green arrow. (B) SEM of the 
selection bed depicting high-aspect ratio (30 x 150 µm, w x d) sinusoidal 
microchannels and the output channel. (C) Blood processing setup in a 
biological safety hood showing blood filled syringes set on a Harvard 
apparatus multi–syringe pump. The syringes are each connected to inlet 
capillaries interfaced to the CMMC selection devices. (D) DAPI fluorescent 




capture efficiency maximized by balancing conditions to optimize the encounter rate, 
which increases at higher flow rates, and the antigen/antibody reaction time, whose 
probability is reduced at higher flow rates. [37, 38] From previous studies, the 
optimal linear velocity for CTC recovery was found to be 2.0 mm/s. However, our 
findings indicated that the optimal translational velocity was less than that for CTCs 
(1.1 mm/s) indicating that the reaction rate is much slower for the anti-CD138/CD138 
interaction compared to the anti-EpCAM/EpCAM association. A number of factors 
determine the rate dependent probability of association; (i) the expression level of 
the target molecule on the surface of the cell; (ii) adhesion strength between the 
antibody and antigen; and (iii) the accessibility of the antibody to its recognition 
element.[30, 38] CTCs are adherent cells and have a tendency to stick onto 
surfaces, which could increase reaction time lowering the strict dependency on flow 
rate. Also, the expression level of epithelial adhesion molecules in many cell types is 
very high; approximately 500,000 for breast cancer cell lines and 1,000,000 for 
colorectal cancer cell lines. [39, 40] However for CMMCs, which are primarily 
hematopoietic cells, they tend to be non-adherent and thus, have less of a tendency 
to stick onto surfaces. Though the exact expression level of CD138, which is the 
selection antigen we are using herein, has not been documented for CMMC model 
cells lines, we can assume that it is lower than CTC model cell lines as seen in 
tissue culture of both cells types. RPMI 8226 cells expand as suspended cells in 
growth media while MCF 7s (epithelial based CTCs) tend to attach and flatten onto 




Lower reaction rates of the anti-CD138/CD138 pair in the case of CMMCs 
compared to the anti-EpCAM/EpCAM pair can be attributed to the expression of the 
antigen molecule CD138 also referred to as Syndecan-1 molecule. In MM, the 
systems of adhesion are regulated by cytoplasmic and extracellular mechanisms. 
Syndecan-1 molecules are the principal MM receptor systems of the extracellular 
matrix. Major roles of these molecules are to control tumor cell survival, growth, 
adhesion and bone cell differentiation in MM. Reports have indicated that the 
expression of CD138 is significantly decreased in MM cells and this has been 
associated with poor clinical outcomes. [41-45] Also the loss of Syndecan-1 is 
associated with the loss of anchorage dependent growth. Therefore, MM cells adapt 
a mesenchymal morphology and behavior. [43, 45]  This low expression may result 
in a lower reaction rate requiring lower linear velocities to maximize the recovery as 
observed in the CMMC translational studies 
In order to evaluate the capture sensitivity of the CMMC selection assay, we 
seeded 20, 150, 250 and 500 RPMI-8226 cells per 500 µl of blood. The best-fit linear 
function to the data plotted in Figure 4.3B had a slope of 0.6865 (r2 = 0.9994). This 
demonstrated the ability of the assay to maintain capture recovery at different seed 
levels within the tested range. In addition the ability to detect varying numbers of cells 
makes this assay suitable for the detection of varying numbers of CMMCs from patient 





   
4.3.3 On-chip Phenotype and Clonal Identification of RPMI-8226 Cells and 
CMMCs from Clinical Samples 
 
Multiparametric flow cytometry (MFC) immunophenotyping has been used in 
clinical research studies for the differential diagnosis of MGUS, SMM and active 
MM.[46] There has been growing consensus on the use of a panel of antigens for the 
Figure 4.3  (A) Graph showing cell capture efficiency versus cell translational velocity. 
In these experiments an estimated 500 RPMI-8226 cells were seeded into RPMI-1640 
total cell medium. The cells were prestained with a live nuclei cell dye and were 
introduced in the CMMC selection device at linear velocities ranging from 0.4-2 mm/s. 
Capture efficiency was determined by the ratio of RPMI-8226 cells captured on the 
CMMC selection device to the total number of RPMI-8226 cells selected on chip and 
collected in the effluent. Number of cells captured was determined by both brightfield 
and fluorescence microscopy. (B) Calibration plot of RPMI-8226 cells seeded (20-500 
cells/0.5 mL) of healthy donor blood and processed through the device at the 
optimized linear velocity of 1.1 mm/s.  Capture sensitivity for the CMMC selection 




detection of both normal and aberrant plasma cells in the bone marrow or in the 
peripheral blood. In particular, six-color analysis of CD138, CD38, CD45, CD56, 
cytoplasmic Ig κ, and cytoplasmic Ig λ, has been employed in MFC for the detection of 
both normal and aberrant clonal fractions of plasma cells. [1, 47] Each of these antigen 
markers have a functional role and are classified as: (i) Co-receptors for plasma cell 
signaling; (ii) molecules involved in cell-to-cell adhesion; (iii) molecules that facilitate 
growth of plasma cells; and (iv) proteins involved in cell survival. [32] Both CD138 and 
CD38 are used in combination and are found to be expressed in plasma cells. CD138 in 
particular is a heparin sulfate proteoglycan that promotes cell surface adhesion to 
collagen, fibronectin and thrombospondin. CD56 is found in some cases of active MM 
and has been correlated with the aggressiveness of the disease and thus, a useful 
marker for follow-up of minimal residual disease. [46, 47] For specific identification of 
clonal populations within the plasma cell population, the addition of both cytoplasmic 
immunoglobulin (Ig κ) and (Ig λ) light chain markers have been utilized. Normal plasma 
cell populations will have approximately equal expressions of both light chain 
cytoplasmic immunoglobulin markers, while pathological plasma cells will show higher 
expressions with κ/λ ratios >0.5. [48] 
 Although flow cytometry has been shown to be more clinically sensitive than 
morphological methods, flow cytometry does have some drawbacks for the analysis of 
pathological plasma cells in peripheral blood. For instance, the depletion of plasma cells 




not an enrichment technique and therefore the analysis is only limited to detection and 
renders the plasma cells detected inaccessible for further downstream analyses such as  
 
Figure 4.4 In-situ immunophenotyping and cytoplasmic staining of CMMCs.  Panels 
(A) and (B) represent RPMI-8226 cells and CMMCs selected in a polymer microchannel 
via anti-human CD138/CD138, respectively. Positive CMMC surface markers are 
presented by micrographs: (b,g) CD56-PE; (c,h) CD38-APC; while (d,i) are negative 
control marker CD45-FITC for leukocyte identification. DAPI was used for nuclei 
identification (a,f,l). Panel (C) represents cytoplasmic staining of RPMI-8226 cells, which 
are the λ light chain expressing cells, using anti human Igκ-PE (m) and anti-human Igλ-
APC (n). (D) H&E image of a released plasma cell from the CMMC selection bed using 
enzymatic release via trypsin. All bars represent 10 µm. 
 
propagation and molecular profiling. Microfluidics has, on the other hand, been shown 
to be more sensitive in the detection and enrichment of rare occurring cells compared to 
flow cytometry. [18, 22, 24, 40] The advantages of using microfluidics compared to flow 
cytometry include the fact that smaller samples are sufficient for the analysis, samples 
are contained in an enclosed device therefore minimizes sample contamination, no 
sample pre-processing steps are required, and finally, assay cost reduction due to the 




immunophenotyping of the plasma cells. Studies involving the enrichment of CTCs 
using microfluidics have demonstrated on-chip immunophenotyping for the identification 
and enumeration of CTCs captured on chip. [24, 49] Following the same concept, we 
performed in-situ immunophenotyping of plasma cells selected by CD138 from either 
cell suspensions of RPMI-8226 in media as well as plasma cells selected from clinical 
samples. For surface staining, the following criteria was used to identify both normal 
and aberrant plasma cells; CD38+/CD56+/DAPI+/CD45- and/or CD38+/DAPI+/CD45- 
and/or CD56+/DAPI+/CD45- (see Figure 4.4 and 4.5). All other phenotypes were 
considered to be contaminating cells. Our results indicated that successful on-chip 
immunophenotyping was achieved in both RPMI-8226 model myeloma cell line (Figure 
4.4A) and in CMMCs enriched from clinical samples (Figure 4.4B).  Standard on-chip 
fluorescence imaging conditions were optimized using the RPMI-8226 cell line as a 
control as we already established the phenotype using flow cytometry as discussed in 
Section 4.1.  
For cytoplasmic light chain staining, the approach we adopted used fluorescently-
labeled anti-cytoplasmic Ig (k) and anti-human Ig (λ) to identify clonal populations of 
CMMCs captured on-chip. In order to establish monotypic clonality using cytoplasmic 
light chain staining conditions, we used RPMI-8226 as a standard because it has 
already been established that RPMI-8226 is a lambda light chain expressing cell line 
(See Figures 4.4C and 4.6A).[31]  Therefore, for one patient, we identified clonal 
populations of Kappa expressing cells, which formed a greater majority of the total 









Figure 4.5  Alternative confirmatory phenotypes for CMMCs isolated from a 
patient sample. Panel (A) represents 6 CD138 selected cells that were found to 
be CD56+ (b) and CD38– (c). Panel (B) shows a mix of two phenotypes side-by-
side, 3 CD38+/CD56+ positive cells (g,h) next to 2 CD56+/CD38- cells (h). Both 
panels show dim to no expression of CD45 (c,i). Nuclei were stained with DAPI 





4.3.4 CMMCs in SMM and Active MM Clinical Samples 
A total of 20 MM patient samples were analyzed in a blind study in order to 
determine the correlation of disease state and number of CMMCs selected. MM patients 
diagnosed were diagnosed with either SMM (n = 6) or active MM ( n =14 ). For active 
MM patients, we isolated an average of 347.8 ±300.4 CMMCs/mL, median = 213 
CMMCs/mL with a range of 100 to 742 CMMCs/mL. CMMCs were selected in all 
patients with active MM. For the controls, in most cases no CMMCs were observed. We 
also analyzed blood from 6 patients who had been determined to have asymptomatic 
SMM. We found an average of 13.2 ± 8.9 CMMCs/mL for this group of patients. Based 
Figure 4.6 Panels A and B represent cytoplasmic staining of a clinical sample 
with active MM (B) using anti-human Ig κ-PE (b,e) and anti-human Ig λ-APC (c,f)  
and (C) cytoplasmic staining of RPMI-8226 cells as a control. Results indicated 
strong Kappa expression for approximately 70% of the cells enumerated and 
weak expression of about 10% of the total cells captured on the device for the 
clinical sample. Imaging conditions:  5x objective, 1.2 s exposure time for PE 




on the Kruskal-Wallis test (p = 0.00005), there was a significant difference in the 
CMMCs/mL between asymptomatic SMM, and symptomatic MM, and controls. Pairwise 
Wilcoxon Rank-Sum tests suggested that there was a significant difference between 
active MM and healthy patients (p = 0.0006). Between SMM and controls there was also 
a statistically significant difference in terms of CMMC numbers (p = 0.04). Comparison 
between asymptomatic SMM and symptomatic MM patients also indicated a significant 
CMMC number difference (p = 0.0006). This data is summarized in the box plot shown 
in Figure 4. 7. 
 
Figure 4.7 Box plots presenting count of CMMCs selected in chip from MM patient 
blood samples. Data are normalized to 1 mL. Lower and upper edges of box show 
25th and 75th percentiles, respectively. Solid line in box represents median, and 




4.3.5 KRAS Mutational Analysis of Isolated CMMCs (PCR/LDR/CE) 
RAS mutations in codons 12, 13 and 61 have been found at high frequencies in a 
number of cancers such as pancreatic, colorectal, lung and thyroid cancers.[50-58] 
The RAS genes encode membrane-associated guanosine triphosphates (GTPases), 
which are important signaling intermediates involved in the responses to a number 
of growth factors.[50] It therefore followed that alterations in the RAS gene may 
affect cell growth leading to cancer. RAS mutations have been shown to have 
diagnostic significance in colorectal cancer, whereby patients with mutated KRAS do 
not benefit from anti-EGFR therapy, whereas patients with wild-type KRAS 
genotypes do benefit from this therapy. [56, 58, 59] 
 In multiple myeloma, while the pathogenesis of the disease is not clearly known, 
reports have hypothesized that activating mutations of RAS oncogenes may 
contribute to interleukin 6-independent growth of myeloma cells and the suppression 
of apoptosis.[60] Both NRAS and KRAS mutations have been documented with a 
frequency of occurrence of 39% in newly diagnosed patients. It has been reported 
that NRAS mutations within codon 61 are more frequent than NRAS mutations found 
in 12, 13, and KRAS mutations in most MM cases. [61] The same study also 
indicated that KRAS mutations had prognostic significance with tumor burden and 
survival rate while NRAS mutations did not. Other reports also indicated that multiple 
mutations were found in some patients indicating heterogeneous populations of 




In this study, we performed KRAS mutational analysis from purified genomic 
DNA extracted from both RPMI-8226 cells captured on the selection device and from 
CMMCs captured on chip from 4 clinical samples.  In order to evaluate the sensitivity 
of our CMMC selection assay for subsequent KRAS mutational analysis, we seeded 
RPMI-8226 cells ranging from 20 to 750 cells into 0.5 mL of total cell medium and 
subsequently enriched them using the CMMC selection device. These cells were 
then released from the selection bed via trypsin, enumerated using an impedance 
sensor and the eluent was purified for its gDNA content with the purified material 
subjected to PCR. In addition, CMMCs selected from 4 clinical samples using the 
CMMC selection device were also released and subjected to PCR. gDNA extracted 
from HT-29 cells as well as RPMI-8226 cells were used as positive controls for the 
PCR analysis. PCR products from all 4 patient samples were submitted for Sanger 
sequencing for the possible detection of SNPs in the KRAS gene. Results seen in 
Figure 4.9f showed a single mutation found in patient 36 at the 37 th nucleotide, 
where G was substituted for A; this denotes the G13S mutation, which results in a 
glycine substitution for serine in the resulting protein product. Although direct 
nucleotide sequencing is a well-established technique, the sensitivity was not 
adequate for the detection of low abundant mutant copies in a high background of 





LDR coupled to PCR is a method that has been shown to detect single-point 
mutations in DNA with sensitivities approaching 1 mutant copy in 4,000 wild type 
copies and is thus better equipped to detect KRAS mutations from heterogeneous 
Figure 4.8 Agarose gel electrophoresis of PCR products generated from (A) 
RPMI-8226 cells and (B) CMMCs from 4 patient samples. PCR was run with 35 
cycles with an initial denaturation step of 2 min and final extension for 7 min. Each 
cycle consisted of: 94°C (30 s), 59°C (30 s), 72°C (40 s). The gel was stained with 
ethidium bromide and run at 4.8 Vcm-1. (A) Gel electropherogram for PCR 
performed on RPMI-8226  cells with; (a) no gDNA template; (b) gDNA template 
from HT-29 directly (positive control); (c) gDNA from 20 RPMI-8226 cells; (d) gDNA 
from 150 RPMI-8226 cells; (e) gDNA from 500 RPMI-8226 cells; and (f) gDNA from 
750 RPMI-8226 cells. Lanes a-f contain 5 µL of DNA amplicons. (B) Gel 
electropherogram for PCR performed on CMMCs obtained from 4 clinical samples 
analyzed using the CMMC selection device: (a) No gDNA  and used as a negative 
control; (b) gDNA template from RPMI-8226 directly used as a positive control. (c) 
gDNA from patient 35; (d) gDNA from patient 36; (e) gDNA from patient 37; e) 
gDNA from patient 38. Positive controls consisted of harvesting either HT-29 or 
RPMI-8226 cells from the culturing dish (~1,000 cells), lysing them, performing a 




samples compared to Sanger sequencing.[62-64] Briefly, following PCR 
amplification of the gene fragment of interest, the amplicons are mixed with two LDR 
primers, a common and discriminating primer that flank the point mutation of 
interest. The discriminating primer contains a base at its 3’-end that coincides with 
the single base mutation site. If the 3’ nucleotide of the discriminating primer is not 
complementary to the mutation site being interrogated, ligation of the common and 
discriminating primers does not occur. A perfect match between the 3’-end of the 
discriminating primer to the target DNA does occur, ligation of the common and 
discriminating primers occur and resultant LDR product length becomes the sum of 
nucleotides from these two primers. LDR products are then detected using CGE 
(capillary gel electrophoresis) based on differences in the electrophoretic mobility of 
ligated versus unligated primers. In our experiments, purified PCR amplicons from 
HT-29, RPMI-8226 and CMMCs from patients 35, 36, 37, 38 were used in the LDR 
assay for the detection of possible KRAS mutations in codons 12 and 13. 
Sequences used in this study for both discriminating and common primers for each 
possible mutation were designed from Khanna et al. and are listed in Table 2. [63] 
Genomic DNA from the HT-29 colorectal cell line was used as a negative control for 
these studies as it is well documented that it bears no KRAS mutations. gDNA from 
the RPMI-8226 cell line has been documented to be heterozygous, bearing both the 







Figure 4.9 LDR and Sanger sequence analysis of sequence variations in the KRAS 
gene for codons 12 and 13 with the gDNA secured from RPMI-8226 cells, HT-29 cells, 
and CMMCs isolated from clinical samples. LDR consisted of 20 cycles. Initial 
denaturation was performed at 95°C for 2 min. Each cycle consisted of: 95°C (30 s); 
60°C (2 min); and 4°C as a final hold. LDR products were analyzed using CGE 
performed at a capillary temperature of 60°C with an initial denaturation step prior to 
injection at 90°C for 3 min.  CGE injection was performed at 2.0 kV for 30 s and 
separation was done at 6.0 kV.  CGE electropherograms for various samples are 
shown in (A-F). LDR product peaks are represented with an asterisk *. (A) shows the 
49 nt LDR product denoting the G12A mutation found in RPMI-8226; (B) and (D) show 
no LDR products at the c12.2 C locus for HT-29 and patient 35, respectively; (C) 
shows a 54 nt LDR product denoting the G12S mutation for patient 35; and (E) shows 
a 42 nt product denoting the G13D mutation for patient 36. DNA size markers of 20 
and 80 nt were co-electrophoresed with the LDR products. (F) Sanger sequencing 
trace for gDNA secured from patient 36 at codons 12 and 13 with an additional peak at 




Results from the CGE electropherograms (Figure 4.9a-e) indicated the presence of 
a 49 nt LDR product in the RPMI-8226 analyses denoting the G12A mutation (Figure 
4.9a) while no LDR products were seen in the HT-29 analysis (Figure 4.9b) for all 
mutant primer sets tested; these results are in agreement with reported studies.[40]  A 
summary of the LDR products observed from the 4 patient samples analyzed are 
presented in Table 4.3.  Multiple KRAS mutations were found in all of these samples 
indicating the heterogeneous nature of the cells captured from the respective blood 
samples. Patients 35 and 38, whom were known to have active MM, showed multiple 
LDR products as well as higher band intensities compared to patients 36 and 37 
indicating higher fractions of KRAS mutant copies in their gDNA than patients 36 and 
37, who were classified with the SMM (see Figure 4.8).  These results are in agreement 
with early studies that indicated the frequency of these activating RAS mutations are 
associated with advanced stage MM compared to earlier stages of MM.[57, 61]                 
 






In this study, we have demonstrated the use of a polymer-based microfluidic 
device that has the capability to select CMMCs directly from whole blood as a 
potential diagnostic tool for MM. This device was able to isolate CMMCs, which are 
mesenchymal type cells, at a recovery of ~71% directly from whole blood using 
CD138 as the selection antigen. The CMMC selection device required no sample 
preprocessing, such as the lysis of RBCs, minimizing CMMC loss. We have 
previously demonstrated the scalability of this device and therefore, it could be 
reconfigured to process larger volumes of blood (7.5 mL) so as to provide higher 
number of cells for extensive molecular profiling studies. [24]  The ability to perform 
on-chip immunophenotyping as well as clonal testing was demonstrated for CMMCs 
selected and underscores its potential use in prognostic investigational studies for 
MGUS, SMM and active MM disease states. Preliminary clinical data presented here 
on SMM and active MM demonstrates the device sensitivity to the disease state. 
Future studies will also include MGUS group of patients in the clinical studies and 
focus on patient monitoring for drug targeting studies and gene expression profiling 
for MM clinically relevant markers. 
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CHAPTER 5. FUTURE STUDIES: DEVELOPMENT OF A MODULAR WORKSTATION 
FOR CTC GENOTYPING 
5.1  Background 
Until recently, affinity based technologies focused on CTC detection and analysis 
have primarily targeted the EpCAM antigen for the specific capture of epithelial based 
CTCs in blood circulation. However, growing trends on CTC based studies have 
indicated the existence of tumor cells bearing other additional phenotypes. In 
particularly, it has been suggested that CTCs expressing invasive phenotypes down-
regulate and lose their epithelial antigens (including EpCAM) partly by a process called 
the epithelial-to-mesenchymal transition, EMT. [1-3] It has also been hypothesized that 
in some epithelial-based cancers, like mCRCs, CTCs consist of different sub-
populations that may have a continuum of phenotypes besides the epithelial one. [1, 4, 
5] Therefore, the ability to enrich different CTC sub-populations may be compromised if 
only EpCAM is used as the selection target. [6, 7] It is critical to consider the use of 
orthogonal selection agents that target, for example, invasive phenotypes, to better 
predict early and/or metastatic disease. Therefore, it will be necessary to use a 
combination of mAb for CTC selection.  
We will generate CTC selection strategies that will recover with high efficiency 
two different CTC phenotypes. One antigen is associated with an epithelial phenotype, 
EpCAM(+), and the other is directed at a more invasive phenotype, seprase(+), a serine 
protease localized in the invadapodia. Seprase, which is an integral membrane 




enhance tumor growth and proliferation. Seprase is differentially expressed on the 
invading front of human malignant tumor cells, especially localized within the 
invadopodia. Chen and co-workers have developed an invasion-based assay that 
consists of a collagen adhesion matrix (CAM) to collect CTCs by their ability to invade 
and ingest the CAM, which is enabled by seprase. [8-10] Seprase has been found to be 
overexpressed on tumor cell surfaces in >90% of human epithelial cancers; [11] it is 
highly expressed in CRC and PDAC tissues. [12] 
The use of microfluidics for the selection and enumeration of CTCs from clinical 
samples has been reported. [13-18] However a system for the recovery of CTCs from 
whole blood, their enumeration and correlation of phenotype with genotype for particular 
CTC sub-populations has yet to be reported. The development of an integrated 
workstation that can offer these capabilities is paramount because molecular 
information obtained from CTCs can generate clinical information that cannot be 
garnered from enumeration data alone. We will use two selection targets, seprase and 
EpCAM, for this workstation to select CTCs that have an invasive and/or epithelial 
phenotype, respectively. The CTC selection units will be configured into thermoplastic 
modules integrated with other task-specific modules to build a fluidic bio-processor, 
which is an integral component to the workstation acquiring molecular and phenotype 
data on CTCs (Figure5.1).  
The challenge with genotyping gDNA from CTCs is the low copy number of the 
assay’s input. This is especially true for mCRC, which typically show low yields of 




reverse transcription PCR with mRNA surrogates because of their higher copy number . 
[20, 21] [22, 23] CTC analysis of gDNA for mCRC demands minimal sample handling to 
reduce sample loss and contamination. The proposed workstation will target these 
issues. We will detect point mutations in KRAS, BRAF and PIK3CA genes isolated from 
CTCs of mCRC patients using the modular workstation equipped with a fluidic bio-
processor that can carry out highly multiplexed assays using PCR/LDR. [24-27] 
Collaborative work between the Soper and Barany laboratories has demonstrated that 
PCR/LDR assays can be carried out in microfluidic architectures, [26, 28] but these 
systems have not been utilized for CTC molecular profiling. We will employ a 
continuous readout strategy using molecular beacon probes formed from an LDR and 
FRET with CCD time-delayed integration, CCD-TDI, [29] detection. 
In Chapter 2, we developed a modular microfluidic system that could isolate, 
enumerate and phenotype CTCs. [30] To improve and build upon this system, our future 
objective would be to develop a modular workstation that  will select circulating tumor 
cells (CTCs) from two orthogonal sub-populations can provide phenotypic and 
genotypic information about CTCs using CRC and PDAC as case examples ( see 
Figure 5.1). The innovative concepts in this workstation will include: (1) Serial 
arrangement of two CTC selection modules targeting seprase(+) and/or EpCAM(+) 
CTCs. To improve CTC recovery, nano-texturing of the channel walls and floors will be 
accomplished using 3D molding. [29] To release the CTCs from the antibody-decorated 
selection surface, we will investigate bifunctional oligonucleotide linkers, which will have 




cell array composed of a multi-layered structure with valving and fluidic layers 
possessing excellent optical properties and a laser to eject the cells individually from 
specific addresses of the array. (3) Integration of molecular processing strategies of 
CTCs using an automated work flow in a closed architecture with continuous readout. 
 
Figure 5.1 Schematic of the bio-processor, an integral component of the CTC 
workstation. The bio-processor is composed of modules for CTC affinity selection 
(Seprase and EpCAM), impedance sensor (CD), cell array with valving fluidic layer, 
SPE module, and imaging module for the real-time monitoring of molecular beacons via 
FRET produced as a result of a successful LDR. The fluidic motherboard also contains 
continuous flow thermal reactors for lysis, PCR and LDR. The PCR is multiplexed 
containing primers for the appropriate gene fragments to be interrogated. The LDRs are 
spatially multiplexed with each thermal reactor monitoring a specific locus. While the 
system shows a 6-plex LDR, this can be scaled for higher multiplexing as needed. The 
workstation also contains a scanning microscope for phenotyping cells in the 2D array, 
the imaging microscope for CCD-TDI readout, thermal control units, electronic control 







5.2  Enrichment of Invasive and Epithelial Phenotype CTCs from Whole Blood 
using Serially Arranged Modules Positioned on a Fluidic Motherboard 
 
 One of the main aspects of CTC enrichment is to achieve maximum yields due to 
their rare occurrence in blood.  The design, fabrication and evaluation novel CTC 
selection modules that contain 3D nanotextures in thermoplastic channels (PMMA or 
COC) decorated with antibodies targeting different CTC sub-populations will be 
determined. These modules will be arranged serially on a fluidic motherboard. We will 
also investigate the use of oligonucleotide bifunctional linkers to increase the load of 
mAb to the selection bed surface and provide a flexible and simple approach to release 
the CTCs from the selection surface. 
5.2.1 Bi-functional Linkers 
We will incorporate, oligonucleotide bifunctional linkers with a modified nucleotide 
base engineered into them that can be cleaved enzymatically or photolytically to release 
CTCs following selection. Bifunctional linkers will consist of single-stranded 
oligonucleotides of varying lengths and sequence content, containing a primary amine 
at the 5’ end and a thiol group at the 3’ end. The polymer surfaces (substrate and cover 
plate) will be UV-activated following hot embossing. The two pieces will then be 
compression-sealed at room temperature and the bifunctional oligonucleotide injected 
into the fluidic network in the presence of EDC/NHS (Scheme 5.1). This is followed by 
thermal fusion bonding of the cover plate to the substrate near the Tg of the substrate 
(~105oC for PMMA). Figure 5.2 shows a fluorescence scan of PMMA that has been UV-




EDC/NHS chemistry. As can be seen, both before and after thermal treatment, the 
amount of oligonucleotide remains constant due to the thermal stability of the 
oligonucleotide and its inability to be buried into the substrate when heated. Following 
thermal fusion bonding of the assembled cover plate, the antibody, which has been 
treated with succinimidyl trans-4 (maleimidymethyl) cyclohexane-1-carboxylatate 
(SMCC), reacts with the thiol groups (Scheme 5.1). 
 
 
The strategy provides the ability to use different cleavable entities that are 
engineered into the oligonucleotide linker, such as a photocleavable or dU residue; 
these residues can be cleaved using light or a USER enzyme system, respectively 
Scheme 5.1 Single-stranded oligonucleotide bifunctional linkers used for 
covalently attaching mAbs to polymer surfaces bearing accessible carboxylic 
acids. The oligonucleotide linkers (see upper left) can contain any sequence, 
but is shown with a string of ~15 dT units that do not contain a primary amine so 
as not to be cross-linked to the surface. X1,2 can be a uracil or photocleavable 
residue as seen in the upper right. Following device incubation with target cells, 




(Figure 5.2). For a dU residue, we can use the urasil-specific excision reagent that 




5.2.2  Nanotextured Surfaces 
Previous research has shown that nano-texturing can improve recovery of CTCs 
or other cell types on nanopillars, [31-35] roughened PDMS[36] or silica nanobeads. 
[37] Nano-texturing increases the number of anchoring points for protrusions emanating 
from the CTC surface. [35] However, in all reports, nano-texturing was done only to the 
floor of the selection devices. We have developed an innovative replication-based 
Figure 5.2 Effect of thermal fusion bonding on the stability of oligonucleotide 
bifunctional linkers. After modified oligonucleotide linkers were covalently attached 
to UV-activated PMMA, the PMMA was (A) heated to 107ºC for 20 min or (B) not 
heated. The fluorescence intensity profiles from a vertical section of two spots 
(see dotted yellow line) in (A) and (B) are shown in (C). To interrogate the stability 
of the attached oligonucleotide linkers, solution complements to the linkers 
bearing a fluorescent reporter were hybridized to the linkers. As can be seen in 
(C), no difference in the fluorescence intensity resulted. (D) UV-activated PMMA 
reacted with EDC/NHS coupling reagents and a single-stranded oligonucleotide 
linker containing a 5’ amino group and Cy3 at its 3’ end. A single dU residue was 
added internally to the linker. After coupling, the linker was subjected to the USER 
system, which cleaves the linker at the dU residue. The loss of fluorescence is 
indicative of the cleavage. Spot (a) is a linker with no dU residue, while spot (b) 




technology that will allow integration of topological nanostructures into microfluidic 
channels in 3D. [37-39]A schematic showing the processing strategy is depicted in 
Figure 5.3  and is based on polymer 3D molding, which enables the rapid production of 
3D patterns over large areas with high throughput and at low-cost. One of the key 
components for the process is the use of a flexible intermediate stamp with the desired 
nanostructures that can conformally mold into non-planar surfaces. PDMS was chosen 
as the intermediate stamp because it can stretch during the 3D fabrication process and 
return to its original dimensions following embossing. Figure 5.3 presents SEMs for 3D 
molded structures where nano-bumps (~200 nm in diameter x 100 nm height) or micro-
pumps (~6 µm in diameter x 5 µm height) were formed on the floor and side-walls of a 
fluidic channel equipped with a cover plate. While the cover plate was not subjected to 
nano-texturing, it could also contain these structures 
We will fabricate a test device for evaluating different nano-texturing modalities 
and operating conditions to optimize CTC recovery, especially for cells with the 
antigenic targets positioned on sub-cellular protrusions. The test device will consist of 
microchannels 150 µm wide and 30 µm deep. These channel dimensions are based on 
our previous data showing these dimensions provide high recovery of CTCs.[13] 
However for this test device, we will switch the depth and width from previous versions 
to produce low aspect ratio channels to permit interrogation of UV-activated channels 
for both their chemical (XPS, confocal fluorescence microscopy, water contact angle 









Figure 5.3 The top panel shows the process strategy for performing 3D molding 
using a PDMS intermediate molding tool containing nano-textures. The finished nano-
textured chip is shown with ridges, but the nano-structure architecture can be altered 
through lithographic changes imposed on the PDMS intermediate molding tool. (A-C, 
E) SEM images of PMMA CTC selection channels containing nano-textures with 
bumps that range from 200 nm (A-D) to 5 µm (E). (D, F) Fluorescence microscope 
images of nano-textured channels that were sealed with a cover plate using solvent-
assisted bonding. Fluorescein was used as the dye seed in a 1X TBE buffer (pH = 
8.5). These images demonstrate no leakage following cover plate bonding. For SEMs 
(A, E), the CTC device was sealed with a cover plate, dipped in liquid N2 and fractured 
so as to produce a cross section of the nano-textured channel to show the integrity of 
the nano-features. In (A), the nano-texture structures are not visible at the 
magnification used but can be seen in (B), before cover plate bonding; (C), after clover 




5.2.3 Seprase and EpCAM 
The ability to enrich sub-populations of CTCs using mCRC and mPDAC as 
models will be investigated. The sub-populations will be selected based on Seprase and 
EpCAM expression. Figure 5.4  shows expression differences between several selected 
cell lines. We will generate two CTC selection modules; the bed of one module will be 
decorated with mAb for Seprase (D8, D28, etc.) and the other module will contain anti-
EpCAM antibodies. Both modules will be interconnected to the fluidic motherboard of 
the workstation in a serial arrangement (Figure 5.1). To initially evaluate the serial 
selection process, we will use Hs5427T (Seprase(+)) and SW620 (EpCAM(+)) cell lines 
seeded into a buffer to serve as positive controls. Because of the modular set-up of the 
system, we can investigate the selection of Seprase(+) and EpCAM(+) CTCs in each 
module to understand cross-reactivity. Following the positive control experiments, the 
cell lines will be seeded into “normal” blood to determine leukocyte infiltration during this 
dual-selection process. Finally, the serial selection process will be used to evaluate 
CTC sub-type numbers in mCRC and mPDAC patients. 




5.3  Generation of an Addressable 2-Dimensional (2D) Cell Array for 
Immunophenotyping via Fluorescence Imaging 
 
After the affinity selection of CTCs, we need to immunophenotype them using an 
automated workflow strategy with minimal sample handling. In addition, we may want to 
address groups of CTCs that have a common phenotype, or even individual CTCs to 
correlate phenotypes with genotypes. We should note that because of the CTC 
selection process from whole blood, we will have already sorted CTCs based on two 
divergent phenotypes, Seprase(+) and EpCAM(+). 
5.3.1 Dual Electrode Pair Impedance Sensor 
We have developed an impedance sensor that can detect CTCs based on size to 
discriminate them from interfering leukocytes and other materials. [13, 17, 40, 41] The 
sensing was accomplished using a resonance impedance measurement employing a 40 
kHz waveform, which produced signal amplitudes dominated by the cell size. Figure 5.5 
provides results for SW620 cells spiked into buffer. [13, 17, 40] Also shown are 
leukocytes that were isolated from a buffy coat and measured using impedance 
sensing. There was some overlap in the signal amplitudes between the two cell types; 
the misclassification frequency was ~15%. We will look to improve the discrimination 
between interfering cells and CTCs by adding an additional measurement channel. We 
will use our existing sensor and place another electrode pair in series operating at a 






The high frequency impedance measurement can provide information about the 
intracellular and cell membrane composition; [42, 44, 45]  the low frequency 
measurement provides information about cell size (Figure 5.5).  Scatter plots can be 
constructed from signal amplitudes from each sensor .[43] For example, the x-axis will 
consist of cell impedance amplitudes for an 100 kHz channel while the y-axis plots 
impedance amplitudes at >1 MHz. [46] We can also monitor electrical phase shifts, 
which can provide cell viability information. 
Figure 5.5 Single-cell electrical impedance detection. (A) Histograms for 
impedance response for leukocytes (blue bar) and SW620 cancer cells (red 
bar). (B) SW620 (red) and leukocyte (blue) cell size measured optically. (C) 
Plot of impedance response, phase and magnitude, as a function of the 
voltage frequency applied to the electrodes. Taken from ref.[42] with 
permission.  (D) New electrode design in which thin films electrodes are 




5.3.2 2D Cell Array 
In most cases, microfluidic chips for the positive selection of CTCs carry out 
fixation, permeabilization, staining and rinsing on the selection surface and thus need to 
scan the entire selection bed in three dimensions, significantly increasing processing 
time. [15, 47, 48] To eliminate this, our 2D cell array will define the position of a single 
cell within the array once it has been released from the selection bed  
Several examples of cell arrays using microfluidics have been reported that 
consist of microwells with the cells entrapped using magnetic [49] , dielectrophoretic 
[50-53] ,hydrostatic [54], optical [55, 56]  or confinement [57]  forces. Here, we will 
generate a low-density 2D microwell array module for immunophenotyping CTCs with 
the ability to individually address each pixel of the array. We do not require high density 
arrays because the sample has already undergone pre-selection 
In Chapter 3, we presented a 2D cell array as an imaging module where CTCs 
released from the HT-CTC module were collected and stained with fluorescently labeled 
markers for phenotype identification. [58] Collection efficiencies of 96% for fixed cells 
and 85 % for live cells were obtained; however, the collection efficiency for CTCs from 
patient samples was 72%, indicating a loss through suction, or infiltration of leukocytes 
with similar dimensions to CTCs. This module was interfaced to the staining and 
imaging module via capillaries which may account for dead volume that may lead to 
sample loss. For the modular workstation, the 2D cell array will adopt a different format 




The proposed cell array consists of microwells positioned in an X by Y 
arrangement (Figure 5.6A). Each well will be approximately 25 µm deep with a diameter 
of 25 µm because these dimensions are slightly larger than most CTCs; a well aspect 
ratio of 1 can typically accommodate a single cell.[59]  The microwells will be laser-
drilled through a suspended polymer membrane made by double-sided hot embossing. 
The bottom of each microwell will be sealed against a three-layer structure made from 
fluorinated ethylene propylene (FEP), which possesses good transmissivity at most 
optical wavelengths. Each row of the array will contain a microchannel underneath that 
is terminated with a valve, Figure 5.6B. [60] After bonding of the FEP layers to PMMA, 
laser ablation can be used to drill through the FEP top plate to allow hydrodynamic 
access to each well of the array. The microwells will be made from PMMA because of 
its good biocompatibility and minimal amounts of non-specific adsorption it shows. The 
valving and microchannels layers will use FEP because of its relatively large elongation 
at break value [60],and its Tg, which is close to PMMA. FEP’s Tg allows it to be 
thermally fusion bonded to PMMA. FEP has a refractive index of 1.344, which is similar 
to that of water. Therefore, the holes created on the bottom of each microwell will not 
degrade image quality. An additional advantage of FEP is that it has a higher Young’s 
modulus than PDMS so when applying a slight negative pressure, it will not pull the 








The module works by imposing a low flow of a cell suspension across the 
microwell array. Cells can be injected into the well by gravity and/or a small negative 
pressure applied to each well through the FEP fluidic layer. The entrapped cells within 
the wells have been fixed, permeabilized and stained prior to release from the selection 
surface and can be imaged using a 4-color microscope. The microscope we will use for 
phenotyping CTCs will have a mercury arc lamp, a filter cube to select the appropriate 
filter set and a CCD transducer. The microscope will be mounted on an XYZ motorized 
Figure 5.6 (A) Schematic of the 2D cell array. The array consists of microwells made 
from PMMA and a transparent FEP layer (3 layers) that serve as the fluidic, valving 
and through-hole units for this module. (B) Fabrication method for the polymer valves; 
this is accomplished using 2-sided embossing and laser drilling. The small arrows 
show the flow direction when the valve is open. To close the valve, a mechanical 
solenoid is used.[29] (C) Cross-sectional view of the microwell with the FEP layers 
serving as the well floor with access hole to the fluidic network. The total force (FT) 
acting on the cell to resist movement is gravity (FG), hydrodynamic (if applied, FH) and 
Stokes (FS). For a HeLa-type cell, FT ≈ FG ≈ 29.9 pN. For a 1064-nm laser beam of 
modest intensity, a scattering force, FS, will be able to eject the cell from this well. FH is 
applied using either positive or negative operation of a syringe pump and valves, 




translational stage. [61] We will use the standard panel to characterize CTCs including 
DAPI (blue), CD45 (FITC; green), and cytokeratins (phycoerythrin; red). If we require a 
fourth antigen in the panel to determine Seprase(+) cells expressing EpCAM or a 
cancer stem cell marker, we can use AlexaFluor 680. The microscope can image the 
array through an access port machined into the fluidic motherboard from the backside 
(see Figure 5.1). 
To address each microwell of the 2D cell array, we will investigate the use of 
radiation pressure produced by a 1064-nm Nd:YAG laser fiber coupled to the scanning 
microscope.[62-66] For a laser beam that is not tightly focused, a scattering force will 
typically exceed the gradient force and thus propel the cell along the optical axis. 
Therefore, when the microscope is placed in line with a well, radiation forces will eject a 
cell from that well when this force exceeds FT (Figure 5.6C). To assist in the ejection of 
cells from a well and keep the laser power low to avoid thermal effects, we can also 
open the valve along a row of the array to apply a slight positive FH. To evaluate cell 
ejection, we can monitor the array in real time using the imaging microscope.   
To test the operational metrics of this module, we will use SW620 and Hs2857T 
cell lines. For the initial experiments, the cells will be visualized using brightfield 
microscopy to determine cell entrapment efficiency. Both the cell suspension flow rate 
and negative pressure applied through the FEP fluidic layer will be investigated to 





5.4  Integration of Fluidic Modules for Continuous Molecular Processing of 
CTCs even at the Single-Cell Level 
 
We will expand on the use of a molecular assay for detecting point mutations in 
gDNA using PCR/LDR with FRET readout. [67, 68] In our previous publications using 
this assay for CRC, only HT29 and LS180 cell lines were used and not CTCs isolated 
from clinical samples. Specifically, we will detect the presence/absence of point 
mutations in KRAS, BRAF and PIK3CA using PCR and spatial multiplexing with 
different primer pairs for the LDR for processing all mutations from a single input, and 
thus, requiring only a single color. Spatial multiplexing involves splitting the PCR 
products into equal volumes and feeding this into a series of LDR continuous flow 
thermal reactors (linear amplification). Each reactor will be seeded with LDR primers 
specific for the locus being interrogated. The donor/acceptor dye pair we will use is 
Cy5/Cy5.5 due to the relatively large Förster radius associated with this dye pair (61.7 
Å) and the red emission of the acceptor, Cy5.5 (λem ~700 nm), which reduces 
background fluorescence improving the signal-to-noise ratio in the measurement. [69, 
70] In addition, the donor/acceptor dyes will be attached to the 3’ and 5’ ends of LDR 
generated molecular beacons using a 3-carbon spacer to provide optimal energy 
transfer efficiency. [68] This assay is attractive for mass-limited samples because of the 
two stages of amplification used, PCR and LDR. 
5.4.1 PCR/LDR/FRET Assay for the Detection of KRAS Point Mutations 
For this task, we will integrate the modules for molecular processing of mCRC 




phenotype. This phase of the project builds from our recent publication concerning the 
molecular profiling of mycobacterium tuberculosis bacterial cells as detailed in the 
preliminary results. [29] However, instead of using the universal array as the readout 
platform for the PCR/LDR, we will employ a continuous readout format using LDR 
formation of molecular beacons and spatial multiplexing with CCD-TDI readout . The 
modules that we will utilize for this phase of the processing pipeline include: (1) 
Continuous flow thermal reactors for CTC lysis, PCR and LDR. Polycarbonate will be 
used as the substrate for the motherboard due to its high Tg, minimizing microstructure 
deformation during thermal processing and its large elongation at break to 
accommodate valves [29] (2) SPE module made from polycarbonate that possesses a 
high density of microposts formed during the embossing step used to make the fluidic 
network The choice of polycarbonate here is predicated on the fact that this material, 
when exposed to 254 nm UV-light, generates a surface with a high propensity to let 
nucleic acids condense on its surface when a cell lysate is suspended in polyethylene 
glycol and NaCl. The attractive feature of the SPE module is that multiple cells can be 
sequentially lysed and immobilized to the extraction bed to analyze a group of cells.  
All modules will be interconnected to the motherboard using low-dead volume 
interconnects laser-drilled into the module and motherboard and conformally sealed 
with plastic tubing.[29] This gives us the ability to disconnect any module from the 
motherboard and replace it with a new module. In addition, we have the flexibility in 




connecting input/output ports can be inserted into the motherboard to eliminate 
unnecessary processing steps. 
5.5  Optical Read Out Module 
In this task, we will generate an optical readout module for molecular beacon 
probes that are produced from the LDR continuous flow thermal cyclers. A diagram of 
the fluidic module for this purpose is depicted in Figure 5.7A. It consists of an 
embedded polymer waveguide and fluidic channels placed orthogonal to the waveguide 
embedded into the cover plate of this module; the evanescent field is used to excite 
fluors in the fluidic channels. We have generated a similar polymer waveguide that was 
made from COC and embedded into a PMMA substrate. [71]  Unfortunately, the 
refractive index difference between the waveguide core (COC) and the cladding 
(PMMA) was minimal so the penetration depth of the evanescent field into the adjacent 
fluidic channel was small (~100 nm) when light was launched into the waveguide near 
the critical angle. In this application, we will use FEP as the cladding material for the 
core COC waveguide. The refractive index of FEP is 1.344 compared to 1.48 for PMMA 
and 1.53 for COC. Therefore, the penetration depth of the evanescent field using FEP 
should be on the order of 500 nm. With a higher penetration depth of the evanescent 
field, we can produce sampling channels for this optical reader that are on the order of 2 
µm wide with a depth (0.5-1.0 µm) that can be produced using optical lithography and 
generate high sampling efficiency of the LDR-generated molecular beacons. [72] Also, 
the channel width is sufficient to fit a series of channels within the field-of-view of a high 




the duty cycle. [73] We have prepared channels in various polymers consisting of these 
dimensions (Figure 5.7B). In the present application, we will require the appropriate 
number of channels to interrogate all of the relevant mutations, with one channel 
serving as a positive control. The molding tool to fabricate this module will be prepared 
via UV-LiGA.  
The COC core waveguide is situated in a guide channel hot-embossed into the 
FEP cover plate. A PDMS stencil containing a cavity defining the coupling prism is 
placed on top of the FEP cover plate reversibly sealed to the PDMS stencil. A COC 
melt, which utilizes a solvent for COC that does not damage FEP, is allowed to fill the 
cavities defined by the PDMS stencil and FEP channel. For the PMMA-embedded 
waveguide, we used toluene as the solvent for COC. For FEP, we will initially test 
toluene, but other solvents can be investigated as well. Following removal of PDMS 
stencil, the FEP cover plate is bonded to the FEP fluidic substrate.  
For reading fluorescence generated when molecular beacons flow over the 
planar COC waveguide, we will use an imaging CCD camera operated in TDI mode, 
which provides better signal-to-noise ratio and higher duty cycle compared to a 
snapshot operational mode for the CCD. [72] The gain in the signal-to-noise ratio for 






Figure 5.7 (A) Schematic of the optical readout module that consists of input 
connects to accept the output of each LDR thermal reactor, which are poised on the 
motherboard. This module consists of a cover plate with an embedded COC planar 
waveguide and readout channels that are approximately 2 µm in width and 350-500 nm 
in depth at the detection zone (evanescent excitation of solution molecular beacons). 
(B) Molding tool is prepared via UV-LiGA. 
 
In our previous work using CCD-TDI readout, double-stranded DNA stained with an 
intercalating dye was monitored; however, the excitation beam was launched at the side 
of a microchannel array instead of using a waveguide. 
5.5.1 Characterization and Clinical Application of the Modular Work 
Station 
 
One challenge in evaluating new technologies is the limited predictive value of 
traditional preclinical models, such as tumor cell lines. [74]  Primary human tumor 
xenograft models have been proposed as a significant advancement over conventional 
xenograft models. Unlike cell lines where there is dependence on various sub-
populations that are able to survive on a plastic dish, PDX tumors retain the 
heterogeneity from which they were derived. Recent reports suggest that patient tumors 
directly explanted into immunocompromised mice exhibit response rates to cytotoxic or 




use human tumor xenografts for evaluating the ability of the workstation to select 
various sub-populations of CTCs to learn about CTC numbers for each selection 
phenotype (seprase and EpCAM) for mCRC and mPDAC 
 We will design PCR and LDR primer sets for codons 12 (6 loci) and 13 (1 locus) 
in KRAS for genotyping mCRC CTCs using PCR/LDR with FRET readout. Prof. Francis 
Barany will be the consultant in guiding our primer design for PCR/LDR. [26, 27, 75, 76] 
We will also design primer sets for the BRAF V600E mutation (1 locus) and PIK3CA 
mutations in the p85, C2, helical and kinase domains (2 loci; exons 9,20).[77].  
 We will first isolate and analyze CTCs from established PDXs using the 
workstation. Each mCRC PDX represents an individual patient tumor and will be 
expanded to 5 mice per PDX to account for variabili ty. As our mCRC PDXs have been 
characterized for KRAS and BRAF mutations, we will select 5 KRAS mutant (mt) 
(codons 12 and 13), 5 KRAS wild-type (wt) and 2 BRAF mt mCRC PDX. We will 
evaluate an additional 10 KRAS wt mCRC PDX for PIK3CA mutations. As the expected 
frequency of mutations in PIK3CA is 30%, we anticipate the analysis of 15 KRAS wt 
mCRC PDX will be sufficient to detect 3-5 PIK3CA mts. All PDX blood draws (~500 µL, 
left ventricle) will be analyzed for KRAS, BRAF, and PIK3CA mutations using PCR/LDR 
and compared to our known analysis of mutations from the human tumor tissue and 
correlated to the phenotype. We will also compare the KRAS, BRAF and PIK3CA 
mutations in EpCAM(+) and seprase(+) mCRC CTCs. 
 We will next evaluate the utility of the workstation prospectively in patients with 




month. Our PDX Program will allow us to perform a prospective validation of CTCs in 
patients and compare our mutational analysis of driver genes with the matched de-
identified tumors. We will prospectively collect matched blood and biopsies from 60 de-
identified patients. We calculate this sample size will be needed to detect at least 1 
patient tumor with a BRAF mutation. [77] DNA from tumor specimens will be analyzed 
using validated PCR/LDR assays. Comparisons between bench-top and the workstation 
genotyping of CTCs will be carried out throughout the course of this study. The metrics 
for operational performance will consist of CTC limit-of-detection to get quality genotypic 
data for CTC sub-populations, sample loss and potential contamination issues. For 
bench-top genotyping, CTC modules will be operated as stand-alone units.[78] Due to 
the configuration of the fluidic motherboard and the cleavable linkers we are employing, 
we can collect separately seprase(+) and EpCAM(+) CTCs into microfuge tubes for 
bench-top processing. 
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